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Early clinical trials with new chemotherapeutic agents must be
performed quickly and efficiently in a setting that allows a low
probability of erroneously rejecting an active agent.
A phase I clinical trial was conducted with methylene dimethane
sulphonate. The MTD was 225mg/sqm which was reached in 7 escalation
steps using the modified Fibonacci series. The dose limiting toxicity
was cumulative thrombocytopenia. Neutropenia was mild but 1/3 of
patients at higher doses (lOOmg/sqm - 225mg/sqm) required blood
transfusions during treatment with MDMS. Non-haematological toxicity
consisted of grade 0-2 nausea and vomiting of short duration, and
increasing degrees of alopecia at doses above lOOmg/sqm. The doses
recommended for phase II testing were 125mg/sqm in patients who had
received previous chemotherapy and 150mg/sqm in those who had not.
During the MDMS study I became concerned at the numbers of patients
treated at doses with little or no chance of therapeutic activity.
Dose escalation schemes for phase I clinical trials of new
chemotherapeutic agents have traditionally been rather conservative
with the result that over 50% of patients receive doses below those
subsequently recommended for phase II testing. A survey of phase I
studies published between 1971 and 1986 suggested that the dose of
drugs showing no toxicity at the starting dose (n) could immediately
be increased to 5n with consequent saving of two dose steps. It was
decided to combine this idea with those of Dr. Collins (Collins et
al, 1986) who suggested the use of pre-clinical pharmacology data to
guide dose escalation in phase I clinical trials.
A phase I clinical trial of Amphethinile using an intermittent iv
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schedule was conducted. The dose escalation scheme incorporated both
the ideas outlined above. An HPLC method was developed to measure
amphethinile in serum and urine and the AUC at the LD10 in the
mouse was found to be 310ug/l.h-l. This was adopted as the target AUC
for the trial. The MTD was 1200mg/sqm, thirty times the starting
dose. This was reached in four escalation steps, a saving of five
steps compared to the modified Fibonacci series. Methods such as
these for increasing the speed of escalation therefore appear to be
of practical value.
The dose limiting toxicity in this trial was neurotoxicity
consisting of light headedness, lethargy and a sense of detachment.
It is likely that some of the toxic effects seen at higher doses were
due to the Solutol vehicle and it was felt that the drug could not be
recommended for phase II testing using this schedule.
A phase II and pharmacokinetic study of 4-Demethoxydaunorubicin
administered orally was conducted in patients with advanced breast
cancer. These patients had had no prior chemotherapy but the
protocol included an option for early cross-over to Adriamycin in the
event of progression. Comparison of the survival of patients in this
trial with those in previous trials of conventional chemotherapeutic
regimens at this institute showed no disadvantage for the 4-DMDNR
treated patients. The objective response rate in the trial was 15%
and there was no evidence of alteration in the kinetics of 4-DMDNR
with continuous weekly therapy.
In conclusion the efficiency of phase I clinical trials can be
substantially improved using the methods outlined above. In addition
the data from phase II studies may be improved by using new agents
first-line with early cross-over to an active regimen on progression.
3
List of Tables
1 Phase I trials by year of publication
2 Animal species used to determine starting dose
3 Numbers of patients treated at therapeutic doses
4 Escalation procedures used
5 Number of dose escalations required to reach the first
toxic dose and the MTD
6 Drugs where toxicity occurred at the starting dose
7 Dose limiting toxicity for all 61 drugs
8 Objective responses
9 Median values for WBC and Platelet nadirs at each MDMS dose
level
10 Blood transfusion requirements following MDMS therapy
11 Non-haematological toxicity
12 Differential WBC toxicity
13 Busulphan in AML in remission
14 Serum levels of 4-DMDNR following iv administration
15 4-DMDNR pharmacokinetic parameters following iv administration
16 4-DMDNR pharmacokinetic parameters following oral
administration
17 72 hour urinary recovery of 4-DMDNR and 13-OH4DMDNR
18 4-DMDNR AUC and elimination half life following repeated
weekly administration
19 13-OH4DMDNR AUC and elimination half life following
repeated weekly administration
20 Seven day 13-OH4DMDNR levels during continuous treatment
21 4-DMDNR Phase II in breast cancer: Patient characteristics
4
22 Characteristics of patients treated with Adriamycin
23 Amphethinile retention times with alterations in mobile
phase
24 Amphethinile LD10 in BDF mice
25 Amphethinile serum concentrations in BDF mice at the LD10,
LD5 and LD2.5
26 Pharmacokinetic parameteres of Amphethinile in mice
27 Amphethinile metabolite AUC in mice
28 Pharmacokinetic parameters of anphethinile in man
29 Urine recovery of Amphethinile
30 Amphethinile metabolite AUC
5
List of Figures
1 Method of residuals
2 Two compartment model
3 Structure of MDMS
4 Effect of MDMS on Yoshida sarcoma in rats
5 Structure of 4-Demethoxydaunorubicin
6 Chromatogram of 4-Demethoxydaunorubicin
7 4-DMDNR and 13-OH4DMDNR plasma decay curves following
iv administration
8 4-DMDNR AUC and elimination half life in patients
receiving at least 6 months therapy
9 13-OH4DMDNR AUC and elimination half life in patients
receiving at least 6 months therapy
10 4-DMDNR and 13-OH4DMDNR plasma decay curves following
oral administration
11 Seven day levels of 13-OH4DMDNR during continuous weekly
therapy
12 Survival of patients with advanced breast cancer
treated with VAP/Cyclo, CMF and 4-DMDNR
13 Structure of Amphethinile
14 Plasm decay curves of Amphethinile in patients
receiving 200mg/sqm
15 Plasm decay curves of Amphethinile in patients
receiving 400mg/sqm
16 Plasm decay curves of Amphethinile in patients
receiving 800mg/sqm
6
17 Alteration in kinetics of Amphethinile with 50% dose
reduction in patient FL
18 Plasma decay curves of Amphethinile in patients
receiving 1200mg/sqm
19 Plasma decay curves of Amphethinile adminstered orally
and intravenously to patient JB
20 Ultraviolet absorbance scan of Amphethinile
21 Plasma decay curves of Amphethinile in mice
22 Amphethinile chromatogram
23 Plasma decay curves of Amphethinile in man





The concept of curative drug therapy for human disease dates back
to the use of cinchona bark (containing quinine) and ipecac
(containing emetine) for the treatment of malaria. These remedies
were discovered in the seventeenth century and were introduced into
Europe frcm South America by the Jesuits. In a situation not
dissimilar to that of cancer treatment today they were used without
knowledge of the cause of the disease, nor of the identity or action
of the active principle. Further progress in the treatment of
infectious diseases was not made until the turn of the 19th centuary
when Paul Ehrlich discovered the anti-parasitic properties of
arsenicals. From 1903-1915 Ehrlich devoted much of his attention to
the development of these agents. He synthesised a long series of
organic arsenic conpounds and developed animal models to test the
effect of these drugs. The 606th of these arsenicals was highly
active against trypanosome infections and rabbit syphilis. Ehrlich
named this drug Salvarsan, "saviour of mankind". It was the first man
made chemical shown to be active against human parasitic disease
and he coined the term "chemotherapy" to describe such a compound.
The first indication that a systemic treatment might also be used
for the treatment of cancer was the demonstration by Lissauer in 1865
of the anti-tumour effect of potassium arsenite (Fowler's solution).
Ehrlich was also employed to work on the problem of cancer and
although he discovered the first alkylating agent, ethylenimine, in
1898 nearly half a century passed before similar compounds began to
be used in the treatment of human cancer.
The modern age of cancer chemotherapy may be said to begin with the
work of Huggins and Hodges in the late 1930s. Their observations on
serum acid phosphatase levels in patients with carcinoma of the
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prostate provided a rational basis for the use of endocrine
manipulations in this disease (Huggins and Hodges 1941). This was the
first example of the use of a "marker" to follow the effect of a
systemic therapy in the treatment of cancer.
The gas warfare programmes of the two World Wars provided the next
great stimulus to cancer research when it was noticed that members
of the armed forces dying of mustard gas poisoning developed marked
aplasia of the lymphoid organs. In the early 1940's mustard gasses
were submitted for study to Goodman and Gilman at Yale university. In
a series of experiments on rodents they demonstrated that these
chemicals had profound effects on the lymphatic and haemopoetic
systems. In addition Dr Dougherty at the same institution showed that
nitrogen mustards could produce remissions in spontaneously occurring
leukaemias and lymphomas in rats. These observations suggested that
nitrogen mustard might be of some value in the treatment of
leukaemias and lymphomas in man. The first patient, a terminal case
of lymphosarcoma, was treated at the New Haven Hospital in 1941 with
a dramatic regression of involved glands. Subsequently nitrogen
mustard was used in the treatment of a group of 67 patients
suffering from a variety of neoplastic diseases including
lymphosarcoma and Hodgkin's disease. A number of encouraging
responses were seen in this limited study but because of the secrecy
surrounding the war gas programme the results were not published
until 1946 (Goodman et al 1946). Additional studies by Alpert and
Peterson (1947) and Dameshek et al (1949) confirmed that remissions
could be induced by the nitrogen mustards particularly in the
lymphoid malignancies. Unfortunately the duration of these early
remissions was short but despite this there was hope that advanced
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cancer might soon be curable with drug treatment.
Shortly afterwards in 1947 Sidney Farber noticed that the
administration of folic acid conjugates to children with acute
leukaemia appeared to induce an acceleration in the leukaemic process
(Farber et al 1947). This observation led Farber to experiments with
folic acid antagonists in the treatment of acute leukaemia firstly
using pteroyldiglutamic acid and subsequently the more powerfull
antagonist aminopterin (a forerunner of Methotrexate). Again these
early studies produced encouraging results with 10/16 patients
showing some response to aminopterin therapy (Farber et al 1948).
Following these early successes the search began in earnest to
identify other chemicals with anti-tumour activity. The chemicals
investigated were either natural products from plants or
micro-organisms or synthetic compounds. Some compounds were
synthesised and screened because they bore a structural similarity to
agents of known activity ("rational" approach) others were merely
included in a random screening programme ("empirical" approach).
Regardless of source every anti-cancer agent currently in use was
first tested clinically on the basis of activity in animals bearing
malignant tumours (Venditti 1975, Gellhorn et al 1955, Goldin et al
1979, Goldin et al 1980). The development of transplantable animal
tumours in syngeneic hosts had been pioneered by George Clowes at
Roswell Park Memorial Institute, and four of the more widely used
transplanted tumours, sarcoma 37, sarcoma 180, Walker 256 and Ehrlich
ascites tumour were developed before 1930. One of the earliest
screening programmes was set up by Shear of Harvard University in the
1930s (Shear et al 1947) to test and isolate bacterial
polysaccharides capable of producing haemorrhage and necrosis in
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sarcoma 37.
With the stimulus provided by the war research and the work of Shear
and Huggins and Hodges, the end of hostilities ushered in a new era
of intensified interest in cancer research. Drug development
programmes were instituted at the Sloan-Kettering Institute for
Cancer Research under Rhoads, at the Chester Beatty Institute in
Great Britain under Haddow and at the University of Tokyo under
Yoshida. The Sloan-Kettering Institute rapidly emerged as the
dominating force in cancer chemotherapy. Sarcoma 180, a tumour which
grows in out-bred mice and is therefore suitable for mass screening,
was established as the standard screen. By 1955 approximately 20,000
chemicals had been tested and the Sloan-Kettering programme accounted
for 75% of chemotherapy screening in the USA (Zubrod et al 1977).
In 1953 the US Congress first proposed the establishment of a
National Integrated drug discovery programme and this led in 1955 to
the setting up of the Cancer Chemotherapy National Service Centre
(CCNSC) in Bethesda. (the NSC numbers of conpounds tested in the NCI
programme is a contraction of CCNSC).
One of the earliest tasks of the new National Cancer Institute in
Washington was to decide which, if any, of the available biological
systems could predict activity in the agents that had already found
their way into clinical use. In 1953 the American Cancer Society
commissioned a systematic study of the methods used in different
laboratories for screening potential agents for anti-tumour activity
and this led to a report in 1955 by Gellhorn and Hirschberg. After
examining 74 different assay systems they concluded that no one
system could identify all the agents then in current clinical use
(nitrogen mustard, methotrexate, 6-MP, and actinomycin-D) and also
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that in vivo systems could not be replaced by in vitro non-tumour
models. As a result the NCI selected a panel of three murine tumours
(L1210 leukaemia, sarcoma 180 and adenocarcinoma 755) for use in an
extensive systematic screening programme. This programme continued
for a decade until the mid 1960's during which time busulphan,
chlorambucil, 5FU, the vinca alkaloids, cyclophosphamide, melphalan,
hydroxyurea, mithramycin, Mitomycin-C, Procarbazine, Cytosine
Arabinoside and Daunorubicin all entered clinical use.
In 1966 Goldin, Serpick and Mantel completed a retrospective
analysis of the predictiveness of over 100 tumour models
including those used in the NCI screen. They concluded that all but
one of the clinically active drugs (mithramycin) would have been
selected by the use of the mouse L1210 system and the rat Walker 256
carcinoma. As a result the NCI screen was reduced to these two
tumours. However it soon became clear that the Walker model, being
particularly sensitive, was identifying too many agents (ie had too
low a threshold for activity). This tumour was therefore replaced by
another murine tumour, the P388 leukaemia, which was less expensive
than the rat Walker tumour and more sensitive than L1210. Over the
next 5 years there were a number of changes and new models were
examined until a new procedure was adopted in 1975. By this time
BCNU, streptozotocin, DTIC, asparaginase, bleomycin, and Adriamycin
had been added to the clinical armoury but this represented a small
return for the annual screening of 30-40,000 compounds.
The new system involved a "pre-screen" using P388. Any compound
achieving a certain level of activity in this screen (greater than
20% increase in life span) went on to be tested in a panel of
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transplantable tumours representing the major histological types of
cancer in the western world. The panel consisted of mouse colon
(Colon 38), breast (Mammary Ca CD8F1) and lung (Lewis Lung)
tumours, human tumours of the same histological types (Mammary,
MX-1, Lung, LX-1, Colon, CX-1) xenografted in athymic nude mice, and
two mouse tumours (L1210 and B16 melanoma) which had been found to be
of particular value in the past. In addition, where indicated by
prior information, eg particular organ specificity of a compound,
other ad hoc systems were also employed. If a compound showed
activity in any of these eight tumours it then became a candidate for
pre-clinical toxicology and subsequent clinical trial. It was hoped
that the use of screening models that more closely resembled human
solid tumours in histology, metastatic pattern and growth kinetics
would improve the detection rate of compounds active in these tumours
in the clinic. Moreover results from clinical trials of the agents
discovered should provide information on the extent to which a
pre-clinical model can predict preferentially for clinical efficacy
against human tumours of the same histological type.
At the outset of this tumour panel experiment the impracticality of
screening many thousands of compounds against eight tumours was
recognised. Thus although some compounds were passed straight to the
panel based on "intellectual selection" from structural pattern
recognition (Hodes 1981, Hodes 1981a) or some known biological
activity, the majority of compounds were subjected to the P388
pre-screen. In retrospect this had the major disadvantage that this
screen would continue to detect drugs active in a similar range of
tumours to those already discovered rather than agents with a
different spectrum of activity. Analyses of the results of the
14
tumour panel from 1976-1982 by Venditti et al (1984) and Staquet et
al (1983) confirmed that the pre-screen had a low false -ve rate of
approximately 1% (the low end point - increase in life span greater
than 20% - was selected for the pre-screen in order to limit false
negative results) and in addition there was a close correlation
between the quantitative level of pre-screen activity and the
probability of activity in the panel. Further analysis showed that
95% of compounds active in at least one panel assay were active
against L1210, B16 or MX-1 and thus it was suggested that the panel
be reduced to these three tumours with consequent major cost savings.
However during the past 2-3 years the shortcomings of screening
programmes relying entirely on transplanted tumours in mice were
becoming ever more apparent. Since 1955 over 600,000 natural and
synthetic substances have been tested in the NCI system with a very
low yield of clinically useful drugs. Only 12 of the currently
available anti-cancer drugs have been developed under direct NCI
sponsorship. These include Mithramycin, BCNU, CCNU, DTIC, Cytosine
Arabinoside, Bleomycin, Asparaginase, Adriamycin and Cis-DDP.
Moreover since the introduction of Cis-platin in 1973 and VP16-213
in 1976 no new agents have made a significant impact on improved
survival in any malignancy. Furthermore the emergence of a number of
agents, eg Mitozolamide (New lands et al, 1985) with excellent
preclinical activity which later proved to be inactive in the clinic
was particularly disappointing and raised serious doubts about the
value of the animal based systems used in the selection of anticancer
drugs. As a result of these misgivings several organisations
including the European Organisation for the Research on Treatment of
Cancer (EORTC), the Cancer Research Campaign Phase I/II group and
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the NCI itself are now in the process of changing their screening
programmes in a radical manner.
The panel of murine tumours has been discarded concentrating
instead on the use of specific disease-orientated groups of human
tumour cell lines in corrplementary in vitro and in vivo test systems.
Panels of cell lines representing the major categories of human
cancer and including multi-drug resistant lines are being acquired
and developed and methods of automating the drug testing explored.
This latter facet of the programme is essential since it is envisaged
that eventually each drug will be tested in 100 cell lines at several
different concentrations. The tests are carried out as growth
inhibition assays in plates of mico-wells with extensive use of
computer controlled robots to prepare the plates and of conputers to
record and analyse data.
It has been decided that drugs showing 3 log differences of
response in different cell lines are of interest whereas those
demonstrating uniform activity or inactivity are not. Such
"interesting" compounds will then be tested in a range of human
tumour xenografts. At present the system is able to cope with
approximately 20 compounds per week tested in 50 cell lines
although it is hoped to increase this to 50-100 compounds per week.
Thus even with the degree of automation described above the system
will only be able to put through 25-50% the volume of compounds
previously managed by the P388 screen. However it is hoped that this
radical departure will allow the identification of new classes of
anti-tumour agents with activity against the common solid tumours.
The use of in vitro screening has relied on the development of
the human tumour stem cell assay (HTSC) (Salmon et al, 1978; Von Hoff
et al, 1981; Hamburger et al, 1978) in which cell culture colonies
formed from freshly explanted human tumour tissue are tested for
sensitivity to drugs. This has involved the establishment of growth
of excised human tumours in conditioned soft agar culture media and
determining the inhibition of colony forming units (CFU) with drug
concentrations selected on the basis of clinical pharmacology. This
is a rapid and inexpensive method compared with human xenografts.
However a significant problem lies in the drug concentrations and
times of exposure which with new compounds must be chosen
arbitrarily. Some guidance on this might be provided by pre-screening
against P388 in vivo. Ultimately the use of human tumour cultures as
screens will depend on the ability to establish assays that are
stable and reproducible. This might be achieved by transferring cells
in vitro but they may lose their intrinsic heterogeneity in this way.
Perhaps a more promising technique is to maintain the tumours in nude
mice providing a constant source of cells for in vitro screening.
Work with anthracycline analogues tested in this way has been
reported (Guiliani et al 1980).
The establishment of human tumours in vivo has been achieved in two
main ways. In the first method immune deprived mice, either
genetically thymus deficient (the nude mouse) or thymectomised at
birth, are used as recipients (Giovanella et al 1974). The "takes"
in this system have been shown to vary considerably depending both on
the origin of the tumour and the condition and strain of the animals
used (Sharkey and Fogh 1984). The second method, the renal capsule
method (Bogden et al 1978), uses the fact that the kidney is an
immune sanctuary site and many tissues can be established by
implantation just below the capule of the kidney of the mouse.
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It is unlikely that a perfect non-human model of human cancer will
be found and consequently all models will have limitations.
Nevertheless pre-clinical models have played a major role in
developing the currently available anti-cancer drugs (De Vita 1979).
Finding new drugs will depend on continued progress in three areas of
research; the elucidation of the principles underlying drug action
and drug resistance; the continued improvement in the intellectual
selection of compounds to be tested pre-clinically; and the continued
development of improved pre-clinical models that have greater
predictive value for the clinic. However the next two years may
prove to be a watershed in mass screening of compounds for
anti-tumour activity. The annual budget for the NCI drug development
programme is currently 40 million dollars and if the new in vitro
screening initiative does not show promise within 2-3 years the US
government has threatened to withdraw funding.
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Formulation of new chemotherapeutic agents
The formulation of a compound that appears promising in pre-clinical
screening is an often underplayed but vital part of the development
of the drug. All pre-clinical toxicology must be carried out with the
formulated preparation that will eventually be used in the clinic and
thus before a drug is presented for toxicology an appropriate
formulation must be found. Failure to do this may result in
expensive repetition of toxicology if a drug has subsequently to be
reformulated.
The formulation should be relatively easy to manufacture in amounts
suitable for early clinical trials and it must be stable under
normal conditions of storage. In addition the chosen vehicle should
itself be free from biological effects.
The main factors to be considered in developing a suitable
formulation are the stability and aqueous solubility of the drug.
Other factors to be taken into account include the pH, pKa and
oil/water partition coefficient.
Solubility
Drugs that are administered intravenously must interact immediately
with the predominantly aqueous environment of the body and thus
water solubility is extremely important. A formulation must be found
that allows the drug to be dissolved in a volume of aqueous solution
that can be administered both safely and conveniently.
Drugs of low aqueous solubility may be rendered more soluble by
first dissolving in polar solvents such as Dimethylsulphoxide (DMSO)
and Dirrethylacetamide (DMA). In seme cases it may not be possible to
achieve an aqueous solution and such drugs may be formulated as
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molecular suspensions using surfactant materials such as Cremophor EL
or Solutol HS 15.
Drugs for intravenous use that are soluble in water or polar
solvents are normally presented as a freeze dried powder eg cytosar,
cyclophosphamide, adriamycin, Cis-Platin, methotrexate, mustine,
vincristine and others. Freeze dried preparations have the
advantage of small volume and are normally very stable. Prior to
administration they are reconstituted with the appropriate solvent,
usually water or saline.
Aqueous solubility is less important for orally administered
drugs and some relatively insoluble compounds such as Busulphan are
well absorbed when given in this manner. These drugs however must be
sufficiently lipcphyllic to enable them to be absorbed across the
cell membranes of the GI tract. The oil/water partition coefficient
is a measure of a compound's lipophylicity.
pKa/pH
In addition to lipid solubility the degree of ionisation is also
important for absorption. It has been shown that unionised molecules
diffuse preferentially across the GI mucosa. Acidic drugs will be
predominantly unionised in the stomach and basic drugs predominantly
unionised in the more alkaline environment of the intestine. However
principal sites of absorption also depend on factors such as surface
area of the relevant site. For parenteral drugs the pH at the time
of administration should be close to physiological pH.
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Stability
A drug must be sufficiently stable so that storage under normal
conditions results in an adequate shelf life. In addition it is
important to know the stability of the agent once any reconstitution
procedures have taken place. Drugs that decay rapidly in aqueous
solution will not be suitable for use as prolonged infusions.
Stability to heat will affect the method of sterilisation of a
product. Drugs that are unstable at high temperatures cannot be
autoclaved and will have to be sterilised by other methods eg
ultra-filtration. The effect of pH on stability is important for
both oral and parenteral drugs. Acid labile drugs intended for oral
administration must be protected from the highly acidic environment
of the stomach. Buffer selection for parenteral drugs will be largely
based on the stability characteristics of the drug.
An exhaustive review of the problems involved in formulating new
drugs is beyond the scope of this thesis however it is hoped that
this brief outline may serve as an indication of the complexity of
the task. The importance of this facet of new drug development cannot
be over estimated. A compound may be extremely active in
pre-clinical testing but without an adequate formulation further
progress to toxicology and clinical trial cannot take place.
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Pre-clinical Toxicology
The aims of pre-clinical toxicology are to identify a safe starting
dose for human trials and to characterise potential toxicities.
However the requirements for the animal testing of new drugs has
changed considerably over the years. In 1899 aspirin was approved for
use in humans after toxicology had been performed in one fish and two
frogs! Since those halcyon days a number of countries, notably the
USA, have accumulated such rigorous mandatory pre-clinical testing
requirements that the cost of these procedures has become a serious
barrier to the introduction of new agents. In 1983 the cost of
pre-clinical toxicology in the USA for a single drug was estimated to
be $380,000.
The identification of a safe starting dose for phase I clinical
trials has been made easier for anticancer agents by the
recognition that the maximum tolerated dose (MTD) in terms of mg/unit
surface area is surprisingly consistent between species. This fact
was highlighted by Freireich et al (1966) in a study of 18 anticancer
drugs in the mouse, rat, hamster, dog, monkey and man. As a result of
this study it was concluded that on a mg/kg basis the maximum
tolerated dose in man is about 1/12 the LD10 in mice, 1/9 the LD10 in
hamsters, 1/7 the LD10 in rats, 1/3 the MTD in rhesus monkeys and 1/2
the MTD in dogs. They suggested that it would be reasonable to study
pre-clinical toxic effects in the mouse, rat, dog, monkey and
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hamster, to estimate the MTD (mg/m ) in man, and to start
clinical trials at approximately 1/3 of this dose. This would have
produced a safe starting dose for all 18 drugs involved in this
study. However a subsequent analysis by Homan (1972) of the data of
Freireich et al and that of Schein et al (1970) indicated that if
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this rule was applied to all the drugs studied there was a 5.9%
probability of exceeding the human MTD. In 1973 the NCI Laboratory of
Toxicology revised its protocol for large animal toxicology (Prieur
et al 1973) to provide values for the highest non toxic dose (HNTD),
the lowest dose to produce toxic effects (toxic dose low or TDL)
which when doubled caused no mortality, the lowest toxic dose which
when doubled produces mortality (toxic dose high or TDH) and the LD
which is the lowest dose to produce drug-induced death. The
recommendation was that phase I clinical trials should commence at
1/3 TDL in the most sensitive large animal species.
In 1975 Goldsmith et al published an analysis of mouse, dog and
monkey toxicity data on 30 drugs. They concluded that by using 1/3
TDL in the most sensitive large animal species 5 of the 30 drugs
would have produced significant toxicity in the first patient. In
addition they suggested that closer attention ought to be paid to
rodent data since the LD10 and LD90 in mice were found to offer good
quantitative prediction of human toxicity. However they concluded
that the major emphasis should remain on the monkey and the dog.
In 1981 Rosencweig et al reported an analysis of toxicology for 21
drugs for which experimental results in mice and dogs and clinical
results all using the same schedule were available. The data
confirmed that mice and dogs are equally relevant for predicting the
MTD in man. Thus the ratios of MTD in man to 1/6 LD10 in the mouse
and of MTD in man to 1/3 TDL in the dog were similarly distributed.
However for a limited number of agents there was a significant
difference in the information provided by the mouse and the dog and
thus a combination of data from both species could be useful for
determining acceptable starting doses in man. In order not to lose
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the economic and time advantages of concentrating largely on the
mouse it was proposed to use 1/10 LD10 in the mouse (in no case in
the drugs tested did this exceed the TDH in the dog) as the starting
dose for phase I clinical trials providing this dose was entirely
non-toxic in the dog. If toxicity was seen in the dog further work in
this species would have to be done to determine the starting dose.
During the same period similar initiatives were taking place in
Europe with the exception that large animal testing has been
completely dropped and the toxicity check of the mouse 1/10 LD10 dose
is undertaken in the rat.
Thus it appears to be possible to arrive at a safe starting dose
using a system involving only rodents. However it is important to
know if exhaustive testing with large animals is more likely to alert
the clinicians to the potential hazards of the drugs. The answer is
no. It is now appreciated that marked inter-species variation exists
in the sensitivity for certain drug side effects. Thus testing in the
monkey and the dog failed to predict important toxicities such as
cardiotoxicity in the anthracyclines and over predicted others
notably renal and liver damage in various other compounds (Goldin et
al 1980). It became clear that the predictive value of a test for any
type of toxicity depended largely on the prevalence of that toxicity
so that the predictability will be relatively high for common
toxicities eg myelosuppression and relatively low for rarer ones. In
a study of 25 anticancer drugs Rosencweig et al (1981) found that the
predictive value for common toxic effects in man was greater than
0.85 compared to 0.05-0.54 for rarer side effects. Moreover there was
no clear superiority of animal findings over the mere knowledge of
the prevalence of these toxicities in man. Experienced clinicians
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will already be anticipating the likely occurrence of common side
effects and have at their disposal curative measures for the majority
of these. In addition the close monitoring of patients in phase I
clinical trials should alert the investigators rapidly to any unusual
toxicities thus minimising harm to the patients.
In the light of these observations the requirement for exhaustive
large animal histopathology prior to human use has been dropped in
some countries. In Europe pre-clinical toxicology now relies entirely
on testing in mice with a check that the dose selected for phase I
study is entirely non-toxic in the rat. This concentration on rodents
for pre-clinical toxicology allows testing to proceed much more
rapidly and at greatly reduced cost than was previously possible. The
cost of this procedure for the most recently tested drug in the CRC
programme completed in May 1986 was approximately $20,000. However
despite the scientific and economic arguments in favour of a rodent
based toxicology programme the FDA in America still requires large
animal testing to be performed.
In summary it has been established that animal toxicology is a
relatively inefficient predictor of unusual toxic effects in man and
that extensive pre-clinical testing is therefore not cost effective.
In addition all animal species tested including rodents are similarly
accurate in quantitative prediction of toxicity in man and therefore
the use of mice for determining the starting dose for phase I
clinical trials provides a major saving in both time and money. In
Europe the present policy is to use 1/10 LD10 in the mouse as the
starting dose, provided this is totally non toxic in the rat.
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The Phase I Clinical Trial
As has been outlined in the previous sections a great deal of time
(often over 10 years), money and effort is involved in bringing a new
compound through to clinical trial in man. However once the clinical
trial commences most of the pre-clinical data becomes irrelevant and
the performance of the drug in terms of toxicity and therapeutic
effect determines future development (Von Hoff et al 1977).
The main (some would say only) aims of the phase I trial are to
determine the spectrum of toxicity of the agent in man and to
identify a suitable dose for phase II testing. A further goal is
to record any antitumour activity although at this stage of drug
development this is of lesser importance (Carter 1977, Schein 1977,
Gottleib 1974, Williams and Carter 1978, Karon et al 1973). These
three basic aims of the phase I trial can be stated as follows:
(1) To establish a safe starting dose for phase II trials for
a new drug on a given schedule via a given route of
administration both for previously treated and previously
untreated patients.
(2) To determine the qualitative toxicity (organ systems involved)
as well as the quantitative toxicity (predictability, grade,
duration and reversibility).
(3) To look for any antitumour activity of the drug.
All phase I studies should achieve these aims and in addition where
the appropriate assay techniques are available the collection of
basic pharmacokinetic data is becoming increasingly important.
In the past phase I trials have attenpted to determine the maximum
tolerated dose (MTD) of a drug for a given schedule. A difficulty
arises however in the definition of MTD. Some investigators describe
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it as "maximum deliverable" dose which is not associated with
lethality while for others it represents the first evidence of
"treatment-limiting toxicity" (Wooley and Schein 1979). To an extent
the maximum deliverable dose will depend on the supportive care that
is available. For example it is now possible, with the advent of
autologous marrow transplantation, to administer considerably higher
doses of alkylating agents than was previously possible. In practice
such attempts to further escalate doses is only carried out with
drugs of proven value when used under conventional conditions. A
further point about the MTD is that it will almost always be higher
for patients who have not received prior chemotherapy. This applies
particularly to myelosuppressive agents. In recent years previously
untreated patients have been increasingly entered in phase II studies
of diseases where existing therapy is of little or no benefit. Thus
it has now become standard practice to define a maximum safe dose for
phase II testing for both types of patient.
In practice the dose limiting toxicity for the majority of drugs
is myelosuppression and in this case reversible grade 3 WHO (WHO
1979) toxicity (WBC 1.0-1.9 x 10^/1, platelets 25-49 x 10^/1)
represents an acceptable starting point for phase II trials.
For agents which are non-myelosuppressive the end point for the
phase I trial can be much more difficult to determine and is not
usually dependent on the extent of prior chemotherapy. In such
cases comparison of clinical pharmacokinetics with preclinical data
at antiturrour doses in animals may provide a valuable guide to the
target dose for the trial.
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Patient Selection
Patients entered in phase I studies must be carefully selected if
the quality of the data generated by the trial is to be high. The
experience of the investigator is often the best arbiter as to
whether a particular patient will be suitable for the study. This is
especially true when assessing performance status and life
expectancy. For example a patient with relapsed small cell lung
cancer may have a performance status of 1 (WHO) but a life expectancy
of only a few weeks whereas a patient with liver metastases from
colon carcinoma may have a similar performance status but a life
expectancy of several months. The investigator must also decide
whether the patient is likely to to default from follow up
since if this happens much effort may be wasted. The following are
generally accepted criteria for inclusion of patients in phase I
trials (Carter 1977, Gottleib 1974, Wooley and Schein 1979, Williams
and Carter 1978, Karon et al 1973):
(1) There must be a histological diagnosis of malignancy.
(2) The patient must have failed on all established forms of
treatment or have a tumour for which no effective therapy
exists. In this context there may be some argument as to what
constitutes effective therapy. While no patients with breast
cancer, lymphoma or ovarian carcinoma would be entered in a
phase I trial without having had extensive prior treatment
some would argue that for other conditions eg renal carcinoma,
colon carcinoma and possibly non-small cell lung cancer no
effective chemotherapy exists and would include these patients
in the trial. Other investigators would argue that there are
regimens that have given response rates of the order of 20-30%
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in these conditions and would therefore not feel able to deny
patients such treatment. These response rates have not however
been associated with increased survival compared to untreated
controls and therefore it is doubtful if they are of great
value. In practice during the early stages of a phase I trial
all patients entered have normally had prior chemotherapy.
Towards the conclusion of the trial when potentially
therapeutic doses are being studied a higher proportion of
untreated patients will be entered.
(3) Since the dose limiting toxicity of the majority of drugs is
myelosuppression patients with compromised marrow function due
to their disease should not be included. Thus those with
leukaemia and often lymphoma are not suitable, in addition
some patients with solid tumours particularly breast cancer
may have heavy marrow infiltration and these should also be
avoided. In general only patients with solid tumours are
entered, separate phase I studies being undertaken in
leukaemia once the initial data are known.
(4) It is not necessary for patients to have evaluable disease
since the study is basically a toxicity trial but, as
mentioned previously, evidence of activity in the phase I
trial is likely to stimulate greater interest in the drug.
(5) Most investigators stipulate a lower age limit of 16-18 years.
This is because retrospective analyses have shown that
paediatric patients may tolerate considerably higher doses of
drugs than adults (Von Hoff et al 1977). Separate phase I
trials are therefore carried out in children. An upper age
limit of 70 years is often laid down in phase I and phase II
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protocols. However it is the biological rather than
chronological age that is important and once again the
experience of the investigator is of more value in determining
the suitability of a patient than a rigid age limit.
(6) Although it is unlikely that patients with advanced malignancy
would be pregnant it is usually stated that such patients
should be excluded on the grounds of possible teratogenicity.
(7) The anticipated life expectancy of the patient is an important
consideration. In order to allow sufficient time to assess drug
related toxicity a minimum life expectancy of 12 weeks is
required. Unfortunately physicians frequently overestimate
survival (Wooley and Schein 1979, Parker 1972).
(8) Sufficient time should have elapsed to allow recovery from
prior chemotherapy. This is normally taken as four weeks or six
weeks for drugs such as the nitrosoureas and mitomycin-C that
have a delayed nadir and slow recovery of marrow function.
Extensive radiotherapy will also compromise marrow function and
time must be allowed to recover from such treatment.
(9) The majority of drugs are excreted by the liver or kidneys or a
combination of both. Major dysfunction of these systems will
lead to prolonged systemic drug exposure resulting in increased
toxicity and therefore phase I patients should have normal
renal function and normal bilirubin although some rise in
hepatic transaminases is allowed (usually less than 50% above
the upper limit of normal. Major degrees of heart failure,
symptomatic dysrhythmias or other serious medical conditions
also disqualify patients from phase I trials.
(10) Patients should be on as few additional drugs as possible
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although many will require analgesics or other symptomatic
therapy.
Dose Escalation
The process of dose escalation is governed by a fundamental
conflict. On the one hand there is a need to go slowly in order to
avoid a sudden jump from a dose with no obvious toxicity to a lethal
dose. On the other hand there is a need to proceed rapidly so that
large numbers of patients are not treated at doses of no
potential therapeutic benefit. Although the phase I trial is
primarily a toxicity study it is ethically difficult for
investigators to treat patients at doses with little or no likelihood
of a therapeutic effect. Moreover inefficient escalation procedures
slow the overall pace of new drug development and limit the
opportunities for patients with unresponsive tumours to be treated
with potentially effective agents in phase II trials. Moreover
following the completion of a phase I study the valuable information
is that obtained at or near the maximum tolerated dose and the wealth
of data on patients treated at lower doses is largely irrelevant. For
these reasons it is important therefore to look for ways of
escalating doses as rapidly as possible.
The most widely used method of dose escalation is the so called
modified Fibonacci search scheme (Carter et al 1977, Selawry and
Hansen 1969), and in order to explain this there follows a brief
historical digression.
Leonardo Fibonacci, also known as Leonardo of Pisa, was the most
distinguished mathematician of the middle ages. His father was a
Pisan merchant who sent the young Leonardo to study calculation in
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North Africa. There he learnt the art of the nine Indian figures (9,
8, 7, 6, 5, 4, 3, 2, 1) and became increasingly interested in
mathematics. His major work, Liber Abacci, appeared in 1202 and
described in detail the use of this counting system (also called
Hindu-Arabic numerals). The sequence of numbers that now bears his
name derived from a problem set out in Liber Abacci:
" A certain man put a pair of rabbits in a place surrounded
on all sides by a wall. How many pairs of rabbits can be
produced from that pair in a year if it is supposed that
every month each pair begets a new pair which from the
second month on becomes productive?"
The resulting number sequence:
1, 1, 2, 3, 5, 8, 13, 21, 34 etc
describes the number of rabbits present at each month. Each term of
the series is obtained from the sum of the two preceeding terms and
it was the first recursive sequence known in Europe. The relationship
between the members of the series was not however stated in a formula
(Un+2 = Un+1 + Un)
until the development of algebraic notation in the early 17th
century. In 1753 Robert Simson at Glasgow university noted that as
the numbers increased in magnitude the ratio between succeeding
numbers approached the constant phi.
The term Fibonacci series was coined in the 19th centuary by the
French Mathematician Edouard Lucas and in the ensuing years
several interesting properties of the sequence were discovered. For
example if each number is divided by its right hand neighbour a
series of fractions is obtained which are found widely in natural
phenomena. When new leaves grow from the stem of a plant they spiral
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round the stem and the spiral turns as it climbs. The amount of
turning from one leaf to the next is a fraction of a complete
rotation around the stem and this fraction is always one of the
Fibonacci fractions. These fractions are also found in the
arrangement of petals on a sun flower, of whorls on a pine cone and
of segments on a pineapple.
The Fibonacci series was modified empirically in the following
manner for use in phase I trials:










This scheme allows rapid initial escalations with smaller
increments as the toxic range is approached. In effect only the first
three terms bear any resemblance to Fibonacci's original series of
numbers but the concept of the ratio between successive members of
the series approaching a constant is retained.
Using this scheme the maximally tolerated dose of a new agent has
usually been reached in 2-12 (median 6) escalation steps (Carter et
al 1977, Penta et al 1979, Greishaber and Marsoni 1986)). It follows
that on average 50-75% of patients in a phase I trial using this
escalation programme will receive sub-therapeutic doses. Moreover
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since each dose level will take 6-8 weeks to complete the average
study will last 9-12 months and many considerably longer. It is
important therefore to examine alternative escalation procedures in
an effort to by-pass the lower doses. A number of investigators have
used 100% dose increments until toxicity is encountered with
progressively smaller increments thereafter (Gottleib 1974). Although
this method often allows a more rapid escalation compared to the
Fibonacci scheme the choice of dose increments remains largely
empirical.
A different approach is to use pre-clinical pharmacokinetic data
from animal experiments as a guide to dose escalation. This arose
from the observation that for many drugs the MTD in man is close to
2
the LD 10 in the mouse expressed as mg/m (Collins et al
1986). However a number of agents do not conform to this rule and
suggested explanations for this variation in toxicity between mouse
and man include:
(1) Species differences in drug metabolism/elimination/binding
(2) Schedule dependency
(3) Species differences in target cell sensitivity.
Differences in metabolism and distribution, ie pharmacokinetic
differences, can be overcome by looking at the area under the
concentration x time curve rather than relying solely on the dose.
This should allow a more accurate inter-species comparison of
systemic drug exposure. This theory was tested retrospectively on a
series of eight drugs by Collins et al (1986). They found that in 5
cases the AUC was an effective predictor of toxicity and for these
drugs the number of escalation steps could be reduced by between
20-50% using pharmacokinetic data. In one case, Adriamycin, the ratio
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of doses at the mouse LD10 and human MTD was 5 whereas the ratio of
AUCs was 0.8. This was the most striking example of the AUC providing
a more accurate correlation with toxicity (Green et al 1983). For a
further drug, PALA, the AUC ratio was over conservative and would
not have reduced escalations significantly. For two others, F-ara-AMP
and Dihydroazacytidine, man was less tolerant than mice but since
toxicity was observed in both cases at the initial dose level no
problems with patient safety were encountered. However such cases
could be potentially dangerous if the dose was escalated above the
MTD on the basis of AUC information.
It is instructive that all three drugs where the correlation of
dose and AUC with toxicity between species was least secure were
antimetabolites and therefore it appears that this is a class of
compounds where the use of pharmacological data to aid dose
escalation may not be applicable. However even if such data been
used in dose escalation in no case would patients have been put at
higher risk.
Although pharmacokinetic differences may be the main reason for the
poor inter-species correlation of dose with toxicity for some
compounds, other factors must also be considered. As idicated above
schedule dependency must be excluded. The importance of this arises
from the observation that for drugs with equal clearance values in
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mice and men a bolus dose of equal mg/m will have somewhat
different time courses (Skipper et al 1970). Thus in mice the peak
drug level tends to be higher with a more rapid fall compared to man.
This would lead to greater toxicity in mice if a threshold existed
that was at the limit of the level reached in man. Conversely if
toxicity depended on duration of exposure then effects would be more
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marked in man. This is likely to be the problem with the
antimetabolites. Some indication of schedule dependency can be
obtained from comparison of the single and daily x 5 pre-clinical
toxicology data. If the LD10 values are of the same order then major
schedule dependency can be ruled out.
Differences in target cell sensitivity is another area that could
account for variations in toxicity between mouse and man. However
testing for such differences is difficult and would have to rely on
tissue culture experiments. At present limited testing of marrow
toxicity using a bone marrow progenitor colony inhibition assay is
being evaluated.
Drugs that are metabolised to active compounds may also cause
problems where the metabolite is a major factor in producing
toxicity. Such compounds are unlikely to be suitable for dose
escalation based solely on the AUC of the parent compound.
There are clearly several factors to be taken into account before
opting to employ pharmacological data to guide dose escalation but
once this has been decided upon the procedure is as follows:
(1) Determine mouse LD10
(2) Determine mouse AUC at LD10 and two other doses.
(3) Begin phase I at l/10th mouse LD10
(4) Measure human AUC at the starting dose
(5) Choose escalation strategy based on how close initial human
AUC is to target AUC.
It is important to determine the kinetics in at least three doses
in the mouse in order to detect any evidence of non-linearity which
would make rapid escalations in the subsequent clinical trial
potentially more dangerous. It is also important to ensure that the
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LD10 in the mice used for the pharmacology experiments is similar to
that found during pre-clinical toxicology. Ideally therefore these
mice should be of the same strain. In addition it is desirable that
the pre-clinical and clinical pharmacology should be carried out in
the same laboratory to avoid another potential source of error.
The escalation strategy should attempt to achieve an AUC in
patients of a similar order to that at the LD10 in mice. Thus if the
AUC at the starting dose was well below the target AUC then rapid
early escalations would be indicated. Collins and his colleagues
proposed two methods of escalation. The first, the square root or
geometric mean method, in which the first dose escalation factor is
equal to the square root of the ratio of the AUC at the mouse LD10 to
the AUC at the phase I entry dose. Where there is a large difference
in the AUC at the mouse LD10 and the AUC at the phase I starting dose
as in the example of adriamycin, this method will result in the first
escalation being seven or more x the starting dose. The second scheme
was the more conservative extended factors of two method. This
employs 100% escalations until the range of the target AUC is
reached. Subsequently escalations can be completed using a modified
Fibonacci style series. A combination of these two schemes may
prove to be the most efficient. An initial escalation of the order of
100% would allow the detection of non-linearity in the kinetics. If
the kinetics appeared to be linear more rapid escalations might be
contemplated depending on the difference of the initial AUCs from
thew target AUC.
Several advantages accrue from more efficient dose escalation in
phase I trials. Firstly the patients benefit from having a greater
chance of receiving a potentially therapeutic dose of drug. Secondly
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a great deal of time and resources may also be saved. However this
may be offset by the extent of pre-clinical testing that is carried
out. An exhaustive search for schedule dependency and target cell
sensitivity will be expensive and time consuming and may outweigh any
advantage gained. It is important that any new approach to dose
escalation should be relatively simple and should not incur great
additional expense. The scheme suggested above fulfils these
criteria.
In addition to the above approaches to dose escalation in phase I
studies I felt that a review of the published literature might offer
further insight into the problem. I have therefore researched phase I
trials published since 1970 and there follows an analysis of the
data obtained from this review.
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Phase I Trial Survey
Methods





European Journal of Cancer and Clinical Oncology
Cancer Chemotherapy and Pharmacology
Clinical Oncology
Investigational New Drugs
In addition a literature search was performed on the Mezline data
base to identify any missing trials.
Only the first phase I study performed in nan was included ie
reports of studies of alternative schedules where the starting dose
was based on previous human data were not acceptable. Studies of
biological response modifiers and non-cytotoxic agents eg
differentiating agents were also excluded.
The following information was abstracted from each study, where
this was provided:
The total number of patients treated
The starting dose
The method by which the starting dose was derived
The dose escalation scheme
The escalation point at which toxicity was first noted
The escalation point at which the MTD was reached
The number of escalations to the recommended phase II dose
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The dose limiting toxicity
The number of toxic deaths
The number of responses
The number of patients receiving the dose recommended
for phase II trials.
Results
Sixty-one phase I clinical trials were identified that were
published between January 1971 and June 1986 and which fulfilled the
above criteria. The literature references to these studies are
contained in Appendix II. The number of trials published by year were
as follows:
















As can be seen the majority of the studies that contained
sufficient information for inclusion in this review were conducted
in the second half of this sixteen year period. This is probably due
to the progressive adoption of accepted methods of conducting such
studies and a trend to more uniform reporting of the results. During
the 7 years fran 1977 - 1983 applications were filed with the Food
and Drug Administration in America to conduct investigational
clinical trials with 30 new compounds (Venditti 1983). The present
survey includes data from the trials on 23 of these drugs. Studies on
a further 4 of the drugs could not be used because of non-standard
methodology or insufficient data. It would appear therefore that this
survey includes almost all the drugs that have come through the NCI
screening programme and in addition has picked up most of those from
other sources. Approximately six new compounds per year currently
undergo phase I clinical testing.
Starting Dose
As discussed previously there has been considerable debate as to
the most relevant animal species for arriving at a safe starting dose
in man. This uncertainty is reflected in the methods used in the 61
trials under review. The animals used were:
Table 2 Animal Species used to Determine Starting Dose






13/22 trials relying on mouse data used 1/1Oth LD10 as the starting
dose with the remainder using fractions varying from l/30th to 1/2
LD10. 18/24 trials using information from the dog to calculate the
starting dose used 1/3 Toxic Dose Low.
Table 3 Numbers of Patients Treated at Therapeutic Doses
Number of Trials 61
Total number of patients 2101
Number of patients per trial, median (range) 30 (12-73)
Number of patients in whom no toxicity was seen 610 (29%)
Number per trial with no toxicity, median (range) 10 (0-27)
Number of drugs recommended for phase II testing 54 (87%)
Number of patients in these 54 trials 1873
Number of patients receiving the dose
recommended for phase II :
total 812 (39%)
median, (range) per trial 14 (5-30)
Table 4 Escalation Procedure
Modified Fibonacci series 41 (67%)
100% increments 8 (13%)
25-50% increments 4 (6%)
Fixed dose increments 5 (8%)
Based on animal data 1 (2%)
Dose reduction 2 (3%)
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Table 5 Escalations Required to Reach First Toxic Dose and MTD
All 61 Trials
No. of escalations to 1st toxic dose, median (range) 3 (0-7)
No. of escalations to MTD 7 (0-15)
41 Trials using Fibonacci escalation
No. of escalations to 1st toxic dose 3 (0-7)
No. of escalations to MTD 7 (2-15)
I have estimated the number of escalations that would have been
required to reach the MTD using the 100% increment scheme for the 41
trials employng the Fibonacci series. This was done by using 100%
increments from the starting dose until the first toxic dose was
reached and then 50% increments thereafter.
No. of escalations to MTD with alternative scheme, median 5 (3-8).
Among these 61 drugs there were 4 (6%) where the MTD was less than
5 x the starting dose. This represents the third escalation of the
modified Fibonacci series. These drugs are listed in table 6.
43


























* : n = the starting dose









Pleuropericardial pain 2 "
Haemolysis 1 (2%)
Toxic Deaths
Toxic deaths occurred in 13 trials (21%). There were 23 deaths
recorded representing 1% of all patients treated in the 61 studies.
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Fifty three responses that satisfied the WHO criteria for partial
or complete response were seen in a total of 22 trials. Thus
objective tumour regression occurred in only 3% of all patients
treated but were seen with 36% of the agents tested. There was
insufficient data in the majority of reports to say whether these
responses occurred predominantly in patients who had had previous
chemotherapy or those who had not. The objective responses seen are
listed in table 8. Of the drugs where responses occurred in phase I
testing:
5 are currently undergoing phase II study.
3 have been discarded because of excessive toxicity or lack
activity in phase II.
5 have been licensed for use.
The fate of the remaining nine is at present unknown.
Of the 40 agents where no activity was seen in phase I testing only
one, VP16 213, is currently in routine clinical use. There was thus a
significantly greater chance of a drug entering routine clinical use
if responses were seen in phase I testing (p < 0.01 using Chi Sq test
with one degree of freedom).
Discussion
Several interesting conclusions can be drawn from this survey.
Firstly in only 4 trials (6%) was toxicity seen at the starting dose
and in only one of these was the initial dose subsequently shown to
be the MTD. In all other trials (94%) where no toxicity was seen at
the starting dose for no drug was the MTD less than 5 x the starting
dose. Indeed the median number of escalations to the MTD was 7,
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equivalent to 9 x the starting dose in the modified Fibonacci series.
These data suggest that it would be safe to treat the first patients
at the equivalent of 1/10 Mouse LD10 and if this was entirely
non-toxic to then escalate to 5 x this dose. This information could
be usefully incorporated into the geometric mean dose escalation
schemes proposed by Collins et al (1986) for use with pharmacological
monitoring. In cases where there is a great discrepancy between the
AUG at the mouse LDlO and the AUC at the phase I starting dose this
procedure would produce a first dose escalation which might be 7-10
or more x the starting dose. Such an initial escalation might be
considered hazardous since no data on the linearity of the kinetics
in man would be available. On the other hand the alternative
escalation suggested of 100% increments may be over conservative. The
information from this survey implies that a maximum initial
escalation of 5 x the starting dose (5n) is entirely safe provided no
toxicity occurred at the starting dose. Using the geometric mean
method a 5n escalation would have resulted if the AUC at the starting
dose had been 4% of the target AUC. Thus it would appear safe to use
a 5n escalation providing the starting dose is entirely non-toxic and
the AUC at the starting dose is less than 5% of the target AUC. Once
pharmacokinetic data is obtained at at least two dose levels
subsequent escalations can be modified taking into account the
linearity of the kinetics.
This scheme would miss out 2 early steps on the Fibonacci series
and possibly more later in the trial as kinetic data became available
and would therefore significantly reduce the numbers of patients in
the study and its duration.
The survey also suggests that escalation procedures based on 100%
47
increments are more efficient, reaching the MTD in a median of 2
escalations fewer than the modified Fibonacci method. The greatest
reduction occurs where the MTD is more than 30 x the starting dose.
In these cases the number of escalations may be reduced by up to 50%
by using the 100% scheme.
The range of dose limiting side effects was similar to that seen
in the drugs in routine clinical use apart from a slight excess of
CNS toxicities. This probably reflects the reluctance of physicians
to use such agents unless they are clearly very effective. Perhaps
these drugs should be tested in patients with brain tuirours since is
possible that CNS toxicity indicates high concentrations of drug
reaching the brain.
As might be expected the total number of responses seen in this
survey was very low amounting to 3% of all patients entered. There
are several reasons for this. Firstly a considerble proportion of the
patients entered in phase I trials do not have measurable disease and
therefore by definition a partial response cannot occur (clearly a
complete remission could still be recorded). Information on the
numbers of patients with measurable disease is rarely included in
published reports. The other major factors contributing to the low
response rates are the extent of disease and prior chemotherapy. Most
patients are entered in a phase I trial at a relatively late stage in
their disease and will often have received several chemotherapeutic
agents. Such patients are well known to be unlikely to respond to
further drugs particularly since over 60% are treated at doses below
those subsequently recommended for phase II testing. However
although the actual number of responses was low they occurred
in a relatively high proportion of the studies, 36% (22 trials). Of
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these 22 drugs 5 have been licensed for clinical use (CBDCA,
4-Epiadriamycin, Ifosfanu.de, Cis-Platin, Mitoxantrone) whereas only
one of the 39 drugs in which no activity was seen in phase I is
currently in use, VP16-213. Statistical coirparison of these results
showed that there was a significantly greater chance of a drug
eventually entering routine clinical use if responses were seen in
the phase I trial, p < 0.01. Whether or not this merely reflects the
greater interest stimulated by an apparently effective agent is open
to debate. Estey et al (1986) recently analysed the responses seen in
54 agents introduced into NCI-sponsor ed phase I trials from
1974-1982. Objective responses were reported in 4.2% of patients and
39% received doses greater than or equal to the dose recommended for
phase II, results very similar to those reported above. They went on
to compare the response rates in the phase I and phase II trials of
the 38 drugs completing at least one phase II trial. The median phase
I response rate for those considered active in phase II was 4.3% and
for those considered inactive was 2.7%. This difference was not
statitically significant. These data lend weight to the proposal that
no drug should be withheld frcm phase II purely on the grounds of
inactivity in phase I.
In summary this survey confirms that a high percentage (39%) of
patients in phase I trials are treated at doses with little chance of
any therapeutic activity. These numbers may be reduced by employing
escalation schemes based on 100% increments which appear to be more
efficient than the traditional modified Fibonacci series. In addition
the dose of drugs showing no toxicity at the starting dose can
immediately be escalated to five times this level providing the AUC
at the starting dose is less than 5% of the target AUC with
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rrmsomipnt- further saui nas in time and Dahi enh resources.consequent further savings in time and patient resources.
-
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Numbers of Patients Required In a Phase I Trial
The usual practice is to enter three patients at each non-toxic
dose level (Carter et al 1977, Gottleib 1974, Williams and Carter
1978, Rosencweig et al 1985) . The first patient at each dose level
should be observed for at least three weeks in order to exclude dose
limiting effects at that dose before further patients are entered. It
has also been suggested that six patients should be entered at
doses showing any toxicity. These recommendations have been put
forward in the past to ensure that no harm comes to patients from
rapid dose escalations before a previous dose has been adequately
studied. However I believe that rigid adherence to "rules" such as
those set out above has led to to phase I trials being unnecessarily
slow and involving too many patients at sub-therapeutic doses. In my
view it is unnecessary to study more than two patients at non-toxic
doses. We are not really interested in non-toxic doses in a phase I
trial so why waste time and resources and deny patients the
opportunity of potentially more effective treatment by entering
further patients. A similar argument can be advanced for reducing the
number of patients studied at doses resulting in non-limiting
toxicity. Normally the appearance of nausea and vomiting or WHO
grade 1 haematological toxicity is the first sign that a dose with
demonstrable biological activity has been reached. However
gastrointestinal toxicity is rarely dose limiting and should not in
itself be a barrier to further dose escalation. Grade 1
haematological toxicity is also not dose limiting. Obviously the
worry is that in other patients grade 2 or 3 toxicity might be seen.
However if nothing worse than grade 1 effects occur in 1/3, 2/3 or
even 3/3 patients at any dose level the likelihood of this
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representing the MTD are remote. I would therefore recommend that two
patients are entered at each non-toxic dose level and at levels
producing types of toxicity, eg nausea, vomiting, alopecia, that are
unlikely to be dose limiting. Three patients should be entered at
doses causing grade 1 haematological toxicity and 6-10 patients at
the dose recommended for phase II trials. This would normally be a
dose causing reversible grade 2/3 toxicity.
Although haematological toxicity is dose limiting for the majority
of drugs, renal, hepatic and neurotoxicity may also cause problems.
In such cases it is less easy to be dogmatic regarding numbers of
patients studied and the pace of dose escalation. Renal toxicity is
primarily objective, causing few symptoms in its early stages, and
only becomes limiting if recovery does not occur. In addition it is
often possible to ameliorate the effects by measures such as
hydration (cis-platin) or alkalinisation (methotrexate). If
consistent disturbance of renal function is noted at any dose level
(2/3 or 3/3 patients) that fails to recover, then further patients
should receive the same dose with appropriate hydration procedures
and other measures considered necessary. Further dose escalation
should proceed with circumspection. Hepatic and neurological damage
are less easy to measure. In the case of hepatic toxicity patients
often describe a flu-like syndrome comprising fever, lethargy and
malaise. The severity of these symptoms often correlates with the
degree of disturbance of the transaminases but inter-patient
variation and the similarity of the symptoms to those that are often
present in cancer patients may make determination of the MTD
difficult. Clearly if transaminases do not return to pre-treatment
levels then no further escalations should be undertaken.
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Neurological toxicity in many ways is the most distressing of all
types of toxicity both for the patient and the physician. Peripheral
neuropathy can be disabling and may be permanent. Central effects, if
serious, can preclude further use of a drug. At present there is only
one drug in regular use, Ifosfamide, that results in CNS toxicity in
a significant proportion of patients. Most investigators would agree
that neurotoxicity exceeding WHO grade 1 (transient lethargy) would
be unacceptable for phase II trials unless there was evidence of
excellent therapeutic activity.
In general it is better not to re-enter patients at higher dose
levels. This policy allows a more accurate determination of
cumulative toxicity at any particular dose. Alternatively it can be
argued that intra-patient escalation reduces the numbers of patients
in a trial and allows each patient more chance of receiving a
therapeutic dose. A compromise might be to treat each patient with at
least two courses at any one dose level but thereafter allow
intra-patient escalation first ensuring that all previous toxic
manifestations had resolved.
In summary the requirements for patient entry to a phase I study
should minimise the the number of patients treated at non-toxic and
minimally toxic doses. The majority of patients should be studied at




It is the duty of the physician conducting the trial to ensure that
before entering a phase I study all patients have a clear
understanding of the purpose and limited expectations of the trial.
They should realise that the chances of a therapeutic response are
small and that they may suffer unforseen toxic side effects.
There is much debate as to whether consent should be in written or
verbal form. Some physicians are very much opposed to written consent
arguing that the use of a single explicit explanation may be
inappropriate for some patients. However all patients entered in a
phase I study should receive a similar explanation and be able to
fully understand the trial. Those who cannot ought not to be
included.
In practice it is unlkely that obtaining written consent for phase
I trials would be a problem. If the trial has been properly explained
to the patient and they were assured that whatever happened they
would continue to receive all appropriate supportive care then very
few would refuse to sign a consent form. Moreover in the current
climate of increasing litigation it may be prudent to introduce
formal written consent for new drug trials. However at present the
MRC guidelines require only verbal consent.
The ethics of the structure of the trial should also be considered.
Although a phase I trial is primarily a toxicity study I believe that
it is unethical to treat large numbers of patients at non-toxic and
therefore almost certainly sub-therapeutic doses. Efforts such as
those outlined above to facilitate rapid dose escalation and reduce
patient numbers at each dose level should be pursued. Some might
argue that this will lead to patients being exposed to unacceptable
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risks of dangerous toxicity. However if the trial is properly
conducted this risk should only apply to one patient at most.
Moreover since effective supportive measures exist for the common
life threatening toxicities encountered their effects can be
minimised. It can also be argued that patients experiencing the
highest degree of toxic side effects have the greatest chance of a
therapeutic response. It would seem therefore to be ethically
preferable to use a trial design that enters limited numbers of
patients at low doses and that employs a rapid dose escalation
procedure together with very careful monitoring. A further advantage
of this scheme is that effective agents will move more rapidly into
routine clinical practice. It is surely unethical to withold
potentally effective therapy from patients due to inefficient phase I
procedures.
Whatever the design of a phase I trial it is recommended that
approval for the trial is sought from the local ethical committee.
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The Phase II Trial
The phase II trial represents another vital step in the development
of a new drug. It takes many years and a great deal of expense to
bring a drug to phase II testing but the agent may be discarded in a
few short months eg Triglyceryluridine (TGU), if therapeutic activity
is not demonstrated. It is therefore of the utmost importance that
the design and conduct of phase II trials is correct if active agents
are not to be discarded (false negatives).
Selection of Drugs
In theory all agents that demonstrate tolerable and reproducible
biological effects should proceed to phase II testing. However many
agents do not receive full phase II evaluation for a variety of
reasons (Marsoni et al 1984). These include unmanageable toxicity,
side effects that are not clearly dose dependent and lack of activity
in the phase I trial. Drugs with dose limiting side effects other
than myelosupression are particularly likely to be evaluated
incompletely (Marsoni et al 1984). The reasons for this are likely to
be pragmatic for it is often more difficult and time consuming both
for the patient and physician to undertake phase II studies with
these drugs. Paradoxically there is a great need for such drugs
particularly for use in combination therapy where the addition of
agents with similar toxicities, especially myelotoxicity, is a
problem. Clearly dose limiting toxicity other than bone marrow should
be an incentive rather than a disincentive to phase II testing.
The absence of responses in phase I trials should also not impede
progress to phase II testing. This is true for a number of reasons.
The majority of patients included in phase I trials at present do not
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have evaluable disease and thus cannot be assessed for response. In
addition these patients are usually heavily pre-treated and in the
early stages of the trial receive very small doses. The likelihood
of a response under these circumstances is low.
Thus except for severe unpredictable toxicity there are no good
medical or scientific reasons why a drug's clinical development
should not proceed to phase II testing.
Selection of Diseases
The phase II evaluation of a new drug is essentially a screening
process to determine whether the drug is worthy of further clinical
evaluation in phase III trials. In the 1960s such studies were
conducted on a drug orientated basis with a large number of patients
with different tumour types entered in each trial. However these
trials were wasteful of patient resources and often produced results
that were difficult to interpret principally because of a lack of
information on patient characteristics. It is now recognised that a
more efficient method of evaluating a new drug is to perform a number
of separate trials in a series of selected tumour types. Since it is
rarely possible to test a drug in all the tumour types in which
activity might occur the concept of "signal" tumours has arisen to
allow extrapolation of the results in a small nuirber of trials to
cover the majority of human cancers. A study of the 22 agents that
have come through the NCI screening programme to phase II study since
1975 (Wittes RE et al 1985) has shown that activity occurred only in
acute leukaemias, the lymphomas, small cell lung cancer and carcinoma
of the breast and ovary. In addition all drugs currently marketed for
indications other than chronic myelogenous leukaemia are active in at
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least one of these 5 tumour categories. These five tumours could
form the basis of a phase II clinical screening panel but there are
several problems with this approach. The first is that using a group
of tumours to find drugs active in that group will produce a self
fulfilling prophecy and leave little room for the discovery of novel
agents perhaps with a totally different spectrum of activity. This is
a similar argument to that advanced for the change in pre-clinical
screening discussed previously. In addition as therapy improves for
the panel tumours patients available for inclusion in phase II
studies will become progressively more heavily pre-treated making
meaningful phase II results more difficult to obtain. Moreover as the
techniques for growing human tumour cells in vitro become more
refined it may be possible to predict which tumour types an
individual drug will be active in and thus to target phase II trials
towards these cancers. It would appear therefore that the use of a
panel as a basic minimum for phase II testing is warranted but there
should be room for additional studies possibly based on the known
action of the drug or in vitro testing.
Selection of Patients
It is now appreciated that a number of factors relating to the
disease and the patient population can markedly influence response
rates. The patient's performance status has been shown to have a
large effect on survival in lung cancer (Zelen, 1974) and on response
rate in colon cancer (Moertel et al 1974). Patients with a poor
performance status are often unable to tolerate full doses of
chemotherapy and are more likely to develop serious toxicity which in
part accounts for the negative effect on response and survival. In
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addition these patients are likely to have a large tumour burden and
therefore there is a greater chance of resistant cell lines being
present (Goldie et al 1982) which again will reduce the response
rate.
The extent of prior chemotherapy also has a major bearing on the
outcome of a phase II trial. Heavy pretreatment affects the objective
response rate in both solid tumours (Mathe 1973, Wittes 1985) and
hamatological malignancies (Frei et al 1973). Again such patients are
less likely to tolerate full dose chemotherapy and are at high risk
of having developed resistant lines.
When a drug enters phase II trials it should be tested in that
patient group which is most likely to show a favourable effect
provided it is ethically permissible to do so. This criterion is best
fulfilled by patients with maximum performance status, minimum extent
of disease and minimum prior chemotherapy. That which is judged to be
ethically permissible may vary from centre to centre depending on the
viewpoint of individual clinicians. For example sore may wish to
exhaust all the available active drugs in breast cancer before using
phase II agents while others may believe they can be used after
failure of a single front line combination. It is clear however that
if active agents are not to be lost through poor patient selection,
the clinicians involved in phase II trials must be prepared to use
new agents much earlier in the course of many diseases than has been
the practice. Thus most clinicians would agree that in the majority
of solid tumours eg, colon, non-small cell lung and melanoma only
patients who have not received prior chemotherapy should be entered
in trials. Moreover there is a case for using untreated patients in
certain sub-groups of responsive cancers. Thus the prognosis of
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patients with extensive small cell lung cancer, stage IV ovarian
carcinoma and slowly progressive breast cancer will probably not be
altered by the primary use of a new agent. Careful monitoring of the
trial with a design allowing early change to a standard regimen in
the event of progression should be acceptable to most clinicians.
It is also important that patients entered in phase II trials
should have measurable disease otherwise the response rate cannot be
determined and the trial will be meaningless. This may seem obvious
but for many tumours measurement presents a major problem. For
example in lung cancer many patients have masses arising from the
mediastinum which cannot be accurately assessed unless prior normal
X-rays are available. Prostatic cancer metastases occur largely in
bone and are notoriously difficult to measure as are tumours normally
confined to the abdominal cavity such as ovarian, pancreas and
gastric carcinoma. The more widespread availability of CT scanning
and the promise of NMR scanning may in future help to overcome some
of these problems.
The use of survival as an end point for phase II studies has been
entertained but there are a number of problems with this. Firstly it
is difficult to standardise the time from when survival should be
assessed. There are several options here. Some would argue that it
should be from the date of starting therapy but different clinicians
tend to start therapy at different stages in the natural history of a
tumour and thus merely starting a drug earlier might give a false
impression of activity. For an individual tumour type survival might
therefore be assessed from the date of diagnosis but this would have
to be closely linked to the stage of the disease since as we have
seen tumour burden has a considerable influence on the chance of a
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response and survival. A further problem with the use of survival as
an end point is the influence of other therapies on the outcome. To
enable valid conclusions to be drawn all patients in the trial would
have to be treated in a similar fashion following relapse or
progression. One way of overcoming this problem would be to
incorporate a crossover treatment arm in the protocol design. This
would help to avoid some of the heterogeneity of subsequent therapy.
Statistical Aspects of Phase II Trials
The main statistical problems involved in phase II trials are
concerned with determining the true response rate of a new agent.
There are two main types of error that can occur, false positives and
false negatives. These two types of error can be controlled and
therfore we must decide which is more important to minimise. Many
believe the false negative result to be the more serious error
(Williams and Carter 1978) since it may discourage further use of an
effective agent and waste a great deal of pre-clinical and phase I
effort. On the other hand false positive results will be discovered
and rectified at a later date through additional trials.
The false positive and false negative errors can be related to type
I and type II errors in statistical hypothesis testing (Colton 1974).
Thus a type I error, rejecting the null hypothesis when true, is
equivalent to a false positive error, and a type II error, accepting
the null hypothesis when false, is equivalent to a false negative
error. The power of the hypothesis test is the probability that the
null hypothesis is rejected for a given response rate under the
alternative hypothesis. The power may be computed for any given
response rate under the alternatve hypothesis (ie that the drug is
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effective). Thus the significance level of a hypothesis test is
equivalent to the probability of a false positive error and the
complement of the power of the test is equivalent to the probability
of a false negative error.
The greater the sample size the greater the precision in the
estimation of the response rate and the smaller the probability of a
false negative result. Biostatisticians can compute the minimum
sanple size requirement according to investigator specifications for
precision and false positive and false negative error probabilities.
Several different trial designs can be used.
Single Stage Design
In a single stage design the activity of the new agent is assessed
on a pre-determined fixed sanple size regardless of results in the
early part of the trial. To determine the minimum sample size the
investigators must specify the minimum acceptable response rate, the
maximally tolerated coefficient of variation for this response rate,
the maximally tolerated significance level for rejection of the null
hypothesis and the minimally tolerated power against a false negative
error. This generally requires a sample size of 20-30 to detect a
response rate of 20-30% with a coefficient of variation of 30%, a
significance level of 5% and a power of 0.80.
Thus if a drug produced a response rate of greater than 20% under
these conditions there would be a 95% probability that the result was




In recent years investigators have become aware of the need for
early termination of phase II trials for ethical reasons when early
data tend to indicate that the treatment is ineffective or to report
results if it appears particularly promising. One method for
achieving early termination is to use a sequential design. In such a
case there is no fixed sarrple size and investigators decide after
each patient is entered whether to continue with the trial. The
methodology allows for control of overall false positive and false
negative error probabilities but there are several problems in the
context of cancer therapy (Byar et al 1976, Pocock 1977). The main
dravfoacks are the administrative burdens of maintaining a constant
vigil over the data and delays between patient entry and response
determination. A compromise between the strictly sequential and the
single stage design is the multi-stage design. Patients are entered
in batches of predetermined size and a decision is made to continue
the trial after each batch depending on the number of responding
patients observed up to that point. Multi-stage methods allow for
control of overall false positive and false negative error rates. A
number of different multi-stage designs have been proposed (Schultz
et al 1973, Fleming 1982, Herson 1979, Pocock 1977, Sylveter and
Staquet 1977, Elashoff and Beal 1976, Lee et al 1979) however the
most widely used has been that based on Gehan's rule (Gehan 1961). In
this scheme the trial is discontinued if no responses are seen in a
preliminary sample of n^ patients. If at least one response
occurs in the preliminary sample an additional n2 patients are
entered. The size of the preliminary sample n^ is determined by
the specified significance level for the hypothesis test and n2
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represents the number of additional patients needed to estimate the
response rate with the required precision.
A two stage design based on these principles is currently employed
by the EORTC and the CRC for phase II studies of new Chemotherapeutic
agents. An initial sample size of 14 patients is studied. If there
are no responses in this group the trial is stopped. The additional
sample size, n^, depends on the number of responses in the first
14 patients. The number of additional patients is calculated so that
the standard error of the observed response rate will be less than or
equal to 0.10. :





4 or more 11
This scheme ensures that if the drug is active in 20% or more of
patients the chance of erroneously rejecting the drug after the
first 14 patients is 0.044. and provides an efficient method of early
termination for ineffective drugs.
Randomised Phase II Trials
A phase II design that compares the response rate and toxicity of
two or more new agents in a particular tumour has been proposed
(Simon et al 1985). Such a design can have a number of advantages.
Where phase II trials are being conducted on a multi-centre basis,
randomisation helps to ensure that all patients are registered before
treatment starts. This is essential for checking patient eligibility,
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and terminating accrual when sufficient patients have been entered. A
further advantage of this design is that is that differences in
activity and toxicity between agents are more likely to be real
rather than reflecting differences in patient selection and response
evaluation between institutions. In order to undertake a randomised
phase II trial two conditions must be satisfied. Firstly patient
accrual should be rapid and secondly two or more drugs must be
available for testing. With the current pace of new drug development
it is unusual for drugs to become available for phase II trials
simultaneously and this may prove to be the limiting factor in the
widespread adoption of the randomised design. However this
methodology is also applicable to the study of different schedules of
the same drug and its use in this setting is particularly attractive.
In determining sample sizes for randomised phase II trials direct
methods of statistical ranking and selection theory are useful
(Gibbons et al 1977). With the statistical selection theory
criterion, one always selects for further study the treatment with
greatest response rate (or lowest toxicty), regardless of how small
or "non-significant" its advantage over the other treatments appears
to be. Conventional statistical designs used in clinical research
select a treatment as superior only when the data are incompatible
with the hypothesis that the treatments are equivalent and thus
require much larger sample sizes than selection theory designs which




The quality of the response data generated by a phase II trial will
depend on the trial design, careful patient selection and strict
adherence to the protocol.
A major problem lies in assessment of response. Even when a
standard method for calculating tumour size is used there can be a
wide inter and intra-physician variation. This was clearly shown by
Moertel and Hanley (1976). This study was designed to simulate the
conditions encountered in oncological practice when measuring tumours
in the abdomen, lymph nodes and subcutaneous tissues. Sixteen
experienced oncologists each measured 12 simulated masses composed of
solid spheres with diameters ranging from 1.8-14.5cm. The oncologists
deviated in their measurements with a range of 3.4-33.6%. Two of the
spheres were of the same size. Using data from the assessment of the
size of these spheres Moertel and Hanley calculated that false
positive regressions of greater that 25% occurred in 24.9% of cases
and of greater than 50% in 6.8% of cases. On the other hand false
negative progression of greater than 25% occurred in 31.5% and of
greater than 50% in 17.8%. This study was conducted under ideal
conditions and larger error rates can be anticipated in the clinic
when pain and the site of the mass often make measurement more
difficult. Such errors may be compounded by an unconscious bias of
investigators to choose on the positive side when assessing response.
Thus despite carefully stated criteria in the protocol for
determining responses there may be a significant error in the
eventual numerator (number of responses).
In addition to problems with the reliability of the numerator the
denominator (the total number of patients at risk) may also be
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altered by the exclusion of "non-evaluable" patients from the
analysis. The major reasons for declaring a patient non-evaluable
are:
1. Early death
2. Lost to follow-up
3. Failure to complete therapy due to toxicity
4. Refused further therapy
5. Inadequate data
6. Major protocol violation
The largest category is normally those patients who die following a
single course of treatment or who have become too ill to tolerate
further therapy. If it is known that the deterioration or death is
not due to drug toxicity then clearly most early deaths or
progressions represent treatment failures. Despite this there has
been a great deal of debate as to whether such patients should be
included in the analysis of the trial. In practice if protocol
stipualations for patient eligibility in terms of life expectancy and
performance status are strictly adhered to the number of
non-evaluable patients should be greatly reduced. The use of an
eligibility check list can be of value in helping to concentrate
investigators minds. Such a list should be completed before the
patient receives any treatment and is most effectve if administered
by some third party eg the hospital pharmacy or the data centre.
Unfortunately it is a fact of life that investigators often have to
be protected from themselves from entering ineligible or borderline
patients. Under these circumstances the only valid reason for
removing a patient is a major protocol violation such as the wrong
dose of drug.
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Reports of results of cancer treatment should include:
1. Total number registered
2. Total evaluable
3. Comprehensive details of reasons for non-evaluability
If this is done rigorously for all trials then readers would be
able to critically assess the stated response rates and comparisons
of different results in the literature would be more valid.
Tumour Measurement
It is now generally agreed that two categories of tumour are
acceptable for assessing response to therapy. These have been
labelled Measurable and Evaluable.
1. Measurable
Tumours that are measurable can be accurately measured in two
perpendicular diameters. These include superficial lymph nodes,
subcutaneous masses and pulmonary metastases completely
surrounded by aerated lung tissue.
2. Evaluable
Tumours that can only be measured accurately in one diameter are
considered to be evaluable. This group includes most palpable
abdominal masses and pulmonary metastases that are incompletely
surrounded by aerated lung. Disease in some difficult sites that
is measured in a particular specified way is also said to be
evaluable eg:
Hepatomegally - the sum of three measurements from the xiphoid
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and both mid-clavicular lines to the liver edge.
Should be accompanied by scan or biopsy evidence
of liver involvement.
Mediastinal or hilar mass - These can only be accurately
assessed when a pre-involvement X-ray is
available for comparison.
Not Measurable or Evaluable
Certain types of tumour involvement are now known to be so
difficult to assess accurately that their measurement cannot be
accepted as a reliable indicator of response. Principal amongst these
is bone disease. This makes trials in patients with metastatic
prostatic carcinoma very difficult to perform and excludes a
significant number of breast cancer patients from study.
Lung cancer is another common malignancy that can be difficult to
assess. This is particularly true of non-small cell tumours where
patients often have mediastinal lesions complicated by partial
collapse of distal lung segments. Due to the absence of a high rate
of complete remission in this disease response judgements can be
almost impossible. Other difficult sites include lymphangitic
pulmonary metastases, pleural effusions and ascites.
Lesions that have previously been irradiated are also considered to
be not evaluable. This is because they may undergo a slow response to
radiation and thus give a false impression of response to subsequent
chemotherapy. Alternatively the altered blood supply to irradiated
areas may not allow adequate perfusion of the tumour and reduce the
chance of a response.
Patients often have a combination of evaluable and inevaluable
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disease. When this occurs it is important to estimate the percentage
of the tumour burden that is not evaluable and include an overall
assessment of whether this disease is progressing, regressing or
remaining static.
Categories of Response
The guidelines proposed by the Breast Cancer Task Force in the USA
(Hoogstraten et al 1977), those proposed by the UICC project (Hayward
et al 1979) and the report by Miller et al (1981) and the WHO
guidelines (1979) form the basis of the response criteria in general
use today.
Coirplete Response
Complete disappearance of all known disease. All abnormal X-rays
and scans must have returned to normal. For the reasons mentioned
above it is virtually impossible to define a remission in bone
disease and for this reason complex definitions involving sclerosis
and isotope scan appearances are no longer considered appropriate.
The mediastinum also represents an area where it is difficult to
assess whether or not a corrplete remission has occurred. This problem
often occurs in patients treated for Hodgkins disease who had massive
mediastinal disease at presentation. Short of biopsy the only way of
resolving this problem is to wait and see if subsequent relapse
occurs. With the advent of more sophisticated investigations such as
CT scanning and NMR the numbers of patients with residual minor
abnormalities will increase. This problem of when is a CR a CR will
remain difficult to resolve as long as the imaging techniques
available cannot distiguish between tumour and normal tissue.
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Under certain circumstances eg testicular teratomas and ovarian
cancer it may be advantageous to obtain histological confirmation of
complete remission. This is only justifiable when further treatment
is available that will influence the prognosis. Patients with a
biopsy proven CR are said to be in pathological complete remission.
Unfortunately a complete response is not synonymous with cure.
Indeed virtually all patients with breast cancer who obtain a CR and
most of those with lung cancer will eventually relapse and die from
their disease. However since without a complete response there is no
prospect of cure the erradication of all detectable tumour remains
the main aim of oncologists, with progressive extension of the
durability of the CRs the ultimate goal. At present a CR must last a
minimum of four weeks.
Partial Response
At least a 50% reduction in the sum of the products of all
measurable lesions + the sum of the diameters of all evaluable
lesions. If non-evaluable disease represents the bulk of the tumour
burden then there should also be a subjective improvement in these
lesions. If non-evaluable disease is a minor feature it should have
remained static. No lesion may have progressed and no new lesions
appeared. A partial response must last at least four weeks.
No Change
No significant change in measurable or evaluable disease for at
least four weeks (defined as less than 50% decrease and less
than 25% increase in the dimensions of any single evaluable or
measurable lesion). In addition no new lesions must have appeared.
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Progression
At least 25% increase in the measurements of any single measurable
or evaluable lesion or the appearance of a new lesion. If
non-evaluable disease clearly progresses while evaluable lesions do
not then this must obviously be coded as a progression.
Duration of Response
In estimating the duration of a respose the main difficulty lies in
deciding when the response began rather than when progression
occurred. Some authors have used the time that the criteria for a
response are first fulfilled (Hoogstraten et al 1977) while others
suggest that a response begins as soon as treatment starts and
therefore use date of commencement of therapy. The WHO compromised
and defined the onset of a complete response as the date when it was
first recorded but used the first day of treatment as the onset for
partial response. This is the method most widely used today.
Assessment of Treatment Toxicity
A phase I trial is primarily a clinical toxicity study and thus
accurate assessment of toxicity is of vital importance. In addition
the further characterisation of the side effects of a particular drug
forms an important part of the work in a phase II trial. The
information gained from these studies allows investigators to
determine the correct dose and schedule of a drug and how best it
might be combined with other therapies. In cancer treatment the
acceptable level of toxicity generally depends on the likely benefit.
For example one is more ready to accept potentially life threatening
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side effects if there is an opportunity for cure in an otherwise
uniformly fatal condition whereas if palliation of symptoms is the
best possible result then the level of acceptable toxicity is much
lower.
The severity of toxicity at a particular dose of a drug will
largely depend on the type of patients treated. Patients who are
older, have a low performance status or who have received prior
chemotherapy or extensive radiotherapy tend to experience more severe
toxic effects than younger, fitter patients who have had minimal or
no prior treatment. Thus in assessing toxicity it is important first
to define the characteristics of the patient population.
Acute Toxicity
The majority of toxic effects produced by chemotherapeutic agents
are acute or sub-acute in nature. Since patients are normally seen at
frequent intervals in phase I and II studies a great deal of data is
collected. In order to allow more convenient management of the data
together with computerised storage and analysis there has been much
effort directed towards numerical toxicity grading systems. An
additional benefit of the use of a standardised grading system is
that results from different centres may be more readily compared.
Unfortunately there are a number of such grading systems in current
use and the variations in grades for certain important toxicities was
pointed out in an analysis by Vietti (1980). Thus in an attempt to
standardise the reporting of the results of cancer treatment the
World Health Organisation convened two meetings in 1978 and 1979 the
results of which have been published (WHO 1979). The WHO system for
toxicity grading is now the most widely used and it demonstrates
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several usefull features. Firstly there are no vague clinical terms
such as mild or moderate. Instead wherever possible specific
objective statements are used. The aim of this is to reduce observer
error as far as possible. In addition a number of parameters such as
biochemical values are assigned grades according to multiples of the
normal range. This is intended to facilitate comparisons between
results from different laboratories.
There are also drawbacks to toxicity grading scales. The most
important of these is that they measure only the severity of the side
effects and take no account of time of onset or duration. This may be
of particular importance in relation to neutropenia. A neutrophil
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count below 1x10 /I may be of little importance if it lasts only
4-5 days but may result in serious infections if it continues for 2-3
weeks. An area where toxicity grading has been especially difficult
is nausea and vomiting. There are a number of problems with the
grading of this toxicity. The first is once again that there is no
room for assessment of duration of the vomiting. The second is the
problem of giving anti-nausea therapy. The administration of any
such therapy immediately increases the WHO grade to 3. However most
cancer patients, particularly those who have received previous
treatment, know very well that chemotherapy causes nausea and
vomiting and request prophylactic medication. Putting all patients
who receive prophylactic anti-nausea agents into grade 3 is likely to
overestimate the degree of these effects. A further problem is
whether nausea is indeed less severe than vomiting. Many patients
will say that prolonged nausea is a much worse symptom than one or
two episodes of vomiting unaccompanied by nausea. Since these are
such common side effects it might be better to separate them with one
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grade for nausea and another for vomiting. In addition a more
appropriate grading system might be based on duration eg.
Grade Duration
0 - none




The section could be preceeded by a yes/no box for antiemetic
therapy and the subsequent grade interpreted taking this into
consideration. We must be very careful however not to make grading
too complex since it will then begin to lose its value as a more
easily handled form of data. It is also important that
oncologists continue to report their results according to a uniform
system. This does not preclude individual groups experimenting with
changes so that when the WHO reconvenes to discuss the reporting of
cancer treatment their toxicity grading system can be improved.
Chronic and Late Toxicities
Because of the nature of early clinical trials chronic or late
toxic effects are rarely detected at this stage of drug development.
Such toxicities come to the attention of investigators after
extensive experience with a drug in phase III studies and may only
become evident once a significant number of patients have been cured
using a regimen including the drug. As the numbers of long term
survivors increases the problem of late effects also becomes more
important. There has been considerable interest in the sequelae of
the treatment of childhood leukaemia particularly in relationship to
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effects on growth and intellectual impairment. The major late side
effects of the treatment of adult cancer are infertility and the risk
of inducing a second malignancy.
Chronic and late toxicities are the price we have to pay for curing
or inducing long term remissions in patients with otherwise rapidly
fatal conditions. However by the manipulation of chemotherapeutic
regimens it should be possible to minimise these effects eg there is
a suggestion that the use of ABVD rather than MOPP may allow patients
to be treated for Hodgkins disease with reduced likelihood of
infertility and the development of second malignancy (Bonadonna et
al, 1984). Continued research is necessary to reduce as far as
possible the long term morbidity of chemotherapy.
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High Performance Liquid Chromatography
The science of pharmacokinetics depends on an ability to detect and
quantify drugs and their metabolites in biological samples. In order
to do this the compounds of interest must be separated from the other
constituents of the sample and then passed through an appropriate
detection system. Over the past 40 years chromatography has emerged
as the most flexible and efficient method of achieving such
separation.
Although chromatographic-like processes occur in nature eg the
migration of solutions through soils, clays and porous rocks, their
value was not recognised until the 19th century. In 1850 a German
chemist, Runge, developed methods for testing dyes and bleaches
produced from coal tars. He demonstrated the conposition of dye
colours by spotting the mixtures on to special paper producing colour
separations. However Runge and others could not explain the processes
involved in the separation and it was some 50 years before the
Russian scientist Tswett described the underlying principles and
coined the term chromatography.
Tswett separated pigments from a plant extract by washing a sample
of the extract through a column of chalk. He observed coloured bands
moving down the column as solvent was passed through and because of
this he described the method as chromatography (from the Greek
for colour - chroma, and write - graphein). Tswett stated that,
"Chromatography is a method in which the components of a mixture are
separated on an adsorbent column in a flowing system". Recently the
International Union of Pure and Applied Chemistry (IUPAC) has
defined chromatography as: "A method used primarily for the
separation of the components of a sample, in which the components are
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distributed between two phases, one of which is stationary and the
other moves. The stationary phase may be a solid or a liquid
supported on a solid or a gel. The stationary phase may be packed in
a column, spread in a layer, or distributed as a film etc; in these
definitions chromatographic bed is used as a general term to denote
any of the different forms in which the stationary phase may be used.
The mobile phase may be gaseous or liquid." (IUPAC, 1974).
Liquid chromatography (LC) is the generic name used to describe any
chromatographic procedure in which the mobile phase is a liquid and
includes paper chromatography, thin-layer chromatography (TLC)
and variants of traditional column chromatography. In the latter
solvent is gravity fed on to a column of large particles (150-250nm)
and the components of the mixtures are then carried through the
packed column with the passage of the eluent. Separation is achieved
by differential distribution of the sample components between the
stationary and mobile phases. However classical liquid chromatography
suffers from a number of disadvantages:
(1) Column packing is tedious and columns are often used
only once.
(2) The efficiency of large particle columns is low and
analysis times lengthy.
(3) Detection of eluent solutes is by labour intensive manual
analysis.
Thin layer chromatography offered an answer to some of the above
problems but automation is difficult and the procedure therefore slow
and not always easily reproducible. The development of gas-liquid
chromatography in the early 1950s overcame many of the problems of LC
and TLC. This technique relies on each of the components of a sample
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having an appreciable vapour pressure at the operating temperature of
the column. Glass or metal columns are packed with a material such as
PTFE which is coated with the stationary phase. The stationary phase
must be thermally unreactive and non-volatile and materials such as
methyl silicone are normally used. The sample is carried down the
column by an inert gas eg nitrogen or helium and the separation
processes involves an equilibrium being established by the solute
between the stationary and mobile phases. The partition coefficient
involved depends on solute vapour pressure and the thermodynamic
properties of the bulk solute. The component with the longer
retention time will have the higher heat of solution in the
stationary phase. Altering the amounts of stationary phase on the
column and the operating temperature will alter retention times.
Detectors used with GC columns include flame ionisaticn, nitrogen
phosphorous and electron capture. The principle limitation of GC is
volatility of the sample and although this can be overcome in many
cases by conversion of solutes to suitable volatile derivatives there
remain a large number of compounds, notably many drugs and proteins,
that cannot be analysed by GC.
The key to improving column efficiencies in LC lay in increasing
the rate of mass transfer and equlilibration of solute molecules
between the mobile and stationary phases. This was eventually
achieved by using much smaller particle sizes and increasing the
pressure drop across the column. Such changes required the
concomitant development of equipment capable of delivering and
withstanding such pressures and detectors of greater sensitivity.
Thus it was not until the late 60s that Horvath et al (1967)
constructed one of the first practical HPLC systems for use in their
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work on nucleotides. Over the past 15 years HPLC has become firmly
established as the most widely used of chromatographic techniques. It
is not limited by conponent volatility or thermal stability and in
addition many HPLC detectors are non-destructive allowing the
opportunity for sample recovery for subsequent spectroanalytical
analysis.








Of these various modes partition chroiratography has emerged as the
most widely applicable technique. Classical liquid-liquid partition
chromatography was limited mainly by the problem of the stationary
solvent stripping off the packing material however this was overcome
by the development of packing materials where the stationary phase is
chemically bonded or organo-bonded to an insoluble matrix. The most
corrmon stationary phase is octadecylsilane (ODS) which is bonded to
a silica support. The ODS reacts with silanol groups on the surface
of the silica producing a stable siloxane (Si-O-Si) linkage. Residual
silanol groups are able to adsorb molecules and therefore interfere
with the separation characteristics of the bonded phase. These sites
may therefore be "capped" using trimethylsilyl chloride. The
advantage of such supports is the stability of the siloxane linkages
to column inlet pressures and hydrolysis thus allowing use of
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solvents at up to 6000psi in the pH range 2.0-8.5.
The bound organic moiety is usually a straight chain hydrocarbon
which imparts a hydrophobic character to the silica surface. Aqueous
eluents are generally used with such stationary phases for the
separation of substances encompassing a very wide range of polarity
and molecular size. This technique is termed reverse phase
chromatography. The hydrophobic ligates provide a "soft" nonpolar
surface for eluite retention and also protect the support from
degradation by contact with aqueous elements.
There are three types of bonded phase depending on the
characteristics of the the organic moiety that is bound to the silica
surface: polar, nonpolar and ion exchange.
Chromatography utilising a polar bonded phase has been termed
"normal phase" to differentiate it from reverse phase HPLC. Columns
with a glycerol type function attached to a large pore silica can be
used in size exclusion of biopolymers and other water soluble
polymers.
Bonded phases with fixed ionic functions such as amino and sulfonic
acid groups attached to the surface via an organic moiety are used as
anion and cation exchangers respectively in ion-exchange
chromatography. These columns are useful for the separation of large
organic molecules
Bonded-phases can be quite simply packed into HPLC columns to give
efficiencies of up to 20,000 theoretical plates per 25cm if the 5um
particle size is used. The larger particle size materials give
proportionally smaller numbers of theoretical plates and consequent
reduction in the resolution power of the column. Columns are packed
using a slurry packing procedure with methanol, isopropanol or
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methyl-iodide/methanol as the slurrying liquid. The slurry is driven
into the column at pressures of up to 10,0001b/sqin using hexane.
After packing the column is conditioned to accept eluent. For normal
phase chromatography more hexane is used while for reverse phase
chromatography mthanol is used to remove the hexane.
Reversed Phase Chromatography
Reversed phase chromatography is a branch of HPLC that employs
hydrocarbonaceous bonded phases such as octadecyl-silica in
conjunction with a water/organic mobile phase. The origins of
reversed phase chromatography date back to Howard and Martin (1950).
They treated kieselguhr with dimethyldichlorosilane vapor. With the
non-polar porous support thus obtained they used for the first time a
non-polar liquid such as paraffin oil or octane as the liquid
stationary phase in conjunction with a polar eluent such as
methanol-water. This chromatographic system was the reverse of
conventional systems in terms of phase polarity and retention order.
In reversed phase HPLC the polarity of the mobile phase is higher
than that of the stationary phase. Non-polar solutes will tend to be
retained on the column and their retention times will increase
as the chain length of the bonded-phase increases. Longer solute
retention generally enhances resolution and thus varying the chain
lengths of the bonded phase is a further aid to optimizing the
resolution. Conversely polar solutes are usually separated better on
short chain alkyl phases. The percentage carbon loading (chain
length) is not however as important a consideration as the percentage
coverage of the silica. As noted above residual silanol groups and
their adsorption effects can cause tailing of the peak and thus it is
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preferable to use a reverse phase packing with a high percentage
coverage or one in which the residual silanol groups have been
treated with trimethylsilyl chloride.
It is the very broad range of eluent strength together with the
employment of specific solvent effects that is responsible for the
wide scope of the technique. In general the lower the polarity the
higher the "strength" of the eluent under a given set of conditions.
In most cases water-methanol and water-acetonitrile mixtures are used
and the strength of such eluents increases dramatically with the
concentration of the organic phase. It is advisable to use a buffer
in the eluent in order to maintain an ionic strength greater than
0.01 and a constant pH when ionogenic substances are chromatographed.
Hie Mobile Phase
The mechanism of solute retention on bonded-phase materials is not
fully understood, but the organo-bonded layer may be considered to
act as a thin film of fluid. In reverse phase HPLC water is used as
the base solvent. The eluent "strength" is adjusted by using organic
modifiers usually methanol or acetonitrile.
The use of polar solvents as the mobile phase is as much a
characteristic feature of reversed phase chromatography as that of
non-polar bonded stationary phases. The ideal eluent which is
compatible with the materials used in the chrorratograph and the
column has low viscosity and high optical transparency at low
wavelengths and the appropriate chemical properties as far as solvent
power and elutropic strength are concerned. Low viscosity combined
with high UV transparency make acetonitrile, methanol and
tetrahydrofuran the most popular organic solvents. Most experimental
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situations require an eluent that is stronger than water but weaker
than methanol or acetonitrile. Such eluents can be obtained by mixing
an organic solvent with water so that a very wide range of eluent
strength can be obtained.
Highly polar and ionisable molecules such as acids have a high
affinity for aqueous eluents and wash through the column without
being retained at all by the packing material. Modifications can
however be made to the technique to allow even highly dissociated
molecules to be successfully chromatographed by BPC. This has been
achieved by using ODS-silica materials with aqueous buffer solutions
containing no organic modifier. Solute retention is influenced by
eluent pH which controls the degree of dissociation of the solute and
hence its partition between the bonded organo-phase and the aqueous
mobile phase. Non-ionisable compounds show little change in retention
with variation in pH. The ion-suppression technique can be used for
the analysis of weak acids or bases. For the analysis of acidic
compounds small amounts of acetic or phosphoric acid are added to the
mobile phase. By reducing the pH dissociation of the sample molecules
is suppressed and they thus have decreased affinity for the eluent
and are retained to a greater degree by the ODS phase. The range of
BPC is considerably extended using techniques such as ionic




A liquid chromatographic detector is a device for continuously
locating the presence of solutes in a flowing liquid eluate coming
from a chromatographic column. The electrical signal from the
detector should be proportional to the concentration or mass of the
solute emerging from the column. Most of the commercial detectors
available produce a signal that is proportional to the concentration
of the solute and give a linear response over a wide concentration
range.
Fluorescence Detectors
Many compounds display the property of luminescence, that is, when
they are irradiated with light in the UV region of the spectrum they
undergo electronic excitation and emit light of a higher wavelength,
either instantaneouly (fluorescence) or after sane finite time delay
(phosphorescence). In most cases the fraction of the absorbed energy
that is re-emitted (known as the quantum efficiency) is rather low,
but for a few compounds values of 0.1-1.0 are obtained and these
compounds are suitable for fluorescence detection. A valuable feature
of the fluorescence phenomenon is that the irradiating light can be
filtered out so that the photometer only measures the emitted light
and thus the fluorescence signal starts virtually from zero
intensity. In contrast other photometric detectors such as the UV
absorbance detector rely on measuring small differences between the
light attenuated by the sample and that transmitted by the eluent.
To obtain the maximum signal to noise ratio with fluorescence
detectors it is essential to ensure that the eluent has a low
background fluorescence and that its composition is conducive to
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giving the highest quantum yield for the compound of interest. For
example some compounds only fluoresce well in non-aqueous solutions,
others at certain pH ranges in aqueous solutions etc. The light
source in most conmercial fluorimeters is a xenon arc which provides
a continuum over the the UV range of interest. Excitation filters are
used to allow single wavelength bands to irradiate the photometric
cell and emission filters to filter out all but the light of
interest.
Fluorescence detection is unfortunately the least widely applicable
of all the detection methods for few compounds display quantum yields
of the required magnitude. It is sometimes possible however to impart
fluorescence to compounds by coupling with fluorigenic agents.
Electrochemical Detectors
Monitoring by this principle is only possible when the compound of
interest is electrochemically active under the experimental
conditions used and the eluent has sufficient conductivity. In
general it is only those compounds which can readily undergo
oxidation at the electrode surface that are conveniently detectable.
This is because electrochemical reduction in aqueous solution is
complicated by high background currents generated by the presence of
dissolved oxygen, hydrogen and trace metal cations all of which
undergo reduction. Thus amines and phenols frequently occur as
detected species whereas nitro-containing compounds do not.
In an electrochemical detector the eluent flows through a cell to
which a potential is applied. This potential generates a background
current from the eluent and the current increases if the solute
undergoes oxidation or reduction as it passes through the detector.
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The magnitude of the response obtained depends on the cell design,
the chemical properties of the solute, the solute concentration, the
applied potential and the eluent composition.
The most successful material for the working electrode of HPLC
detectors has been glassy carbon. This is a pyrolytically prepared
form of carbon that combines electrical conductivity with low
chemical reactivity and the ability to accept a highly polished
surface. This latter feature is important since it allows a rapid
flow of solvent across the face of the working electrode thus
preventing build up of electrochemical products.
UV Absorbance Detectors
Chromatographic monitoring by measuring the UV absorbance of the
eluate is the most popular HPLC detection method. The principle of
the procedure is that the light absorbance of a solution in a cell
of fixed length is directly related to the concentration of the
absorbing species. The Beer-Lambert law applies:
loglo/l = abc = absorbance
where a = molar absorptivity or molar extinction coefficient
b = the path length of the cell
c = concentration of the absorbing species
Io = the intensity of the incident light
I = the intensity of the transmitted light
The measurement of absorbance requires the sensing of the
difference between the levels of incident and emitted light intensity
with considerable accuracy. Variable wavelegth detectors use a
deuterium lamp which provides a continuous band of emitted light over
the range 180-400nm. The operating wavelength is selected by means of
a manually operated grating monochromator.
87
Mass Spectrometric Detectors
Mass spectrometers can be coupled to a liquid chromatograph to
obtain spectral identification of a specific conpond. However due to
the comparitively large volumes of eluate and solvent the technique
is difficult and more applicable to gas chromatography.
IR Absorbance Detectors
These operate in an anaiagous manner to UV absorbance detectors
over the region of 2.5-14.5um. Water must generally be absent from
eluents for use with IR detectors.
Refractive Index Detectors
Refractive index detectors operate by measuring the difference in
refractive index between the eluent and the solvent modified eluent.
The type of response therefore is very dependent on the choice of
solvent. All RI detectors are highly sensitive to temperature changes
and hence thermostatic control is essential for operation at the most
sensitive range for these detectors.
Mass Detectors
This type of detector utilises a novel principle. The eluate is
nebulised and carried by an air stream through a heated column in
which the solvent vaporizes and a fine mist of solute particles is
formed. The suspension of particles is then passed through a
monitored light path where scattering occurs and by having a
photomultiplier mounted at right angles to the particle stream and at
a 120° angle to the collimated light source a response
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proportional to the mass of the solute is produced. The response is
not dependent on the the chemical composition of the solute although
the compounds must be involatile and the solvent volatile.
HPLC Method Development
Selection of the column and initial mobile phase conditions for the
separation of a particular compound is governed by past experience
with similar compounds or compounds containing similar chemical
groups. The important factors to be taken into account are the size,
degree of polarity and solubility in aqueous and organic solvents of
the compound under study. Subsequently optimum resolution is
achieved by experimenting with changes in the organic strength and pH
of the mobile phase. For example an increasing organic strength will
reduce the retention time for non-polar solutes while adjusting the
pH will affect the resolution of polar compounds.
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Pharmacokinetic Methods
Pharmacokinetics is the study of the time course of drug and
metabolite levels in different fluids, tissues and excreta of the
body, and of the mathematical relationships required to develop
models to interpret such data. The discipline of pharmacokinetics
evolved in the 1930s with the publication of the first papers
dealing with the subject by Professor Teorell (Teorell 1937 a,b).
During the ensuing years there was a rapid development of the
concepts, methods and applications involved and in 1972 the NIH
formally recognised the existence of pharmacokinetics by sponsoring
an International Conference on Pharmacology and Pharmacokinetics.
Pharmacokinetics originated as a predominantly theoretical
discipline with the formulation of models to fit experimental data
considered an end in itself. However more recently it has been
recognised that pharmacokinetics can play an important part in
determining optimal doseage regimens for individual drugs. Thus
knowledge of elimination half life and clearance indicate that
certain drugs eg Atenolol and phenytoin need only be administered
once daily to maintain an adequate therapeutic level while others eg
propranolol and sodium valproate need to be taken more frequently.
The contribution of pharmacokinetics to cancer therapy is more
difficult to define. For the majority of the 40 or so commonly used
chemotherapeutic agents doses and schedules have been arrived at by
trial and error. Cancer therapy is unique in that drugs are often
used at or close to their maximum tolerated dose principally
because there is evidence that by increasing dose rate and intensity
greater cell kill can be achieved (Connors et al 1984). Thus
appropriate doses can only be arrived at through careful clinical
90
trials. There are however a number of situations where pharmacokinetic
data have been usefull. It is important to know the major site of
excretion of a drug since organ dysfunction can lead to greatly
enhanced systemic exposure and therefore toxicity. For example the
toxicity of cis-Platin is directly related to the glomerular
filtration rate and hepatic dysfunction can significantly reduce the
speed of anthracycline detoxification. Under these circumstances dose
reductions are necessary to avoid excessive toxicity. In addition the
timing of re-infusion of marrow for bone marrow transplantation
depends on the rate of clearance of the cytotoxic drugs used.
In certain situations a knowledge of metabolite excretion has
allowed safer use of agents. Following the administration of
Ifosfamide active alkylating metabolites, notably acrolein, are
excreted in the urine and cause severe dose limiting haemorrhagic
cystitis. Recognition of this problem was followed by the development
of Mesna for local detoxification of these metabolites in the
bladder. The rational administration of mesna depends on a knowledge
of the pharmacokinetics of Ifosfamide metabolism. A further situation
in which pharmacokinetic measurements have been valuable is in the
use of loco-regional chemotherapy. For example important studies have
been necessry to demonstrate a pharmacological advantage at the
peritoneal surface for drugs administered intraperitoneally (IP).
Such an advantage has been demonstrated for a number of drugs
(Ozols 1985) thus promoting interest in the use of IP chemotherapy
for diseases such as ovarian cancer that are largely limited to the
peritoneal cavity.
In recent years pharmacokinetic studies have become recognised as
an essential part of phase I clinical trials. In addition to
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providing useful data for the subsequent deployment of the drug in
phase II trials the information gained may also be used, in
conjunction with animal data, to facilitate more efficient dose
escalation in the phase I trial itself. This will allow more rapid
completion of phase I studies with fewer patients treated at doses
unlikely to have any therapeutic benefit.
The Concept of Compartments
The most commonly employed approach to the pharmacokinetic
characterisation of a drug is to represent the body as a system of
compartments, even though these compartments have no physiological or
anatomical reality. The one compartment model depicts the body as a
single homogenous unit. This does not necessarily mean that the drug
concentrations in all body tissues are the same at any given time
but it does imply that changes in the plasma concentration
quantitatively reflect changes occurring in tissue drug levels. In
addition a one corrpartment model requires that drug elimination is a
first order process ie rate of elimination at any time is
proportional to the drug concentration at that time.
Most drugs entering the circulation require a finite time to
distribute fully throughout the body space. During this distributive
phase drug concentrations in the plasma will fall more rapidly than
in the post-distributive phase. If distribution is related to blood
flow highly perfused organs and tissues such as liver and kidney
should be in rapid equilibrium with the blood. The blood and all
readily accessible tissues and fluids may be treated kinetically as a
homogenous unit referred to as the central compartment. Following iv
administration the levels of drug in all tissues and fluids
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associated with the central compartment should decline more rapidly
in the distributive than in the post distributive phase. In contrast
drug levels in poorly perfused tissues (eg muscle, lean tissue, fat)
will increase first to a maximum and then begin to decline during the
distributive phase. As with the one compartment model drug
elimination and transfer between compartments in multicompartment
systems are assumed to be first order processes.
At some point pseudo-equilibrium is reached and subsequent loss of
drug will occur in a first order fashion indicating kinetic
homogeneity with respect to drug levels of all the fluids and tissues
of the body.
If the plasma concentration is plotted against time for a drug
whose kinetics conform to a one compartment model it can be seen
that the concentration follows a single exponential decay pattern
falling rapidly at first and then progressively more slowly. This is
is a reflection of the first order nature of the elimination
processes. Thus a constant fraction of the drug is eliminated in unit
time. This fraction is determined by the elimination rate constant
(kel).
Because the drug concentration declines exponentially with time a
plot of log cone against time is linear. This line can be described
by the equation:
logC = logCO.-kt
where : k is the slope of the line
C is the drug cone at any time t
CO is the drug cone at time zero
CO can be estimated by extrapolating the line back to the cone axis.
The relationship between drug concentration and time may also be
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described by the exponential function:
C = C0.e-kelt
where kel is the elimination rate constant
The exponential function can be derived from the loglO plot in the
following manner:
(1) Transpose the relationship to the base of the natural log .
For any number x : 2.31og -^x = loggx
Thus: 2.31og 1QC = 2.31og^QC0 - 2.3kt
or : logeC = lo<3ec0~2-
(2) Taking the antilogs of both sides:
C - CO . e-2'3kt
Thus the elimination rate constant is equivalent to 2.3 x slope of
the straight line obtained from the semi-logarithmic plot.
For drugs exhibiting multicompartment kinetics a plot of plasma
concentration against time reveals a multi-exponential decay pattern,
the number of exponentials being equivalent to the number of
compartments. Such a line can be described by the equation:
CO = Ce_Q:t + Be- etc
A plot of log cone against time of this line results in a decay
curve with a series of linear segments again equivalent to the number
of theoretical compartments. For each linear section of the decay
curve events taking place in the relevant compartment are dominant.
For any model, however, a point is reached where equlibrium between
the various compartments is attained. Subsequent loss of drug from
the plasma is then described by a monoexponential process indicating
that the body is now behaving as a single compartment (the terminal
elimination phase).
Although compartmental analysis provides an important insight into
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the behaviour of a drug several useful parameters may be calculated
without recourse to a model. These model independent parameters
include the apparent volume of distribution, clearance, area under
the curve and the terminal elimination half life or biological half
life.
The Elimination Half Life
The elimination half life is the time taken for the concentration
and amount of drug in the body to fall by one half eg from CO to
1/2C0. Using the exponential equation of the curve this can be
expressed as:
0.5C0 = CO . e~keltl/2
or 0.5 = e~keltl/2
keltl/2 0or e = 2
Taking antilogarithms
kel.tl/2 = log 2
or keltl/2 = 0.693
or tl/2 = 0.693/kel
where kel = 2.303.k (calculated from the log vs time plot)
The Volume of Distribution
The apparent volume of distribution is a theoretical value obtained
by dividing the amount of drug in the body by the plasma
concentration. This calculation requires equlibrium to be reached
between plasma and other tissues. The amount of drug is known
immediately after an intravenous bolus but equilibrium is not reached
until the start of the elimination phase ie the terminal linear
portion of the log cone vs time plot. An estimate of the plasma
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concentration that would have resulted had all the drug spontaneously-
distributed into its final volume of distribution is obtained by
extrapolating the line delineating the elimination phase back to time
zero. Using this value:
Vol of Dist" = Dose/Co
The value for the volume of distribution obtained by this method is
often a good estimate but occasionally it is not. The best method is
to divide clearance by the elimination rate constant. As shown below:
Clearance = k . V
Thus V = Clearance/k
For a multi-compartment model the clearance from any individual
compartment will be the same once equilibrium has been established
thus:
Clearance from central compt. = kc x Vc
= Total body clearance
= kel x Vd
where kel = the terminal elimination rate constant
kc = the elimination rate constant from the central compart.
Vc = the volume of the central compartment.
Vd = the total vol of distribution at time zero.
A number of deductions can be made once the volume of distribution
is known. A small volume implies that the drug is largely confined to
the vascular space whereas larger volumes, often exceeding the total
real body volume by many times, indicates extensive tissue
distribution or binding to to cellular elements.
Clearance
Plasma clearance is the volume of plasma cleared of drug in unit
96
time. Clearance must therefore be related to the volume of
distribution and the rate of elimination. In fact clearance is
defined as:
Volume of distribution x elimination rate constant
The clearance may be altered by changes in the volume of
distribution for example a fall in plasm protein concentration for a
highly protein bound drug, or changes in kel. Saturation of
metabolism is a method by which kel can be altered.
If the clearance is known then the actual rate of drug elimination
can be calculated by multiplying clearance by concentration:
Rate of elimination = Clearance . Cone
The rate of elimination can be expressed in another fashion by
returning to the exponential function:
C = C0.e_kelt
Differentiating with respect to time yields:
dC/dt - -kel.C0.e~kelt
o "1
Since C = CO.e it follows that:
dC/dt = -kel.C
Multiplying both sides by V, the volume of distribution gives:
V.dC/dt = V.kel.C
The rate of change of concentration with respect to time multiplied
by the volume of distribution is equivalent to the rate of change of
drug in the body and therefore also to the rate of elimination.
Thus Rate of elimination = Clearance . C = kel.V.C
or Clearance = kel.V
or Clearance/V = kel
or V = Clearance/kel
Thus since tl/2 = 0.693/kel
97
tl/2 = 0.693.V/Clearance
During a small time interval dt the amount of drug eliminated is
equal to Clearance.C.dt, where C.dt is the corresponding small area
under the plasma concentration time curve. For an intravenous
injection the total amount of drug eliminated is equal to the dose
and this can be calculated by adding up the amount in each time
interval from zero to infinity, therefore,
Dose = Clearance . AUC
Clearance can therefore be calculated from a knowledge of the dose
and the AUC. In addition the AUC can be used to calculate the amount
absorbed when a drug is given by an alternative route by comparison
with the AUC following iv administration.
Area Under the Concentration x Time Curve (AUC)
The intensity and duration of any tissue response is probably in
most cases a function of the concentration and persistence of the
drug in the blood. Thus we would expect the size and duration of the
biological effect to be related to the area under the concentration x
time curve.
Assessment of AUC
The simple numerical estimation of area using the trapezoidal rule
requires only a table of experimental data and is applicable to all
methods of drug administration. This method involves calculating the
sum of the products of each individual time interval with the average
drug concentration during that interval. The average concentration is
obtained from:
(cone at start time + cone at end time)/ 2
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When a drug is given as an intravenous bolus and the decline is
exponential the total area under the curve is calculated most rapidly
by dividing the extrapolated zero time concentration Co by the
elimination rate constant, kel.
Proof: Total area = C . dt
„ _ -kelt
since C = Co . e
-kelt j.
area = Co . e . dt
and since Co is a constant
„ -kelt j,
area = Co . e . dt
Which upon integrating between time zero and infinity yields:
Total area = Co/-kel. = Co/-k .0-1 = Co/k
For a drug demonstrating multi-compartment kinetics:
AUC = A/a + B//3 + C/7 etc
The relative amounts that each phase contributes in terms of drug
elimination can be estimated by comparing the relative areas.
If A/a is less than B/fi then the a phase is largely distribution. If
A/a is equal to or greater than B/fi then significant drug elimination
takes place during this phase.
The Two Compartment Model
Normally a one compartment model is not sufficient to describe the
kinetics. As mentioned previously there is often an initial
distribution phase followed by a terminal elimination phase. During
the elimination phase the graph of log cone vs time moves into a log
linear phase. This phase represents elimination from the central
compartment in equilibrium with the second compartment. The slope
of this line can be used to determine the rate constant (3 in a
similar fashion as for kel in a one compartment model, when the time
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is plotted against log^Q then:
0 = 2.3 x slope
When time is plotted against log then:
0 = slope
This rate constant is a hybrid rate constant related to several
individual constants. It governs the overall elimination of the drug.
This can then be used to calculate the half life, sometimes
referred to as the biological half life:
Tl/2 - 0.693/0
The rate constant 0 should not be confused with Kel the
rate constant governing elimination from the central compartment. For
the one compartment model the rate of elimination is governed by the
total amount of drug in the body and thus (3 and kel are identical.
In a two compartment model the two constants are closely related
but will not be identical. In such cases elimination often takes
place only from the central compartment and thus the rate of
elimination at equilibrium will be governed by the amount of drug in
the central compartment rather than the total amount in the body.
Thus kel would be greater than 0 . It is from 0 that the biological
half life can be obtained. Although 0 or the biological half life
obtained there from is a highbrid parameter it is probably the most
important functional pharmacokinetic parameter. kel may be
calculated from:
kel = A + B / (A/a + B/0)
In this equation B represents the apparent concentration if the
drug has been distributed instantaneously throughout both the central
and peripheral compartments. Thus intercept B can be used to
calculate an apparent volume of distribution. A and a are the
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fi9 1 Method of Residuals
Cone
Time, hours
Line (1) is obtained by subtracting the values on the extrapolated
line (- from the actual experimental values giving the residual
concentration.
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intercept and slope of line (1) (fig 1). This line results when Cp
values which lie on the extrapolation of line (3) are deducted from
the real values on line (2). This is known as the method of residuals
(Gibaldi and Perrier, 1975). The slope of the line is used to
determine the rate constant a which is another highbrid value
governing the distribution of the drug into the second compartment.
If A is added to B we obtain Co the theoretical concentration of the
drug in plasma at time zero. This can be used to calculate the volume
into which the drug was initially introduced ie the central
compartment.
Vc = Dose/A+B
The elimination phase is characterised by two parameters, the
elimination half life and the apparent volume of distribution. The
elimination half life is the time taken for the plasma concentration
as well as the amount of drug in the body to fall by one half. All
the drug (97%) will in practice be eliminated in 5 half lives. The
elimination half life is calculated as above:
Tl/2 - 0.693/0
Practical Applications
The experimental data should first be plotted on semilog graph
paper. This will enable a visual assessment of the decay curve
allowing an estimate of which kinetic model is likely to be
applicable. If the data appear to fit a one compartment model the
slope of the line may be calculated using the linear regression
programme on a scientific calculator. The correlation coefficient
will give an indication as to the linearity of the line.
(1) Tl/2 a = 0.693/kel (kel = 2.303 x slope)
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(2) AUC is calculated using the trapezoidal rule
(3) Clearance = dose/AUC
(4) Vd = Clearance/kel
If the data appear to fit a two compartment model the slope of the
elimination phase is determined as for the one compartment model
using only the points applicable to that phase. The correlation
coefficient is a useful check as to whether the correct starting
point for the elimination phase has been chosen.
The points on the first phase are calculated using the method of
residuals described previously. Again linear regression is used to
find the slope of the line.
Tl/2 = 0.693/2.3 x slope
Tl/2 = 0.693/2.3 x slope
AUC is calculated using the trapezoidal rule
Clearance = Dose/AUC
Vd = Clearance/kb
The intercepts A and B can be determined by extrapolating lines a
and b back to the y axis. These values can be used to calculate the
volume of the central compartment:
Vc = Dose/A+B
and as an alternative way of calculating AUC
AUC = A/ + B/
Computer Modelling
Computers can be used to calculate what the ideal concentration
values would have been if the kinetics had conformed perfectly to the
model. The computer performs a series of calculations using the
experimental data and the initial estimates for the slopes and
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intercepts of the linear segments of the curve as a starting point.
At the completion of the calculations new values for A,a: ,B and (3
are determined which can be used to calculate intercompartmental rate
constants, half lives and volumes of distribution. It is common for
experimental data not to fit a model.
For a two coirpartment model the elimination rate constants and
intercompartmental rate constants (fig 2) are calculated as follows:
kel A + B / (A/a + B//3)
k21 (A.a +B.jS)/(A + B)
kl2 a+ (3 - k2l - klO
AUC (A/a) + (b/|8)
Vc Dose / A + b
Vd Dose / (jS.AUC)
VP Vc (kl2.k21)
Vss VI (1 + kl2/k21)
Clearance = Dose / AUC
or Vc . klO
or Vd . |8
Where A and B are the intercepts on the concentration axis
and a and @ are the respective elimination rate constants.
Vc is the volume of the central compartment
Vd is the volume of distribution at time zero
Vp is the volume of the peripheral corrpartment
Vss is the volume of distribution at steady state
kel is the elimination rate constant
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kl2 is the costant governing movement of drug from the
central to the peripheral compartment
k21 is the constant governing movement of drug from the
peripheral to the central compartment
fig 2 Two Compartment Model
Input
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A Phase I Study of Methylene Dimethane Sulphonate
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fig 3 Methylene Dimethane Sulphonate
Introduction
Methylene dinethane sulphonate (MDMS) is the first member of the
homologous series of straight chain dimethane sulphonic acid esters.
Members of the series 2-10 were first synthesised in 1950 in an
effort to identify new alkylating agents following the success of the
nitrogen mustards. They were formed by the reaction of methane
sulphonyl chloride with the appropriate alkanediol under anhydrous
conditions (Emmons and Ferris, 1953). These compounds were tested for
their antitumour activity against the Walker 256 carcinoma (Haddow
and Timmis 1951), their neutrophil depressing activity (Elson 1958)
and their immunosuppressive activity (Berenbaum et al 1967). In all
cases optimal biological activity was observed with the 4-carbon
chain member of the series, 1,4-dimethanesulphonyloxybutane
(Busulphan). Further studies showed Busulphan to be most selective in
producing a greater depression in neutrophils than lymphocytes (Elson
1958) and this drug soon became established as the treatment of
choice in the management of chronic myeloid leukaemia. During these
studies the n=2 compound showed a lack of activity and probably for
this reason the n=l diester was not investigated until later.
MDMS was synthesised by the reaction between silver
-methanesulphonate and dibromomethane in 1953 (Emmons and Ferris).
However it was not until 1965 that Fox and Jackson reported the
activity of this drug in the Walker carcinoma. Subsequently Fox
(1969) demonstrated that single doses of MDMS administered to rats
bearing established 14 day old (20-30g) tumours resulted in cures in
approximately 90% of animals (fig 3). Comparable doses of Busulphan
failed to produce complete regression of the tumour and the level of
inhibition was much less than with methylene dimethane sulphonate.
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fig 4 Effect of MDMS on Yoshida Sarcoma in Rats
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Although it has demonstrated significant activity in rat tumours MDMS
is largely inactive in murine tumours other than the TLX/5 ascites
tumour.
In 1976 Nias and Fox in experiments with HeLa and Chinese Hamster
(ovary) cells showed that MDMS exerts its maximal cell kill at the
end of Gl and the beginning of S phase with the lowest activity at
the end of S and during G2. In more recent years studies of the first
9 straight chain dimethane sulphonic acid esters have demonstrated
that MDMS produces approximately three times more DNA-DNA
crosslinking than Busulphan at a comparable treatment level in cell
culture (Bedford and Fox 1983). Moreover there appeared to be a
correlation between cytotoxicity in these systems and the degree of
crosslinking caused by different members of the series. MDMS is a
small molecule (molecular wt. 204) and it has been estimated that the
distance separating the alkylating moieties following the elimination
of methane sulphonic acid is of the order of 2.3A (Bedford and Fox
1983). This distance is too small to span the more usual nucleophile
distances but is compatible with that between the atoms involved in
the DNA interstrand hydrogen bonds. It is possible therefore that
MDMS may act by replacing such a bond.
The high activity in the Yoshida tumour, apparent greater formation
of DNA crosslinking compared to Busulphan and possible novel site of




The formulation was carried out by Dr. Vezin, CRC Formulation unit,
Dept. of Pharmacy, Strathclyde University, Glasgow. Before
embarking on the formulation the main considerations to be taken into
account were:




Preliminary work indicated that the LD10 in mice was of the order
of lOmg/kg. Thus for the average adult a single dose might be
expected to range from 5 - 80mg.
Aqueous solubility
The aqueous solubility is calculated to be 7 - 8 mg/ml at 21°C.
However the drug has a strongly hydrophobic surface requiring fine
pulverisation to increase the rate of dissoloution. Solubility in
aqueous solution is therefore slow.
Stability
MDMS hydrolyses rapidly in aqueous solution to formaldehyde +
methane sulphonic acid. The half life of this reaction is 22min at
37°C.
The instability of the drug in aqueous solution suggested that iv
bolus rather than infusion would be the appropriate method of
administration. Instability also meant that a simple aqueous
formulation was not possible and therefore the drug would have to be
presented in non-aqueous solution or as a powder with reconstitution
in an aqueous vehicle immediately prior to administration.
MDMS was found to be readily soluble in alcohols, lipophyllic and
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polar solvents. The most elegant formulation proved to be a freeze
dried preparation. MDMS (1.25g) was first dissolved in
Dimethylsulphoxide (DM90, 50ml) containing less than 1% w/v water.
Appropriate aliquots of this solution were placed in vials and these
freeze dried under vacuum until all visible trace of DMSO had gone.
This preparation appeared to be stable for over 12 months when
stored at 4°C. The drug is particularly soluble in dimethyl
acetamide (over lOOmg/ml) and thus this agent was chosen for
reconstitution. Dimethylacetamide (DMA) has been used in the
formulation of several chemotherapeutic agents including AZQ, mAMSA,
VM26, PCNU, N-methylformamide and Hexamethylmelamine. Although there
was a suggestion of hypersensitivity to DMA in one trial (Posada et
al, 1984) and elevation of hepatic transaminases in another (Earhart
et al, 1981) these have not been confirmed by subsequent studies and
the compound appears to be safe and free from biological effects at
the doses used. A potential problem with polar solvents is that they
may react with plastic containers. However a study by Vishnuvajjala
and Cradock (1984) demonstrated negligible dissolution of PVC bags by
5 and 10% DMA solutions when stored for periods of up to 20 hours.
Significant reaction with the plastic only occurred when the
concentration of DMA exceeded 60%. In addition we have compared the
Infra-red spectra of pure DMA with that of pure DMA that had been
stored in a standard polypropylene syringe for four weeks and there
was no evidence of any reaction. Syringes manufactured from the more
reactive polystyrene should not however be used for drawing up pure
DMA.
Vials for clinical use have been prepared containig 20mg, 50mg and
lOOmg MDMS. These are rconstituted with 0.5ml DMA; 10-20ml sterile
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water is then added to each vial providing a final solution
containing 2.0mg/ml MDMS and 5% v/v DMA for injection. Reconstituted
drug must be used immediately to avoid significant hydrolysis.
Formal testing of the vials for clinical use have shown them to be
over 99% pure and entirely free from contaminants and pyrogens.
Preclinical Toxicology
Preclinical toxicology was carried out according to the
requirements of the CRC Phase I Committee by Life Science Research.
These requirements included :
(1) To identify the LD50 and LD10 with 95% confidence limits
for IV and IP schedules.
(2) To identify target organs and systems
(3) To assess the time course of any toxic effects
(4) To identify delayed or irreversible effects at sub-lethal
doses
Acute Intravenous Toxicity in Male Mice
The acute intravenous toxicity was investigated in groups of male
mice of the Charles River CD-I strain at doses in the range
54-150mg/kg. Mortality and signs of reaction to treatment were
recorded during a 28 day observation period. All decedents and mice
killed on day 29 were subject to necropsy.
The principal sign of reaction to treatment was an ungroomed
appearance which persisted until death or day 13. Deaths occurred in
all doseage groups usually between day 6 and 9. No animal survived a
dose of 100 or 150mg/kg. There were no consistent findings on




of the study the acute median LD50 and LD10




Acute Intraperitoneal Toxicity in Male Mice
The acute intraperitoneal toxicity of MDMS was investigated in
groups of the Charles River CD-I strain at doseages in the range
20-101mg/kg. MDMS was administered at a constant volume of 20ml/kg in
0.5% w/v carboxymethylcellulose.
Overt signs of toxicity were similar to those with the acute iv
schedule. Death occurred in groups given a dose of 45mg/kg or above,
usually between six and eight days after treatment.
Necropsy of decedents and animals surviving to 28 days again showed
no consistent changes.
The acute intraperitoneal median LD50 and LD10 were as follows:




Subacute Intraperitoneal Toxicity in Male Mice
MDMS was administered at seven doseages in the range 1.4-43mg/kg at
a constant volume doseage of 20ml/kg on 5 days per week for four
weeks in 0.5% carboxymethylcellulose in water.
As with iv doses overt signs of treatment were confined to
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non-specific signs of ill health. Death occurred in groups treated at
5.4mg/kg or above with no animal surviving treatment at lOmg/kg or
above.
No significant lesions were found on necropsy of decedents or mice
surving to 29 days.
The median LD50 and LD10 were as follows:





A supplementary study was performed to assess any temporal changes
in haemograms and bone marrow cytology in male mice following a
single intraperitoneal administration of MDMS at a dose approximately
equal to l/10th LDlO; and to detect any changes in bone marrow
cytology or histological abnormalities following single
intraperitoneal administration of a dose approximately equal to the
acute median lethal dose.
The haemograms demonstrated a treatment related reduction in total
leukocyte count largely attributable to a reduced lymphocyte
population and an absence of eosinophils among treated mice during
the first week of observation. Bone marrow cytology revealed no
consistent treatment related changes.
Histological examination showed peritonitis involving several
abdominal organs together with degeneration of the germinal
epithelium and interstitial cell hyperplasia of the testes in animals
killed 21 and 28 days after treatment. There were no other consistent
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histological changes.
Toxicity Check in the Rat
Groups of male rats were treated with MDMS using a 4x5 day
intraperitoneal schedule at a dose equivalent to 1/10 mouse LD10. No
toxic effects attributable to MDMS were seen.
Suiimary
The LDlO in mice using the acute iv schedule was 47mg/kg. This is
2
equivalent to 141mg/m and thus the starting dose for phase I
2
testing was chosen as l/10th of this dose ie 14mg/m .
Haematological monitoring revealed a possible treatment related
reduction in circulating leukocytes during the first week after
treatment but no consistent marrow changes were seen. In addition
there were no significant histological changes other than in the
testes and local sclerosant effects on the peritoneum. These studies
therefore indicate that MDMS may be marrow toxic and may produce
infertility.
Clinical Trial
The phase I clinical trial of MDMS commenced in January 1985. The
major points from the protocol were as follows.
Patient Eligibility
(1) Histological diagnosis of malignancy
(2) Any solid tumour type
(3) Age between 16 and 75 years
(4) Performance status 2 or less, life expectancy over 3 months
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(5) Patients should have received conventional therapy where this
exists
(6) Patients must have had no chemotherapy in the 4 weeks prior to
commencing MDMS (6 weeks for nitrosoureas and mitomycin-C) and
must have recovered from the toxic effects of prior treatment
(alopecia excluded).
9
(7) Minimal haematological requirements were WBC above 3x10 /l,
9
platelet count above 100x10 /I.
(8) Minimum renal and hepatic function were, serum creatinine
0.12mmol/l, normal bilirubin, hepatic transaminases less than
50% above the upper limit of normal.
(9) Patients with CNS involvement were excluded.
(10) Patients with serious co-existing medical conditions were
excluded.
Consent
In line with the current policy at this institute patients were
informed verbally of the experimental nature of the treatment and the
limited therapeutic expectations of the study. They were given every
oportunity to decline to take part and were assured that if they
decided not to enter the trial they would continue to receive all
available supportive therapy.
Following such an explanation 2/41 patients declined to take part.
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Starting dose, patient entry and escalation procedure
2
The starting dose for the trial was 14mg/m using an
intermittent bolus schedule with an initial interval between doses of
21 days. It was intended to enter 3 patients at each non-toxic dose
with increasing numbers at doses exhibiting toxic effects. Dose
escalation was by the modified Fibonacci series. There was no within
patient dose escalation in order not to obscure data on cumulative
toxicity. It was planned that patients would receive at least 2
courses of therapy. Further courses could be given in the event of a
response occurring.
Prior to commencing the trial the protocol was submitted to the
Christie Hospital Protocol Review Committee, the CRC Phase I
Committee and the South Manchester Ethical Committee. In addition




All platelet and leukocyte counts are expressed as the value x 10
Dose Level
14 mg/sqm Date start 15:1:85
Patient Diagnosis Age Performance Major Disease
Status Site
KM SCLC 61 2 Liver
BT SCLC 63 1 Mediastinum
PM Melanoma 34 2 Peritoneum
Prior XRT Prior Chemotherapy
KM Spine Ifosfamide, VP16
BT Mediastinum Ifosfamide, VP16
PM Mediastinum DTIC, Vindesine
Course 1 Course 2
WBC Time to Time to WBC Time to Time to
nadir nadir recovery nadir nadir recovery
KM 7.3 14 —
BT 5.0 14 21 4.9 7 14
PM 8.5 14 21
Platelet Time to Time to Platelet Time to Time to
nadir nadir recovery nadir nadir recovery
KM 243 7 —
BT 309 7 14 378 14 21






This dose was entirely nontoxic and no anti-tumour activity
seen.
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28mg/sqm Date start: 14:2:85




DG Ca. Ovary 52 1 Local rec.
AA SCLC 35 2 Mediastinum
DF Melanoma 74 2 Vulva
Prior XRT Prior Chemotherapy
DG None Cis-Plat, Bleomycin, Cyclo., Chlorambucil
AA Mediastinum Ifosfamide, VP16
DF Vulva DTIC
Course 1 Course 2
WBC Time to Time to WBC Time to Time to
nadir nadir recovery nadir nadir recovery
DG 5.5 14 21
AA 4.5 21 21 3.7 14 21
DF 7.2 21 21
Platelet Time to Time to Platelet Time to Time to
nadir nadir recovery nadir nadir recovery
DG 494 14 21
AA 229 14 21 233 14 21






Again this dose was entirely non-toxic and there was no evidence
of therapeutic effect.
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46ntg/sqm Date Start: 14:3:85
Patient Diagnosis Age Performance Major Disease
Status Site
RR SCLC 57 2 Mediastinum
JB NSCLC 57 2 LSCF
JJ Ca.Ovary 36 2 Peritoneum
Prior XRT Prior Chemotherapy
RR Mediastinum Ifosfamide, VP16
JB Left neck Ifosfamide, Cyclophosphamide
JJ None Cis-Plat, Bleo, Cyclo, CHIP, Chlorambucil
Course 1 Course 2
WBC Time to Time to WBC Time to Time to
nadir nadir recovery nadir nadir recovery
RR 9.6 14 21
JB 7.8 7 14 LD 14 21


































Patient JJ experienced grade 3 nuetropenia and grade 4
thrombocytopenia at this dose. This lady had a history of being very
sensitve to chemotherapy and had had a great deal of prior treatment.
Since the remaining two patients treated demonstrated no
haematological toxicity it was decided not to delay escalation by
studying further patients at this dose.
Patients RR and JB both experienced intense burning pain along the
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vein radiating up the arm and over the anterior chest wall as the
injection was given. The pain cleared rapidly when the injection was
stopped but reappeared on restarting. The pain was minimised by
injecting very slowly. There had been no delay in administering the
drug following preparation but subsequently it was noticed that
saline instead of water had been used in reconstitution. When JB had
a second dose with saline used to reconstitute he had no discomfort
on quite rapid bolus administration. The MDMS solution in saline was
later analysed extensively but no reason such as more rapid pH change
could be found to account for the pain.
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70mg/sqm Date start: 15:4:85
Patient Diagnosis Age Performance Major Disease
Status Site
WA Mesothelioma 66 2 Pleura
IT Ca. Ovary 64 1 Peritoneum
WM NSCLC 54 2 Liver
Prior XRT Prior Chemotherapy
WA None Cyclophosphamide
IT None Chlorambucil
WM None Cyclo, Ifosfamide, Adriamycin, VP16, MIX
Course 1 Course 2
WBC Time to Time to WBC Time to Time to
nadir nadir recovery nadir nadir recovery
WA 7.3 14 21
IT 2.9 14 21 2.8 21 28
WM 4.9 14 21
Platelet Time to Time to Platelet Time to Time to
nadir nadir recovery nadir nadir recovery
WA 170 21 28
IT 81 21 28 58 35 49






There was no non-haematological toxicity at this dose. In addition
two patients had no haematological toxicity. Patient IT developed
grade 2 platelet and WBC toxicity and there was a suggestion of
cumulative platelet toxicity. There was no evidence of anti-tumour
activity.
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lOOmg/sqm Date start: 16:5:85
Patient Diagnosis Age Performance Major Disease
Status Site
WH Ca.Rectum 63 1 Liver
PS SCLC 41 1 Liver
MH Ca.Ovary 52 2 Peritoneum
Prior XRT Prior Chemotherapy
WH none none
PS mediastinum Ifosfamide, VP16
MH none Cyclo, Cis-Plat, Melphalan, CHIP
Course 1 Course 2
WBC Time to Time to WBC Time to Time to
nadir nadir recovery nadir nadir recovery
WH 3.9 21 28 3.1 14 21
PS 3.0 21 28





























































The first signs of GI toxicity occurred at this dose with mild
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nausea in two patients. In addition WH developed grade 1 alopecia
following the second dose of MDMS. There was more consistent
myelosuppression with at least grade 1 leukopenia in all three
patients. There was further evidence of cumulative platelet
suppression in the two patients receiving more than one cycle of
treatment. No responses were seen.
125mg/sqm Date Start: 13:6:85
3atient Diagnosis Age Performance Major Disease
Status Site
HL SCLC 65 1 Mediastinum
TL Mesothelioma 54 2 Pleura
FH STS 53 2 Peritoneum
WC Ca.Ovary 58 1 Peritoneum
DH NSCLC 51 2 Mediastinum
GJ STS 64 1 Retroperitoneum
EW Ca.Ovary 68 1 Pelvis
BE SCLC 48 1 Lung
GS Mesothelioma 58 1 Pleura
JT STS 61 1 Pelvis
AN Hepatoma 67 1 Liver
AS* STS 54 2 Lung
GK* Ca.Ovary 48 0 Peritoneum
Prior XRT Prior Chemotherapy
HL Mediastinum Cyclo, VP16, Methotrexate
TL Ant. Chest Cyclo, Adriamycin
FH none Ifosfamide, Adriamycin
WC none Cyclo, Cic-Plat, Bleomycin,, Melphalan
DH Mediastinum Ifosfamide, Cyclo
GJ none Ifosfamide, Adriamycin
EW none Melphalan
BE Mediastinum Ifosfamide, Etoposide
GS none Cyclo
JT none Ifosfamide, Adriamycin
AN none none
AS * Pelvis Ifosfamide, Adriamycin
GK * none Cyclo, CHIP
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Course 1 Course 2
WBC Time to Time to WBC Time to Time to
nadir nadir recovery nadir nadir recovery
HL 3.7 28 28
TL 1.7 28 died
FH 2.0 14 28
WC 1.5 14 28 1.8 21 28
DH 2.9 21 died
GJ 2.3 14 21 2.4 28 35
EW 0.8 21 56 1.2 28 56
BE 3.0 21 28 2.5 14 died
GS 1.0 21 35
JT 2.8 21 35 2.7 21 35
AN 3.0 14 21
AS* 3.1 21 28 3.0 14 21
GK* 2.3 21 35 3.6 21 28
Course 3
WBC Time to Time to
nadir nadir recovery
WC 1.7 7 28
AS* 4.8 21 28
Course 1 Course 2
Platelet Time to Time to Platelet Time to Time to
nadir nadir recovery nadir nadir recovery
HL 189 21 28
TL 26 28 died
FH 95 28 35
WC 116 14 21 139 21 28
DH 36 21 died
GJ 131 21 28 95 28 35
EW 34 21 42 26 28 died
BE 162 21 28 152 14 died
GS 21 21 35
JT 154 21 35 32 21 died
AN 136 21 28
AS* 84 14 21 45 14 28
GK* 45 21 28 96 28 35
Course 3
Platelet Time to Time to
nadir nadir recovery
WC 25 7 42
AS* 47 14 42
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Nausea/Vomiting Alopecia Venous Pain Transfusions
HL 0 0 0 0
TL 0 0 0 0
FH 0 0 0 1
WC 2 3 0 1
DH 0 0 0 0
GJ 0 0 0 1
EW 1 1 0 1
BE 0 0 0 0
GS 1 1 0 1
JT 1 2 0 1
AN 0 0 0 0
AS* 2 3 mild 2
GK* 2 3 0 r\kj
Comment
Thirteen patients were treated at this dose of whom twelve had had
prior chemotherapy. Seven experienced grade 3 or worse haematological
toxicity and ten grade 2 or worse haematological toxicity. In
addition 7 patients required blood transfusions as a result of
treatment. It thus appeared that this would be an appropriate dose
for future phase II trials in patients who have received prior
chemotherapy. 6/13 patients had either grade 1 or 2 nausea and
vomiting. When vomiting occurred it commenced 2-4 hours after
treatment and lasted 2-12 hours. 6/13 patients developed a degree
of alopecia in 3 cases grade 3, requiring a wig. No anti-tumour
activity was seen at this dose.
Two patients (*) had dose reductions performed according to nadir
platelet counts as follows:
nadir platelet count
50 - 75 25 - 49
% of previous dose 75% 50%
This scheme prevented the occurrence of grade 4 thrombocytopenia in
subsequent courses.
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170mg/sqm Date start: 4:7:85
Patient Diagnosis Age Performance Major Disease
Status Site
RS NSCLC 57 1 Lung
BB Ca.Ovary 55 1 Pelvis
DW NSCLC 54 1 Lung
TB NSCLC 56 1 Peritoneum
HP NSCLC 62 1 Lung
JP NSCLC 64 1 Lung







Course 1 Course 2
WBC Time to Time to WBC Time to Time to
nadir nadir recovery nadir nadir recovery
RS 2.5 21 28 2.0 21 28
BB 2.6 21 35 2.9 21 35
DW 2.7 14 21 5.4 14 21
TB 1.6 14 28
HP 1.0 21 35 0.6 28 63
JP 2.8 14 21 2.5 21 28
Course 3
WBC Time to Time to
nadir nadir recovery
BB 2.0 35 49
Course 1 Course 2
Platelet Time to Time to Platelet Time to Time to
nadir nadir recovery nadir nadir recovery
RS 175 21 28 32 21 35
BB 38 21 35 49 28 49
DW 135 21 28 112 21 28
TB 221 21 28
HP 34 21 28 10 42 56+
JP 32 21 28 10 28 56+
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Course 3
Platelet Time to Time to
nadir nadir recovery
BB 11 21 20 weeks
Nausea/Vomiting Alopecia Venous Pain Transfusions
Blood Pits
RS 0 2 none
BB 0 2 none 1 1
DW 0 2 none
TB 2 1 none
HP 2 2 none 2 1
JP 1 3 none 1 1
Conment
At this dose the gastrointestinal side effects were similar to the
previous dose but now all patients developed a degree of alopecia.
Haematological toxicity was again more severe with marked cumulative
thrombocytopenia. In two patients, both of whom had received no
prior chemotherapy, the platelet count did not fully recover before
they died 2 months after the second course of MDMS. In a third
patient who received 3 courses of treatment the platelet count took 5
9
months to reach 100x10 /l. Three patients whose platelet counts
9
fell to 10x10 /I were given prophylactic platelet transfusions




Patient Diagnosis Age Performance Major Disease
Status Site
JS NSCLC 63 1 Mediastinum
MM NSCLC 49 2 Lung
Prior XRT Prior Chemotherapy
JS none none
MM none none
Course 1 Course 2
WBC Time to Time to WBC Time to Time to
nadir nadir recovery nadir nadir recovery
JS 2.1 14 28 1.1 14 35
MM 0.8 21 28 1.0 14 died
Platelet Time to Time to Platelet Time to Time to
nadir nadir recovery nadir nadir recovery
JS 73 21 28 14 28 6 months+
MM 18 14 35 7 14 died
Nausea/Vomiting Alopecia Venous Pain Transfusions
Blood Pits
JS 1 3 0 1 0
MM 2 3 0 4 6
Comnent
The first patient treated at this dose level tolerated the first
cycle of treatment with mild nausea only and grade 2 haematological
toxicity. A second patient was therefore entered. This patient
developed grade 4 platelet and WBC suppression. This was complicated
by recurrent haemoptysis and pneumonia together with elevation of the
bilirubin and hepatic transaminases. The disturbance of liver
function resolved when the fbc returned to normal and the infection
cleared. No specific cause for this could be found. On recovery the
patient was considerably better than before treatment with less
dyspnoea and cough and improved appetite and general well being.
Moreover a repeat chest X-ray demonstrated a significant reduction in
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the size of the tumour mass although not reaching a partial
remission. In view of this it was decided to proceed with a further
course of MDMS but with a 50% dose reduction because of the previous
grade 4 toxicity. Unfortunately despite the dose reduction the
patient once again developed grade 4 haematological toxicity and died
3 weeks following therapy from a combination of pulmonary infection
and haemorrhage.
Patient JS developed grade 4 thrombocytopenia following his second
cycle of therapy but did not require platelet transfusion. By 6
9
months after treatment his count had reached 46x10 /l.
It was now becoming increasingly clear that whereas most patients
who had not had prior chemotherapy could tolerate an initial dose of
2
170mg/m the administration of subsequent doses was restricted
by cumulative thrombocytopenia. It was therefore decided to
2
investigate an intermediate dose level of 150mg/m in previously
untreated patients.
150mg/sqm Date start: 27:3:86




















Course 1 Course 2
WBC Time to Time to WBC Time to Time to
nadir nadir recovery nadir nadir recovery
DT 7.4 14 21 2.1 14 21
HM 2.9 14 21 4.1 14 21
RF 2.1 14 21 2.2 21 28
Platelet Time to Time to Platelet Time to Time to
nadir nadir recovery nadir nadir recovery
DT 156 14 21 42 14 28
HM 137 14 21 56 21 42
RF 128 14 21 35 28 56
Nausea/Vomiting Alopecia Venous Pain Transfusions
Blood Pits
DT 1 3 0 2 0
HM 0 3 0 0 0
RF 3 3 0 2 0
Comment
The results at this dose level indicate that grade 2-3
thrombocytopenia can be expected after two cycles of therapy.
Platelet counts recovered at 3 weeks after the first cycle and at 4-8
weeks after the second cycle. The WBC had recovered by 4 weeks after
both cycles in all 3 patients. This dose therefore appears an
appropriate level to caninenee phase II trials in patients who have
received no prior chemotherapy. It should be possible to administer
two courses without difficulty but for subsequent cycles appropriate
dose reductions, such as those suggested above, will have to be made
according to nadir platelet counts.
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Table 9 Median values for WBC and platelet nadirs at each dose level
Median nadir count (range)*
Dose First Course Subsequent Courses
mg/m WBC Platelets Total WBC Platelets
14 7.3 259 1 4.9 378
(5.0-8.5) (243-309)
28 5.5 229 1 3.7 233
(4.5-7.2) (175-494)
46 7.8 150 1 5.4 394
(1.8-9.6) (24-365)
70 4.9 170 1 2.8 58
(2.9-7.3) (81-320)
100 3.0 111 3 2.9 71
(2.1-3.9) (90-171) (1.2-3.0) (46-103)
125 2.3 95 10 2.6 54
(0.8-3.7) (21-189) (1.2-4.8) (25-152)
150 2.9 137 3 2.2 42
(2.1-7.4) (128-156) (2.1-4.1) (35-56)
170 2.5 86 6 2.2 21
(1.0-2.8) (32-221) (0.6-5.4) (10-112)
225 0.8, 2.1 18, 73 2 1.0, 1.1 7, 14
* Values= xlO^cells/1
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Table 10 Blood transfusion requirements
2










Table 11 Non-haematological toxicity
, 2
Dose,mg/m Patients Nausea/Vomiting Alopecia Venous
14 3 0 0 0
28 3 0 0 0
46 3 0 0 2
70 3 0 0 0
100 3 1 1 0
125 13 7 6 1
150 3 2 3 2
170 6 3 6 0







8.3 (4-13.6) 2.3 (0.6-7.5)
75% (50-95%) 52% (75-91%)
18% (3-43%) 37% (5-73%)
Differential WBC data for 23 courses in patients treated at doses
2 2
ranging from 125mg/m to 225mg/m .
134
Discussion
MEMS was introduced for phase I testing because of its high
activity in the rat Yoshida sarcoma system and a possible unique site
of alkylation. Pre-clinical toxicology suggested that the drug might
have a myelosuppressive action and some depressant effect on
testicular function but no other specific toxicities were noted. The
dose limiting toxicity in this phase I trial proved to be
thrombocytopenia which was cumulative with lower more prolonged
nadirs following second and subsequent courses. Thus although the
2
maximum tolerated single dose was 170mg/m lower doses are
recommended for phase II trials to allow additional courses to be
2
administered safely. These doses are 150mg/m for patients
2
without prior chemotherapy and 125mg/m for patients who have
received prior chemotherapy.
Neutropenia was not a major problem with MDMS. Grade 4 neutropenia
9
(wbc less than 1.0x10 /I) was recorded following only 3 of the
68 courses administered during the study and there were only two
episodes of infection (in the same patient) requiring intravenous
antibiotics. Moreover in contrast to platelet toxicity neutropenia
did not appear to be cumulative. The median WBC nadirs at the doses
9
recommended for phase II testing were 2.3x10 /I for
2 9 2
125mg/m and 2.2x10 /I for 150mg/m thus it is not anticipated that
infections will be a major problem in such trials.
2
At all dose levels above 70mg/m limited nausea and vomiting
occurred in 30-50% of patients. These symptoms began 2-6 hours after
2
treatment and in only one patient, who received 150mg/m ,
continued for more than 24 hours. When vomiting occurred it was
normally limited to 1-2 episodes.
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The only other non-haematological side effects encountered were
alopecia and venous pain. Alopecia was clearly dose related,
2
affecting 100% of patients at doses of 150mg/m and above but only
2
50% of patients at 125mg/m . Two patients experienced severe
venous pain during drug administration. The only possible
explanation for this appeared to be the use of saline instead of
water for reconstitution but despite all injections being given into
a fast running saline infusion only 3 other patients experienced
significant pain. In these cases fresh drug was prepared and
injected without further difficulty implying that delay in
administration following reconstitution with consequent formation of
methane sulphonic acid and alteration in pH was responsible for the
pain.
Busulphan is the only member of the dimethane sulphonic acid ester
series that has entered routine clinical use. Following the first
synthesis of the drug in 1951 (Haddow and Timmis, 1951) it was
subsequently shown to have a marked depressive effect on the myeloid
series in experiments in rats (Haddow and Timmis, 1953). It was thus
selected for clinical trial in chronic granulocytic leukaemia and
rapidly became established as the treatment of choice for this
condition. Busulphan is used as an oral preparation and is normally
given in a continuous daily regimen until control of the white cell
count has been achieved. However if the drug is continued for too
long severe irreversible bone marrow aplasia may result. Busulphan is
therefore considered to be a stem cell poison affecting all marrow
elements but particularly the granulocytic series. Although a very
large number of patients have been treated with continuous daily
Busulphan over the past 20 years, there is very little data on the
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effects of single large doses of this drug. Thus in order to compare
the toxicity of MDMS with that of Busulphan following a single bolus
dose I have abstracted data from the records of patients treated in
this manner in the department of Medical Oncology, Christie Hospital,
Manchester.
The patients involved had all received induction chemotherapy for
the treatment of Acute Myeloid Leukaemia and had remained in
remission for a period of 12 months. Busulphan was then given orally
2
in a single dose of lOOmg/m as a "late intensification" style
therapy. All patients had a normal bone marrow and peripheral blood
count prior to Busulphan. Remission induction therapy consisted of
2 or 3 courses of marrow ablative therapy using Daunorubicin,
Thioguanine and Ara-C.
Comparison of these data on Busulphan (table 13) with the data on
MDMS shows a number of similarities between the two agents. In both
cases there is a greater degree of thrombocytopenia than neutropenia
with delayed marrow recovery. In addition for both drugs the
percentage fall in neutrophils is greater than for that of
lymphocytes, the figures being very similar in each case.
Anaemia affected up to 60% of patients at higher doses following
MDMS therapy but was not seen in the Busulphan group. However the
MDMS induced anaemia was mainly a cumulative effect and was therefore
unlikely to occur after only one course of Busulphan.
Non-haematological toxicity was mild following oral Busulphan. Only
two patients noticed any gastro-intestinal side effects and one
experienced some hair loss. This compares to 25-50% of patients
complaining of nausea and vomiting with MDMS at doses over
2
lOOmg/m and 50-100% developing alopecia. None of the more
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Table 13 Busulphan in AML in remission
Number of patients
Age at diagnosis, yrs: median (range)





















Time to WBC nadir (weeks) 4 (3-11)
Time to WBC recovery " 8 (3-12+)
Time to platelet nadir " 4 (3-11)
Time to platelet recovery " 8 (6-12+)
138
unusual side effects of Busulphan eg pulmonary fibrosis (Leake et al
1963) were seen in either study.
Busulphan is generally considered to be a stem cell poison with
cumulative effects on leukocyte and platelet counts. It exhibits a
greater effect on granulocyte precursors than other members of the
white cell series and for this reason was introduced for the
treatment of chronic myeloid leukaemia. The data presented above
suggest that MDMS has very similar effects on the bone marrow and in
this respect may be considered to be an intravenous form of
2
busulphan. lOOmg/m Busulphan orally appears to be equitoxic
2
with 125mg/m MDMS with respect to marrow tolerance. However at
these doses MDMS results in nausea and vomiting and alopecia in a
significant propotion of patients whereas Busulphan does not. Perhaps
these differences are related to the alkylating range possible with
both molecules (Bedford and Fox, 1983) which will determine their
respective sites of action.
Unfortunately agents producing delayed, cumulative thrombocytopenia
can be difficult to use effectively in the clinic. Unless it is
possible to administer a drug in at least a q 21 or 28 day schedule
many tumours will escape control before the next dose is due.
Moreover there is mounting evidence that in certain conditions,
particularly high grade lymphomas, results can be improved by
increasing the dose rate and intensity of treatment (Connors and
Klimo, 1984). It will be difficult to fit drugs, such as MDMS, into
programmes of this type. However it is possible that, as a presumed
stem cell poison, MDMS might find a place in the treatment of
leukaemia and related disorders prior to bone marrow transplantation.
In common with many phase I studies the therapeutic activity seen
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in this trial was minimal with only a single minor response (less
than 50% reduction in tumour size). However as has been
demonstrated by Estey et al (1986) therapeutic response rates in
phase I trials are poor predictors of activity in phase II and thus a
negative phase I should not prevent entry to phase II. At present
phase II trials with MDMS have commenced in Soft Tissue Sarcomas
within the EORTC and in Ovarian carcinoma within the CRC.
This phase I trial was conducted according to classical guidelines
using a modified Fibonacci escalation series and entering three
patients at non-toxic doses. 15/39 patients (38%) treated in the
trial received a dose below that subsequently recommended for phase
II study. In addition the slow early escalation through non-toxic
doses contributed to the long duration of the trial which took 18
months to complete. However this was also due to the delayed recovery
of myelosuppression. The inportance of avoiding within patient dose
escalations was seen in this trial. If these had been employed the
cumulative nature of the thrombocytopenia would have taken longer to
become apparent and the data on non-haematological effects blurred.
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The anthracyclines are amongst the most important chemotherapeutic
agents. Adriamycin is included in programmes for the curative
treatment of Hodgkins disease, high grade lymphoma, small cell lung
cancer and a number of childhood malignancies including acute
lymphatic leukaemia while daunorubicin remains an important part of
remission induction therapy in acute myeloid leukaemia. In addition
adriamycin is the most active available drug in several solid tumours
including breast cancer and soft tissue sarcomas and is also used in
the management of gastric cancer, myeloma, ovarian cancer and many
other tumours.
However the parent drugs, adriamycin and daunorubicin, have a
number of unwanted side effects. Both cause nausea and vomiting and
alopecia in a high percentage of patients, side effects that can be
very distressing particularly if the drugs are being used in a
palliative setting. In addition they produce myelosuppression but the
duration of neutropenia is short and serious infective complications
uncommon unless combinations are being used. A further problem that
may occur with these drugs is cardiomyopathy. This toxicity is
cumulative and affects a significant proportion of patients at
2
total doses above 550mg/m . The cardiac lesion is irreversible
and the clinical effects may range from mild heart failure to death.
The problem of cardiomyopathy applies more to palliative than
curative treatment. In situations such as the leukaemias and
lymphomas the total doses employed in treatment programmes usually
fall well short of toxic levels. However in the palliative management
of eg breast cancer treatment is usually continued to the
2
550mg/m limit if a response has been obtained.
143
Clearly new anthracyclines that retain the therapeutic activity of
the parent compounds but with reduced nausea and vomiting,
alopecia and cardiomyopathy would be extremely useful. Over the past
15 years a great deal of effort both in Europe and America has been
directed towards developing anthracycline analogues that might
combine these properties. During this time over 400 anthracyclines
have been presented to the NCI screening programme but less than 10
have entered phase I clinical testing. Many claims have been made for
these analogues and although several appear to cause less
gastrointestinal toxicity and alopecia they all cause cardiotoxicity
and as yet none have been shown to have superior therapeutic activity
to the parent drugs.
One of the more interesting anthracycline analogues to be developed
is 4-Demethoxydaunorubicin. In contrast to existing anthracyclines
this drug can be administered orally, a feature of particular value
in the palliative situation. This compound arose out of a study by
Arcamone et al (1976) of the effects of altering the substituent at
the C4 position of the tetracyclic aglycone. Although the substituent
at this position in both adriamycin and daunorubicin is a methoxyl
group this substituent is not present in other analogues such as
Carminomycin which had shown excellent activity in preclinical
testing (Gause et al,1974). In order to investigate the properties
conferred by the C-4 methoxyl substitution Arcamone et al synthesised
4-demethoxydaunorubicin (4-DMDNR) and compared its activity against
L1210 and Sarcoma 180 with that of daunorubicin. The results showed
that 4DMDR was 5-8 times more potent than the parent
compound on a mg for mg basis, although their therapeutic ratios were
similar. Subsequently it was demonstrated that, in contrast to the
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parent drug, 4DMDNR was equally effective when administered orally to
mice bearing Gross leukaemia and Sarcoma 180 albeit at doses 3-4x the
iv dose (Di Marco et al, 1977). In addition it appears that the
major metabolite of 4DMDNR, 13-OH4DMDNR, is of similar antitumour
activity to the parent compound in animal models (Casazza et al,
1983) and that this metabolite has a particularly long serum half
life, with significant amounts still present 7 days after drug
administration.
There is evidence that adriamycin is equally effective but less
toxic when administered in a weekly low dose schedule rather than an
intermittent high dose regimen (Chlebowsky et al 1980, Weiss et al
1976, Mattson et al 1982). An oral preparation would be particularly
suitable for use in this manner since it avoids repeated clinic
visits and injections. Moreover as a result of the long biological
half life of the cytotoxic metabolite, 13-OH4DMDNR, a weekly
schedule would mimic a continuous infusion of antitumour activity.
Continuous infusion therapy is of theoretical advantage in tumours
with slow doubling times where the growth fraction represents a
relatively small proportion of the total cell population. Prolonged
exposure to the active agent should therefore allow greater cell
kill as new cells are recruited to the cycle during the infusion.
4-Demethoxydaunorubicin had shown activity in advanced breast
cancer (Bonfante V et al 1983) and we therefore decided to test the
oral preparation in a weekly schedule in such patients.
This pharmacokinetic study was conducted in conjunction with the
clinical trial to compare the pharmacokinetics of oral and iv
4-DMDNR and to determine whether its metabolism alters significantly
with prolonged continuous administration.
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Methods
All patients entered in the study had advanced breast cancer, a
Karnofsky performance status of 60% or more and no significant
hepatic (bilirubin less than 25mmol/l, transaminases less than 50%
above upper limit of normal) or renal dysfunction (creatinine less
than 0.15mmol/l). 4-DMDNR was administered as a single agent at a
2
dose of 15mg/m weekly. Treatment was given for at least 8 weeks and
continued until progression occurred. It was planned to assess serum
drug and metabolite profiles at 0, 4, 12, 24 and 52 weeks and to
measure the 7 day 13-OH4DMDNR level at each four weekly clinic visit.
In addition the pharmacokinetics of oral 4-DMDNR were compared with
the same dose given iv in five patients.
Blood and Urine Sampling
4-DMDNR was administered following a light breakfast. For the oral
study samples were taken at 0, 0.5, 1.5, 2, 3, 6, 9, 12, 24, 48 and
72 hours and for the iv study additional samples were obtained at 2,
5, 10, 20, and 60 minutes. Blood samples were centrifuged for 10 min
at 500G, the serum separated and stored at -20°C prior to assay.
Urine was collected during time intervals 0-6, 6-12, 12-24, 24-48
and 48-72hrs after drug administration. Total volumes were recorded
and 5ml aliquots stored at -20°C.
Analytical Method
Analysis of 4-demethoxydaunorubicin and 13-OH4DMDNR in blood and
urine was carried out by a modification of the reverse phase HPLC
method described by Israel et al (1978) for adriamycin. Prior to the
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development of this technique the anthracyclines had been measured by
thin layer chromatography. However the light and air sensitivity of
the anthracycline chromophore led to underestimation by these
methods. Moreover the acidic conditions of the silica gels used in
TLC resulted in formation of aglycone artefacts due to the
acid-sensitivity of the glycosidic linkage. The new HPLC technique
allowed the pH of the mobile phase to be carefully controlled to
avoid this problem. In addition the native fluorescence of the
anthracycline chromophore meant that sensitivities of the order of
lng/ml could be achieved.
Extraction Procedure
Stored serum was thawed and 2ml removed. To this was added 3 ml
methanol and the resulting solution centrifuged at 33,000G for 15
mins at 4°C. The supernatant was removed and 4ml chloroform
added. The mixture was then shaken until the chloroform was
completely dispersed and further centrifuged at 500G for lOmins at
15°C. The upper layer was then discarded and the chloroform
solution passed through a phase separation filter to remove any
remaining aqueous phase. The resulting solution was evaporated to
dryness and the residue resuspended in lOOul methanol prior to assay.
Urine was prepared for analysis by the addition of 450ul mobile
phase to 50ul from each sample. This solution was
centrifuged at 11,600G for lOmins at 4°C. 50ul aliquots of the
resulting supernatant were used for analysis.
Standards were prepared by the addition of known amounts of 4-DMDNR
and 13-OH4DMDNR to blank serum and urine. The mean correlation
coefficient of the standard curves thus obtained was 0.997 +/- 0.012
147
with an inter-assay variation of 5.6%. The extraction efficiency was
15% for serum and 60% for urine.
HPLC Method
The HPLC assay was performed using a Waters Associates U6K injector
and 6000A pump in conjunction with a Technicol ODS Hypersil column
(5u particle size and 120A pore size). The column was isocratically
eluted with an acetonitrile/ammonium formate buffer pH4 (45/55) at
a flow rate of 1.5 mls/min. UV fluorescence was monitored with a
Schoeffel FS970 detector using an excitation wavelength of 250nm and
a 550nm emission filter.
Retention times for 13-OH4DMDNR and 4DMDNR were 3 min 40 sees and 4
min 30 sees respectively (fig 4). The limit of sensitivity of the
assay was 0.25ng/ml.
Pharmacokinetic Analysis
Data from the iv study were analysed using a Nelder and Mead
Non-Linear Optomisation computer programme (Box et al 1969).
The AUC from time zero to infinity was calculated by :
AUC = A/a + B /£ + c/7
Where A,B, and C are the intercepts on the y axis andce,/3 and 7 the
rate constants governing the triple exponential decay curve
calculated by the computer programme. The clearance was obtained from
the expression:
Clearance = dose / AUC
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The apparent volume of distribution (Vd) was obtained from the
equation:
Vd = clearance/elimination rate constant
The elimination rate constant was the constant governing the
terminal elimination phase.
For the oral study the elimination rate constant (kel) was
calculated from post peak concentration data using least squares
regression analysis. This constant was used to calculate the
biological half life by the equation:
Tl/2 =0.693/kel
Total area under the curve to infinity (AUC) was calculated
using the trapezoidal rule + C/kel where C represents the
concentration at the final data point. Statistical comparison of
the mean values for AUC and elimination half life at 0 and 24 weeks
therapy was by the paired t test.
Results
Intravenous Study
The experimental serum concentrations of 4-DMDNR together with the
values calculated by the model are shown in table 14.
The plasma concetration of 4-DMDNR following iv bolus
administration described a triple exponential decay curve with
equation:
Ct=Ae~ at+Be" ^ t+Ce~ ^
In addition the data fitted a three compartment model with input
into the central compartment and excretion from one of the
peripheral compartments. The pharmacokinetic parameters derived from
the model together with the AUC and clearance are shown in table 15.
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The AUC and elimination half life following the same dose
administered orally are shown in table 16 together with the
bioavailability for the oral preparation calculated from the ratio of
AUC oral/AUC iv.
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Table 15 Pharmacokinetic parameters of 4-DMDNR following iv bolus
Patient A B C a 0 7 kl k2 k3 k4 ke
(1) 109.10 23.51 7.01 5.50 0.43 0.017 29.2 4.5 65.4 161.1 1.26
(2) 71.52 24.00 3.48 4.05 0.23 0.015 16.8 2.6 57.6 106.7 1.93
(3) 32.39 0.004 5.93 4.08 0.66 0.035 25.1 4.1 201.5 22.1 5.69
(4) 115.18 18.66 4.51 3.92 0.11 0.023 11.1 2.3 59.7 32.2 5.22
(5) 38.66 13.46 2.58 3.26 0.15 0.018 19.6 4.2 87.2 382.3 4.75
Patient AUC CI Vd Vx Vy VZ T1/2Q! Tl/2 (3 Tl/27
ug/1.h-1 1/hr It It It It hr hr hr
(1) 486.4 61.6 489.4 214.8 613.7 1074.5 0.12 1.6 39.6
(2) 353.8 73.4 380.3 252.4 1150.3 844.7 0.17 3.0 46.2
(3) 204.6 122.1 214.5 652.1 152.3 329.2 0.16 1.0 19.3
(4) 394.3 76.0 145.5 216.8 1930.6 439.5 0.17 6.3 30.1
(5) 244.5 102.2 215.1 456.9 2307.0 3640.5 0.21 4.3 38.5
Vd apparent volume of distribution
ke elimination rate constant
Vd apparent volume of distribution
Vx volume of central compartment
vy volume of first peripheral compartment
Vz volume of second peripheral compartment
7T h-« 1 1 intercompartmental rate constants
ke elimination rate constant
A,B,C - intercepts on the y axis




Patient Dose of 4-DMDNR Tl/2el AUC
mg hr ug/1.h-1
(1) 30 10.6 623.3
(2) 25 73.7 814.1
(3) 25 69.3 596.7
(4) 30 49.5 839.6
(5) 25 57.7 609.4
Table 16 Pharmacokinetic Parameters Following Oral 4-DMDNR
4-DMDNR 13-OH
Tl/2el AUC Bioavailable Tl/2el AUC
Patient hr ug/1.h-1 % hr ug/1.h-1
(1) 18.7 190.6 38.9 21.6 259.7
(2) 21.6 79.3 23.5 63.0 599.4
(3) 18.3 36.1 18.9 49.5 236.5
(4) 16.1 35.2 8.9 33.4 200.2
(5) 27.7 69.7 28.9 34.6 358.3
mean 20.4 82.2 23.8 40.4 330.8
+/-SEM 2.0 28.5 5.0 7.1 72.0
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Mean +/- SEM for five patients receiving 15mg/sqm
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The mean short, intermediate and long half lives for 4-DMDNR were
Tl/2(X= 9.6min, Tl/2 (3 = 3.24h and Tl/27= 34.74h, while the mean
elimination half life for 13-OH4DMDNR was 52. lh. For these five
patients the mean elimination half lives for 4-DMDNR and 13-OH4DMDNR
following oral administration were 20.4h and 40.4h respectively.
The mean bioavailability for the oral preparation calculated as
the ratio of AUC following oral administration to AUC following iv
administration was 23.7% (range 8.9-38.9%). The mean ratio of oral
4DMDNR AUC + 13-OH4DMDNR AUC to iv 4DMDNR AUC + 13-OH4DMDNR AUC was
40.6% (range 19.1-58.9%). The decay curves for 4-DMDNR and
13-OH4DMDNR after iv bolus are shown in Fig 7.
Urinary recovery of unchanged drug was 0.41-0.67% (mean 0.53%)
after oral and 2.01-3.31% (mean 2.62%) after iv administration
(table 17). Recovery of 4-DMDNR following oral dosing was therefore
20% of that following iv.
Table 17 72 Hour Urine recovery of 4-DMDNR and 13-OH4DMDNR
oral intravenous
Patient Dose 4-DMDNR %dose 13-OH 4-DMDNR %dose 13-OH
mg ug ug ug ug
(1)* 30
(2) 25 102.7 0.41 778.0 715.0 2.86 2374.0
(3) 25 127.0 0.50 613.0 515.0 2.06 1898.0
(4) 30 203.6 0.67 1190.5 683.0 2.27 1968.0
(5) 25 135.6 0.54 726.1 828.0 3.31 2436.0
: urine volumes unreliable
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The mean ratio of 13-OH4DMDNR : 4-DMDNR detected in the urine was
3.1:1 for the iv and 6.0:1 for the oral route. The corresponding
values for metabolite and parent drug detected in the serum were
2.06:1 for iv and 4.02:1 for oral administration. These results
indicate that there is an increase in 13-OH4DMDNR by a factor of two
when 4-DMDNR is given orally compared to iv.
Study of Repeated Oral Administration
Serum profiles were assayed in ten patients at the start of
therapy. Subsequent measurements were obtained in two patients at 4,
12, 24 and 52 weeks, in two at 4, 12 and 24 weeks and in 4 at 4 weeks
only. Tables 18 and 19 show the AUC and elimination half lives for
4-DMDNR and 13-OH4DMDNR at these times.
Figures 8 and 9 show the change in Tl/2el and AUC with time for
4-DMDNR and 13-OH4DMDNR in patients receiving 6+ months treatment.
For these patients the mean AUC for 4-DMDNR at week 0 was
57ug/l.h 1 and at week twenty four 64ug/l.h ^ (p>0.1). The
corresponding elimination half lives were 23.1hrs and 22.9hrs
(p>0.5). The AUCs for 13-OH4DMDNR at 0 and 24 weeks were
366.3ug/l.h 1 and 378.lug/1.h 1 (p>0.5). The elimination
half lives at these times were 43.5hrs and 44.4hrs (p>0.5).
Following oral administration the peak serum 4-DMDNR concentration
was 3.1 +/- 1.5 ng/ml occurring 2.7 +/- l.Ohrs after ingestion. Peak
13-OH4DMDNR was 7.1 +/- 3.7 ng/ml occurring 3.6 +/- 1.8 hrs after
ingestion.
The decay curves for 4-DMDNR and its metabolite after oral
administration are shown in Fig 10. The 13-OH4DMDNR seven day level
was measured every 28 days in 24 patients. The mean value was
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0.8ng/ml (range 0.18-2.48ng/ml) and there was no evidence of
accumulation (Fig 11, table 20).
There was no correlation between peak drug concentrations or 7 day
metabolite levels and response to therapy in this group of patients.
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Table 18 4-DMDNR AUC and Tl/2 following repeated weekly administration
wk 0 wk 4 wk 12 wk 24 wk 52
Patient AUC Tl/2 AUC Tl/2 AUC Tl/2 AUC Tl/2 AUC Tl/2
(1) 49.3 24.7 50.8 22.3 52.6 10.5 56.1 23.8 54.5 15.0
(2) 49.4 13.0 35.6 18. 2 41.4 15.7 58.2 19. 2 44.5 24.7
(3) 66.5 20. 3 68.1 20. 3 70.2 23.1 71.3 19.8
(4) 64.1 34.6 32.1 16.5 50.4 23.8 72.6 28.8
(5) 76.6 31.5 73.2 33.0
(6) 51.7 17.7 50.8 23.1
(7) 56.6 28.8 78.0 28.8
(8) 47.6 21.6 45.7 26.6
(9) 71.8 19.2
;i0) 76.3 21.6
Table 19 13-OH4DMDNR AUC and Tl/2 following repeated weekly administration
wk 0 wk 4 wk 12 wk 24 wk 52
Patient AUC Tl/2 AUC Tl/2 AUC Tl/2 AUC Tl/2 AUC Tl/2
(1) 305.5 43.3 417.1 53.3 404.9 39.3 311.3 38.5 462.6 40.7
(2) 485.3 38.5 275.9 49.5 402.1 46.2 349.9 40.7 327.4 43.3
(3) 503.2 34.6 414.6 40.7 403.4 46.2 469.5 57.7
(4) 171.3 57.2 170.7 40.7 478.3 53.5 382.3 40.7
(5) 316.3 46.2 404.8 57.7
(6) 363.0 53.3 458.8 63.0
(7) 314.6 69. 3 538.5 57.7




Table 20 7 day 13-OH4DMDNR levels (ng/ml) during continuous treatment
Week
32 362 4 8 12 16 20 24 28
Patient
(1) 0.72 0.31 1.35
(2) 0.61 1.65
(3) 0.23 0.69 0.61
(4) 0.59 0.40 0.43
(5) 0.74 0.24 0.70 0.70
(6) 0.72 0.40 0.40
(7) 1.20 1.10 0.96
(8) 2.30 2.02 1.27 1.12 1.60 0.99
(9) 0.24 0.21 0.18 0.18 0. 33 0.60
(10) 0.27 0.37 0.62 1.23 0.99 1.20
(11) 0.72 0. 39 0.62 0.52 0.72 0.66 1.09
(12) 0.56 0.65 0.78 0.79
(13) 0.64 1.16 0.88 0.56 0.37 0.35 0.10
(14) 1.54 1.96 1.90
(15) 0.50 0.69 0.41 0.43 0.40
(16) 0.76 0.56
(17) 0.80 0.30 1.02
(18) 1.97 1.66 2.48 1.62 2.12 1.84 1.37 1.11
(19) 0.63 0.73 0.61 0.42
(20) 0.80 1.66 1.54 2.13 2.32 1.00
(21) 1.54 0.49 0.79 1.06 1.34
(22) 0.44 1.23
(23) 0.35 0.22 0.36 0.91
(24) 0.56 0.55 0.40 0.53 0.53 0.51
0. 30
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fig 8 4DMDNR AUC and T1/2el in Patients
Receiving at least 6 months Therapy
Hours









13-Oh- 4DMDNR AUC and T1/2el in Patients
Receiving at least 6 months Therapy
Hours
cr. T1/2 13-OH 4DMDNR
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Mean +/- SEM for 5 patients receiving 15mg/sqm
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Mean +/- SEM for : 20 patients at 2 weeks
23 patients at 4 weeks
19 patients at 8 weeks
13 patients at 12 weeks
11 patients at 16 weeks
10 patients at 20 weeks
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Discussion
The assay method used in this study was a modification of that
developed for adriamycin by Israel et al (1978). The method was
relatively simple to perform, in particular the use of phase
separation filters avoided tedious manual removal of the aqueous
phase. In addition the combination of an acetonitrile/ammonium
formate mobile phase at pH 4 with a flow rate of lml/min resulted in
retention times of under 5 minutes for both 4-DMDNR and 13-OH4DMDNR.
Other authors using alternative buffer systems have reported
retention times of 10, 15 and 24 min (Daghestani et al, 1985, Berman,
et al 1983, Moro et al 1983). The method described here therefore
achieves a considerable time saving by allowing samples to be
processed more rapidly. Moreover the limit of sensitivity for the
HPLC system used in this study was 0.25 ng/ml. This represents a 10
fold improvement over previous techniques where measurement has not
been possible below 2ng/ml (Daghestani et al, 1985, Berman et al
1983, Moro et al 1983). Moreover In these studies it was not possible
to detect the parent compound in the blood after 24 hours but we have
been able to show that 4-DMDNR is present for up to 72hrs after
both oral and iv administration. It was also possible to detect
13-OH4DMDNR in the blood 7 days after treatment at levels consistent
with the observed elimination half life of 44 hours.
Previous reports comparing the AUC for 4-DMDNR administered
orally with that following iv injection have suggested that the
drug has an oral bioavailability of approximately 30%. (Berman et al
1983, Kaplan et al 1984, Lu et al 1984). In the present study a
similar calculation produced a mean value of 25% for the
bioavailability of the parent drug. This figure is slightly lower
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than the previous estimates but may be more accurate since
comparisons of oral and iv administration were made in the same
patients to minimise the known inter-patient variability in the
handling of anthracyclines.
Although the boioavailability of 4-DMDNR assessed in this way
appears to be of the order of 25-30% the actual absorption of the
drug is likely to be approximately 40%. The discrepancy arises from
the rapid hepatic metabolism of 4-DMDNR. Following iv administration
significant amounts of 13-OH4DMDNR are present in blood samples taken
2 minutes after injection. When the drug is given orally absorption
into the portal circulation results in a higher proportion being
converted to this metabolite. Thus the ratio of AUC for 13-OH4DMDNR
iv to oral was 2.1 : 1 compared to a ratio of 4.0 : 1 for the parent
compound. In addition the sum of the AUC 4-DMDNR + AUC 13-OH4DMDNR
for oral dosing gave a value of 40% of that for iv injection. These
results indicate that the absorption of 4-DMDNR is somewhat higher
than previously thought but that rapid hepatic metabolism prevents
10-15% of the absorbed dose reaching the systemic circulation.
A number of phase I trials have shown that the the maximum
2
tolerated single dose of 4-DMDNR was 15mg/m by the iv route and
2
50mg/m by the oral route (Kavanagh et al 1985, Kaplan et al
1984, Daghestani et al 1985, Berman et al 1983). The dose limiting
toxicity in these studies was myelosuppression and thus in terms of
marrow tolerance the oral preparation has a biological activity 30%
that of the iv preparation. This suggests that while the parent drug
and metabolite appear to be of equal cytotoxic activity in
pre-clinical testing (Casazza et al 1983) this is not bourne out in
clinical trials. If this were the case the MTD for the oral dose
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would be nearer 50% that of the iv dose than 30%.
In common with others (Berman et al 1983, Daghestani et al 1985) it
was found that the blood levels of 4-DMDNR followed a triphasic decay
pattern (Tl/2 o: =9.6min ,Tl/2=3. 2h and Tl/2 7 =34.7h), the kinetics
conforming to a 3 compartment model. The short alpha half life and
high volume of distribution are probably due to the rapid tissue
binding, known to occur with anthracyclines.
The results of the oral study show that there was no significant
alteration in the metabolism of 4-DMDNR with continuous weekly
treatment. In particular there was no accumulation of 13-OH4DMDNR
and no reduction in biological half life for the parent drug or
metabolite. Although there was some intra-patient variability the
absorption of 4-DMDNR, as assessed by the AUC, the bioavailability
remained constant in the majority of patients.
Studies of the pharmacokinetics of doxorubicin and 4 'epiadriamycin
during successive courses of therapy at 21 day intervals have
demonstrated a small increase in clearance and a shortening of the
alpha half life but no change in the elimination half life for these
drugs (Robert et al, 1983, Gil et al 1983, Vrignaud et al, 1985). The
present study shows that despite using a weekly schedule the
pharmacokinetics of 4-DMDNR also change little with time.
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In recent years the chemotherapeutic management of advanced breast
cancer appears to have entered a plateau phase. Despite the
existence of several active single agents and the early promise of
high response rates with combination regimens it is clear that at
present this is not a curable disease (Harris et al, 1985). Even the
introduction of high dose therapy with autologous marrow rescue has
not had a significant impact on survival. Moreover it appears that
while responses can be obtained and symtoms improved in many patients
only those with life threatening visceral disease, particularly liver
involvement, can be shown to have a survival advantage conferred by
the use of chemotherapy. This realisation has prompted cancer
physicians to search for less toxic chemotherapy in an effort to
palliate symptoms with minimal side effects.
One method of reducing subjective toxicity is by administering
drugs orally. This avoids the necessity for repeated injections and
may allow a reduction in the frequency of clinic visits. Three of the
most active single agents in breast cancer cyclophosphamide,
methotrexate and 5-fluorouracil are available in oral formulations
and they have been combined in a recently reported study (Wagstaff et
al 1985). In this trial the drugs were given on a continuous weekly
basis, cyclophosphamide on Monday, methotrexate on Wednesday and 5-FU
on Friday. The response rate of 53% was similar to that obtained in
other trials with classical CMF and the median duration of response
of 11 months and median survival of 16 months also did not differ
from previously reported figures. Moreover the subjective toxicity of
oral CMF was low with minimal nausea and vomiting and no significant
episodes of alopecia. The use of oral chemotherapy in this manner
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therefore appeared to be an effective way of reducing toxicity
without prejudicing response or survival.
Another method of reducing toxicity is the use of more frequent low
dose chemotherapy. A number of studies have been conducted with
Adriamycin used in this way (Chlebowsky et al 1980, Weiss et al 1976,
Mattson et al 1982). The rationale for these studies is that while
adriamycin is the most active single agent in advanced breast cancer
with response rates of around 50% in untreated patients the toxicity
is substantial. Nausea, vomiting and alopecia occur in most patients
and treatment eventually has to be discontinued because of cumulative
cardiotoxicity. However the severity of these side effects appears to
be related to peak blood concentrations rather than total dose
administered. Adriamycin used in a weekly schedule at doses of
2
20-25mg/m has very little subjective toxicity. Gastrointestinal
side effects are unusual, significant alopecia umcorrmon and the
2
threshold for cardiotoxicity rises to over lgm/m . Moreover
there does not appear to be a significant loss in therapeutic effect.
The major disadvantage of weekly adriamycin is the frequency of
clinic visits. This puts an additional strain on all the hospital
services involved in managing patients being treated with intravenous
chemotherapy. In addition the patients have the inconvenience,
expense and psychological morbidity of frequent hospital attendence
and an increased risk of drug extravasation. Moreover there may be a
tendency for new problems not to be detected in patients who are
seen too frequently.
4-Demethoxydaunorubicin (Idarubicin, 4-DMDNR)) is a new synthetic
analogue of daunorubicin and is the first anthracycline to be
available in an oral formulation. For the reasons outlined above it
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would therefore be particularly suitable for use in a weekly
schedule. Moreover in view of the antitumour activity and long serum
half life of the 13-OH metabolite it was possible that a weekly
schedule might mimic a continuous cytotoxic infusion which may be
of benefit in tumours with relatively slow doubling times.
4-Demethoxydaunorubicin had demonstrated activity in advanced breast
cancer during phase I testing (Bonfante et al 1983) and we therefore
decided to test this drug in a weekly oral schedule in such patients.
Patients and Methods
A phase I study by De Sloover et al (1984) using a weekly x 4 oral
2
schedule demonstrated minimal toxicity with doses up to 15mg/m
but increasing nausea, vomiting and neutropenia at higher doses.
Since one of our aims was to use a continuous therapy we did not wish
to choose a dose that would result in frequent delays.
4-Demethoxydaunorubicin was therefore given at a dosage of
2
15mg/m in a weekly oral schedule. It was planned to
2
escalate the dose by 5mg/m increments until toxicity was seen
that necessitated treatment delays in the majority of patients.
Patients were seen at 14 day intervals for the first 4 weeks and
subsequently every 28 days. The dose was reduced by 5mg/week when the
9
wbc fell below 2.5x10 /I and treatment was delayed by one week
9
if the wbc was less than 2.0x10 /l. Following a delay
4-Demethoxydaunorubicin was not restarted until the wbc was
9
above 3.0x10 /I. Treatment was given for at least 8 weeks,
unless progression of life threatening disease dictated a change to
intravenous chemotherapy, and continued until relapse. When
progression occurred it was our intention to use Adriamycin
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60mg/m in a q21 day schedule in order to obtain data on cross
resistance between these two agents.
Patient entry was according to the two stage design described
previously with an initial sample of 14 patients. The trial
protocol was submitted to the South Manchester Ethical Committee and
the Christie Hospital Protocol Review Committee.
Verbal informed consent was obtained from all patients according to
current MRC guidelines.
Patients
Thirty eight evaluable patients with a median age of 63.5 yr, a WHO
performance status of 0 or 1, and an anticipated survival of at least
3 months were entered into the study. Patients with cardiac failure,
major rhythm disturbances or significant EGG abnormalities were
excluded. Patient characteristics are summarised in Table 21. No
patient had received prior chemotherapy but 32 had one or more
trials of endocrine treatment. Reasons for not using endocrine
therapy included rapidly advancing liver disease (3) and receptor
negative inflammmatory carcinomas (3). Among the 18 patients with
soft tissue metastases as the dominant site of disease there were 10
with locally advanced primary tumours, 3 with involved lymph nodes
and 5 with cutaneous disease. In the group of 8 patients with
dominant bone disease only 2 did not have evaluable disease
elsewhere.
All patients were assessed according to UICC criteria (Hayward
et al 1977) with duration of remission measured from the date of
starting chemotherapy. Toxicity has been graded using the WHO scale
(Miller et al 1981).
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Table 21 Patient Characteristics - 4-DMDNR Phase II
Characteristic %
Age, median (range) 63.5 (33-79)
Menopausal staus : pre 1 3
post 37 97
Post surgery radiation 11 29
Disease free interval,
months median (range) 19 (0-204)
Time from first relapse to 4-DMDNR,
months median (range) 10 (0-132)
Receptor status:




Response to hormone therapy:
Progression 18 56
Static (6 months+) 4 12
PR 8 25
CR 2 6
Dominant site of disease:







The 38 patients received a median of 12 weeks treatment (range 2-60
weeks). Three patients with rapidly progressing liver disease had to
be switched to Adriamycin after 2-4 weeks therapy. Six patients
2
received in excess of 450mg/m total dose of 4-DMDNR. In two
patients, neither of whom had bone disease, the dose was escalated to
20mg/m^/week. In both cases the WBC fell below 2.5x10^/1 after 3
weeks treatment necessitating delay. When the dose was reduced to
2
15mg/m neither patient required further delay of therapy.
2
15mg/m was therefore considered to be the maximum tolerated
dose using this schedule.
One CR (cutaneous) and 5 PRs were seen providing an overall
response rate of 15.7%. (95% confidence limits 6-31%). Partial
remissions occurred in patients with the following dominant sites of
disease. Inflammatory carcinoma (1), lymph nodes (1), retroperitoneal
infiltration + bone (1) and cutaneous deposits (2). In addition six
patients had static disease for a period of at least six months. The
duration of the remissions was 13 months for the CR and 5+,5+,9+,10+
and 14+ months for the PRs. The median tine to objective remission
was 8 weeks (range 4-10 weeks) and responses were evenly distributed




The toxicity of 4-Demethoxydaunorubicin administered in this
schedule was mild. Seven patients (18%) required treatment delays,
six due to neutropenia (grade 3) and one to a severe radiation
recall reaction. Dose reductions were necessary in 13 patients (33%),
9 because of haematological toxicity (grade 2/3 neutropenia) and 4
as a result of unacceptable nausea and vomiting (grade 3). Bone
marrow examinations were performed in six of the nine patients who
had dose reductions following episodes of neutropenia and in all
cases the marrow was involved with tumour. Two of the remaining three
patients had widespread bone disease.
Gastrointestinal toxicity was variable. Twelve patients (31%)
experienced no nausea or vomiting while 14 (37%) had mild nausea
(grade 1) affecting less than 25% of their doses. Six patients also
reported grade 1 nausea but affecting 25-75% of doses and a further
six (16%) had nausea and vomiting (grade 2-3) with every treatment,
in 4 cases requiring dose reductions. Three patients developed mild
alopecia not requiring a wig (grade 1) and there were no episodes of
cardiac failure or EOG abnormalities seen during the study. One
patient developed a radiation recall reaction. This occurred in a
lady who had received postoperative radiotherapy to the chest wall
and lymph node drainage areas and became apparent after the second
dose of 4-DMDNR. The reaction consisted of an extremely painfull
erythematous eruption in the area of previous irradiation together
with dyspnoea and a cough productive of clear sputum. These symptoms
resolved in 7 days with the aid of steroid therapy.
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Treatment on Progression with Adriamycin
Thus far 32/38 patients have progressed on treatment with
4-Demethoxydaunorubicin and fourteen of these have received
Adriamycin. Reasons for not using Adriamycin in the remaining
patients included : too ill to warrant further therapy (6), fear of
alopecia (2), elderly and frail (5), asymptomatic (2), radiation
recall with 4-Demethoxydaunorubicin (1), cirrhosis with rising
bilirubin (previously normal) (1) and prolonged pancytopenia (1).
Patient characteristics of these 14 patients are shown in table 22.
Six patients had rapidly advancing liver disease in 2 cases occurring
as a new site after 12 and 17 weeks 4-DMDNR.
There were 5 PRs (36%) in this group of patients. A further 3
patients had less than 50% regression of their disease with good
symtomatic response for 5, 5, and 8+ months. Cne responding patient
has relapsed after 5 months but the remaining 4 continue in remission
at 6+months after commencing Adrianycin.
Two patients who responded to Adriamycin had previously had static
disease on 4-Demethoxydaunorubicin for 6 months+. These were patients
with lung metastases as the major site. The remaining 3 all had liver
metastases and in two cases were switched to Adriamycin after less
than 4 weeks 4-Demethoxydaunorubicin because of rapidly advancing
disease.
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Table 22 Characteristics of Patients Treated with Adriamycin
Characteristic
Number of weeks 4-DMDNR therapy, median (range) 14 (2-32)
Response to 4-DMDNR : Static (6 months+) 2 14
Progression 12 86




Number of courses of Adriamycin, Median (range) 4 (2-8)
Reason for stopping Adriamycin : Toxicity 1 7
Reached maximum dose 4 28
Progression 8 57
Continues on therapy 1 7
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Retrospective comparison of the survival of three groups of
patients treated with three different chemotherapy regimens.
DMD - 4-Demethoxydaunorubicin
VAP - Vincristine, Adriamycin, Prednisolone
ROT - Oral weekly Cyclophosphamide, Methotrexate, 5-FU
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Discussion
The majority of trials with new agents in advanced breast cancer
are difficult to interpret because the drugs are tested in heavily
pre-treated patients, a situation where even drugs of proven value in
first line management are largely ineffective (Harris et al 1985).
One method of overcoming this problem is to use new agents in
previously untreated patients but with a trial design allowing early
cross-over to an active regimen in the event of progression. Such a
procedure may be criticised as being unethical in that patients are
denied optimal therapy. However if these patients are observed
carefully and transferred to alternative treatment at an early stage
if no response is seen, their chances of responding to such therapy
should not be significantly diminished. Moreover if a response is
seen then these patients will benefit from all the first line agents
still being available if and when they relapse. In the initial stages
of such a trial the patients entered would have to be limited to
those without immediately life threatening disease. Using trial
designs of this type would save a great deal of the time and effort
currently expended on trials in pre-treated patients and would yield
valuable data allowing early rejection of ineffective agents and
preventing false rejection of active compounds.
In the present study 4-DMDNR, previously untested in breast cancer,
was used as first line therapy in patients who had not received prior
chemotherapy. The trial design incorporated a cross-over to
adriamycin in the event of progression and was justified by the
activity of the parent drug and probable reduction in toxicity of the
new therapy. The objective response rate of 16% was low but with the
addition of the patients with static disease for 6+ months this rises
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to 29%. This is thought to be justifiable since patients with static
disease for this length of time have been shown to have an identical
survival to those who obtain a partial remission (Howell et al 1985).
Perhaps low dose chemotherapy of this type may act by controlling
tumour growth rather than producing significant reductions in
measurable disease.
Comparison of the survival of the total patient group to that of
previous groups of patients treated initially with VAP-Cyclo-AC and
CMF at this institute showed no significant difference (fig 12), This
is likely to be due in part to the use of adriamycin on progression,
particularly in the patients with liver disease, where a response
rate of 38% was obtained. Thus the use of an unproven drug as first
line treatment did not appear to prejudice survival in these patients
and delayed the use of more toxic chemotherapy in a significant
proportion of patients. Where responses occurred these were of good
quality and obtained with minimal adverse side effects.
The main subjective toxicity was limited GI toxicity affecting 59%
of patients and there was no significant alopecia. There were no
episodes of cardiac failure seen during the study despite six
2
patients receiving more than 450mg/m , a cumulative dose that
might be expected to result in myocardial dysfunction allowing for an
oral bioavailability of 30%. This suggests that 4-DMDNR is less
cardiotoxic than the parent drug although the weekly schedule may
also have contributed to a reduction in this side effect.
Haematological toxicity was also mild. There was no
thrombocytopenia and neutropenia only occurred in patients with
marrow infiltration or widespread bone disease. There was no evidence
of cumulative myelosuppression.
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For the reasons outlined above the number of patients in the
Adriamycin arm of this study was too small to draw any firm
conclusions on cross resistance between these two drugs. Moreover two
of the five patients who responded to Adriamycin had only had two
weeks therapy with 4-Demethoxydaunorubicin due to rapidly advancing
liver diseese. However there were three patients who progressed after
more than 8 weeks 4-Demethoxydaunorubicin therapy (lung- 2, liver- 1)
who subsequently achieved a partial remission with Adriamycin.
Although this suggests that there may be a degree of non-cross
resistance between these two agents the different scheduling could
also be important. Indeed since this study was activated a number of
authors have published preliminary results of the use of 4-DMDNR in
2
advanced breast cancer used at doses of 40-50mg/m in a q21 day
schedule. These trials have obtained response rates of 30-50%
(Pannuti et al 1985, Bastholt et al 1985) although GI toxicity was
more severe than for the weekly regimen. Thus it appears likely that
in contrast to Adriamycin there is a loss of therapeutic effect when
4-Demethoxydaunorubicin is used in a weekly schedule. The inference
that may be drawn from these data is that high peak levels of
4-Demethoxydaunorubicin or 13-0H4DMDNR or both are important for
antitumour activity rather than the more continuous lower levels
achieved by weekly administration. In the light of these findings
it would be interesting to know whether patients progressing on
weekly 4-Demethoxydaunorubicin would respond to higher dose three
weekly 4-demethoxydaunorubicin Moreover in order to answer the
question of cross resistance between the parent anthracyclines and
4-Demethoxydaunorubicin a randomised cross-over trial using similar
scheduling would have to be carried out.
181
In summary 4-Demethoxydaunorubicin used in a weekly schedule is
well tolerated and has activity in advanced breast cancer.
However this mode of administration appears to be inferior, in terms
of response, to giving the same total dose of drug in a q21 day
regimen, although the weekly schedule is probably less toxic and may
be a more acceptable option in frail elderly patients. Low dose
weekly treatment was clearly inadequate therapy for rapidly
progressive liver disease. Thirty six percent of patients treated
with adriamycin in a q 21 day schedule after failing 4-DMDNR achieved
a partial remission.
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Amphethinile (ICI 134154, CRC 82/07) was first synthesised in the
ICI laboratories at Mereside in Cheshire and aroused interest when it
was shown to terminate pregnancy in rats. This effect occurred
following two injections on day 9 of gestation or one on day 10 and
the qualitative appearance of the degenerating implants suggested
that it might be due to cytotoxic damage. The drug was fully
effective both orally and subcutaneously at a dose of 5mg/kg and
produced other toxic effects at a dose of 25irg/kg. In this test
vincristine was fully effective at a dose of 0.25mg/kg but lethal at
0.5mg/kg. Amphethinile, which has been shown to be a spindle poison
in dividing Hela cells, thus appears to have a better therapeutic
ratio than the vinca alkaloids.
The compound was submitted to the NCI pre-clinical screen and was
shown to be active in L1210, ADJ/PC6 and the Walker carcinoma but
inactive in the TLX/5 and GHS-Pit tumours. Additional testing by
Harold Jackson at Manchester University confirmed the activity in the
Walker and ADJ/PC6 tumours but showed the drug to be inactive in a
Chondrosarcoma and a chlorambucil resistant Walker tumour.
In view of this pre-clinical activity, the possible improvement in
therapeutic ratio compared to existing spindle poisons and the
apparent oral absorption the drug was taken up by the CRC Phase I/II
committee for formulation and pre-clinical toxicology.
Formulation
Amphethinile is a relatively simple synthetic compound with a
molecular weight of 265 and melting point of 190.5°C.
Investigation of the bulk compound showed that it contained
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approximately 1% inorganic material by ash analysis and less
than 2% impurities on TLC and HPLC.
The main problem with amphethinile is that it is extremely
insoluble in aqueous solution, 1.7 ppm at 20°C and 6 ppm at 37°C. It
is highly soluble in polar solvents such as DMSO and DMA but the
solubility in these diluents drops rapidly when the solvent/water
ratio falls below 60/40, and an extremely coalescent precipitate
forms. The volumes of solvent that would be required to prevent this
happening on contact with blood made such a formulation impractical.
Another option was the use of a surfactant like material such as
Cremophor EL. These agents have a hydrophobic "head" and a
hydrophylic "tail" and can surround individual molecules of a
compound forming a molecular suspension in aqueous solution.
Cremophor EL has been used in the formulation of several antitumour
agents (Echinomycin, Teniposide, Diaziquone, Taxol) and also the
systemic antifungal miconazole. Cremophor is the reaction product of
castor oil and ethylene oxide and the main problem associated
with its use is hypersensitivity. A significant proportion of
patients treated with Cremophor containing preparations experience
allergic reactions up to and including anaphylaxis and deaths have
occurred. Some drugs, notably the anaesthetic induction agent
Althesin, have had to be withdrawn for this reason. Solutol HS 15- is
a development of Cremophor that is prepared from
12-hydroxystearic acid, one of the components of castor oil, +
ethylene oxide. It is thus a much "cleaner" compound than Cremophor
and in experiments on Beagle dogs has been shown to cause 10-20 x
less histamine release and is therefore thought to be potentially
less allergenic. The LD 50 for Solutol in dogs is in excess of
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3. lg/kg.
Solutol is a relatively recent development and has not been used
previously in pharmaceutical preparations. For this reason special
permission had to be obtained from the DHSS for its use with
amphethinile. This was granted and Dr Vezin at the CRC Formulation
Unit, Department of Pharmacy, University of Strathclyde was able to





lml 30% Citrate buffer/70% Alcohol
Citrate buffer was prepared from Citric acid 0.1M + Sodium
hydroxide 0.1M to pH 6.
The resulting formulation contains 50% weight/volume solutol
(500mg/ml Solutol). This is a very stable product with no detectable
degradation after four months at 57°C. The solution is a rather
viscous straw coloured fluid and requires 1:10 dilution with N saline
prior to administration.
Preclinical Toxicology
Preclinical toxicology was carried out by BIBRA Ltd., Carshalton,
Surrey according to CRC Phase I Committee protocols.
Acute Intravenous Toxicity in Male Mice
The acute intravenous toxicty was investigated in groups of ten MFl
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strain male mice. These animals were treated with doses ranging from
0 - 225mg/kg as a bolus injection into the tail vein. At doses over
200mg/kg all mice exhibited an immediate catatonic reaction and half
died within 20 minutes of receiving the injection. Following these
observations further mice were treated using Solutol alone and
similar catatonic reactions and deaths occurred. It was also found
that these reactions and deaths could be completely avoided by
administering the solutol slowly over thirty seconds rather than as a
rapid bolus. In addition none of the other effects that were seen
with the amphethinile preparation occurred when the solutol alone was
given. As a result of these findings all toxic effects reported below
with the exception of the catatonic reaction were considered to be
due to amphethinile. All subsequent doses of amphethinile were given
as a slow injection and no further acute catatonic reactions or early
deaths were seen.
Effects on the mice at higher doses included tail necrosis distal
to the injection site, uncoordinated movements and low body
temperature. All deaths occurred within 3 days of treatment but gross
macroscopic post mortem examination showed no treatment related
effects.
mgAg 95% confidence interval
LD 10 137 (98-193)
LD 50 213 (171-263)
Acute Intraperitoneal Toxicity
In addition to estimation of LD50 and LD10 values and
observation of gross effects this study involved detailed
haematological and histological examinations.
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Groups of mice were treated with single intraperitoneal
injections of amphethinile in doses ranging from 125-260mg/kg. All
mice dying as a result of treatment did so within one day. Other
effects observed at higher doses included lethargy, reduced body
tenperature and generalised unsteadiness. There was no reduction in
body weight.
In all treated groups there was a rapid fall in the number of
circulating granulocytes, lymphocytes and platelets by day 3. The
granulocytes and platelets recovered to normal levels by day 10 but
only at the lowest dose was there definite recovery in the lymphocyte
population by day 28. No effect was seen on the red cells.
Histological examination of the marrow, sleen and lymph nodes
showed moderate necrosis in mice dying within 2 days of treatment but
no changes in mice sacrificed at 14 days. These changes may be
responsible for the slow recovery seen in the peripheral lymphocyte
count.
The major histological changes seen were in the testes. Germ cell
and spermatogonial necrosis occurred at all dose levels, in severe
cases leading to tubular calcification, atrophy and interstitial cell
hyperplasia. These changes appeared to be dose related.
A small percentage of the mice dying within two days of treatment
had minimal necrosis of the glandular, squamous or sub-mucosal areas
of the stomach and of the crypt epithelium cells of the small
intestine. No abnormalities in these areas were seen in mice
sacrificed at 14 or 28 days.
No additionl changes were seen in any of the remaining organs











Groups of animals were given a total of 20 IP injections over 28
days at doses ranging from 18.5mg/kg to 150mg/kg. All mice receiving
150mg/kg died within 5 days. Histological examination of these
animals revealed marrow aplasia together with similar changes in the
testes and gastrointestinal mucosa seen with single IP doses. No
marrow changes were seen in mice surviving to 28 days post treatment.
The approximate LD50 from this study was 86mg/kg.
Toxicity Check in the Rat
From the above mouse studies the LD 10 appears to be close to
2
140mg/kg or 420mg/m . The proposed starting dose for phase I
2
clinical trials would therefore be 42mg/m ie l/10th LD10. A
check of this dose was carried out in the rat. Groups of 10 male
Wistar rats were given 20 IP injections at 7.5mg/kg. No toxic
effects were seen.
Summary
At doses over 200mg/kg rapid iv injection resulted in a catatonic
like reaction and in some cases death. However these effects were
shown to be due to the solutol vehicle rather than the amphethinile
and could be avoided by administering the drug as a slow infusion
over 30 seconds. No other solutol related effects were seen
Histological damage was limited to the rapidly dividing tissues of
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the marrow, testes and GI tract with no obvious effects elsewhere.
There was a rapid fall in WBC and platelets with subsequent quick
recovery in granulocytes and platelets but slow recovery of
lymphocytes. When deaths occurred these were early after treatment
coinciding with the time of maximum histological damage to marrow and
gut. No late deaths occurred and residual damage at higher doses was
limited to the testes.
2
As a result of pre-clinical toxicology a dose of 40mg/m has
been selected as the starting dose for phase I trials.
Phase I Clinical Trial of an Intermittent IV Bolus Schedule
The initial phase I clinical trial of Amphethinile using an
intermittent IV bolus schedule was commenced on 21st July 1986 at the
Christie Hospital, Manchester. The trial protocol differed in two
main areas from that used in the MDMS phase I. Firstly the escalation
procedure was modified to take into account both the findings of the
survey of phase I trials described earlier, and the concept of using
preclinical pharmacological data to guide dose selection. The







* It was proposed to escalate to 5n if the first dose was entirely
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non-toxic and the AUC measured at this dose less than 5% of the
target AUC. The target AUC was estimated to be of the order of
300ug/l.h-l from experiments at the LD10 in mice. These experiments
will be fully described later.
If toxic effects were seen and the AUC was less than 20% of the
target AUC then a 100% escalation to 2n was permissible. Smaller
increases of 25 - 50% or dose reduction would be undertaken depending
on the level of toxicity and the pharmacological data. Subsequent
escalations would also rely on these considerations although in the
early stages of the trial a maximum increase of 100% would be
allowed. If it became clear that the AUC was far short of the target
AUC and that the kinetics were linear, then larger dose increases
would be allowed once this information was available. This escalation
scheme is designed to be flexible in order to arrive at the MTD
safely with the fewest possible escalation steps.
The second difference in the protocol was in the numbers of
patients to be treated at each dose level. It was decided to treat
only two patients at each non-toxic dose level to further reduce the
numbers of patients treated at doses with no potential therapeutic
benefit. As has been the practice in the past increasing numbers of
patients would be treated at toxic dose levels with at least six at
the dose recommended for phase II testing.
Results
In the following results section the platelet and leukocyte values
9
are given in units of x 10/1. Clearance is in ml/min, AUC in
ug/l.h-1 and half lives in hours.
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No drug could be detected in the serum at this dose.
Conment
The drug was given as a bolus injection over five minutes. There
were no acute or sub-acute effects and in addition amphethinile was
present in concentrations too low to be measured in the serum. Since
the lower limit of detection of the assay was 0.lug/ml the AUC at
this dose was clearly well below 5% of the target AUC. It was
therefore decided to escalate the dose immediately to five times the
starting dose, 200mg/sqm.
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Patient RH had a grand mal convulsion during the administration of
his second dose of amphethinile. This occurred after approximately
50% of the dose had been given. He made a full and rapid recovery.
There had been no problems with the first course. Patient JC
experienced no side effects. It appeared that this fit was due to a
bolus effect and was possibly analagous to the catatonic state seen
in mice with rapid iv injections. It was decided that future doses
should be given as a short infusion and in view of the lack of other
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toxic effects to escalate the dose by 100%. This was felt to be safe
since the AUC measured at this dose was less than 1/15th of the
target AUC. Plasma decay curves are shown in fig 14.







































































The drug was given as a 20 minute infusion in 250ml saline. Apart
frcm a transient feeling of warmth at completion of the infusion no
side effects were seen. The parmacokinetic data indicate non-linear
kinetics with an increase in elimination half life and 3-4 fold
increase in AUC (fig 15) compared to 200mg/sqm. Allowing for this a
further 100% dose increase would still not exceed the target AUC.
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Dose : 800mg/sqm Date start : 30 : 10 : 86
Patient Diagnosis Age Performance Major Disease
Status Site
FL Sarcoma 24 2 Lungs
MG Ovary 58 1 Abdomen
JB NSCLC 63 1 Lung
SL Sarcoma 26 1 Lung
NB Ovary 58 1 Abdomen
AG NSCLC 67 2 Lung
Prior XRT Prior Chemotherapy
FL Pelvis Ifosfamide , Adriamycin
MG none Cyclo, Cis--Piatin, CBDCA
JB Mediastinum Ifosfamide
SL none Cis-Platin , Mtx, Adriamycin, Ifos.
NB Abdomen CHIP, Chlorambucil
AG Mediastinum Ifosfamide
Platelet nadir
Course 1 Course 2 Course 3 Course







Course 1 Course 2 Course 3 Course






Nausea/vomiting Alopecia Pain Allergy
FL 3 3 3 0
MG 2 0 3 3
JB 1 0 0 0
SL 2 0 3 0
NB 3 0 0 0
AG 2 0 0 0
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Lethargy Light headed Diarrhoea
FL 5 days 15 min 2
MG 3 days - 0
JB 7 days 20 min 0
SL 7 days - 3
NB 7 days 20 min 0
AG 3 days 15 min 0
Pharmacokinetic data
AUC Clearance Tl/2a Tl/2/3
FL 231 79 .33 9.2
70* 131 .43 7.0
MG 112 200 .41 5.5
JB 81 248 .19 4.6
SL 109 227 .83 7.6
NB 122 174 .52 11.3
AG 223 71 .26 12.1
* Second course given at 400mg/sqm
Plasma decay curves are shown in fig 16.
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fig 17 Alteration in kinetics with 50% dose




A range of non-haematological toxicities occurred at this dose
which was given as a one hour infusion in 500ml N saline. Four
patients noticed a feeling of light headedness lasting 15 - 20
minutes towards the end of the infusion. This was not associated
with an increase in pulse rate, fall in blood pressure or any-
neurological abnormalities. Three patients developed severe pain
requiring opiate analgesia. In two cases this occurred within two
hours of the infusion and the pain affected known sites of tumour;
buttock in a sarcoma patient and abdomen in a patient with ovarian
cancer. In both these cases the pain continued for 2-3 days before
fully resolving. In the third case colicky abdominal pain was
associated with severe diarrhoea which began 12 hours after treatment
and continued for 16 hours.
All patients felt very tired and lethargic for up to 7 days after
the amphethinile infusion and all had some degree of nausea and
vomiting related to treatment. Patient MG had an episode of
breathlessness, sweating and vomiting 40 minutes after the first
treatment. This lasted five minutes and was treated with an iv
injection of hydrocortisone. When rechallenged with the drug 3 weeks
later these symptoms recurred immediately after only a few ml had
been infused. The treatment was stopped and she made a full recovery.
This was clearly an allergic reaction probably to the solutol
vehicle.
Neutropenia and alopecia occurred in one patient treated at this
dose. The AUC for this patient was 231ug/l.h-l, a level considerably
higher than that of other patients treated at this dose and
approaching the target AUC of 300ug/l.h-l. This patient also
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experienced severe pain in the buttock area commencing 30 minutes
after the amphethinile infusion finished and because of this her
2
second dose was given at 400mg/m . At this dose she had no side
effects of any kind. Moreover The terminal elimination half life fell
by 2.2 hours and the AUC by a factor of 3. The wbc nadir occurred on
day 7 following therapy and recovered by day 14. Prior to starting
therapy this patient had rapidly progressing pulmonary metastases.
While receiving amphethinile the chest X-ray appearances remained
static for three months before progressing again. This may indicate
an effect of the drug on the tumour.
The pharmacokinetic data appear to confirm that an AUC of 200-300
is required to produce biological effects in terms of haematological
suppression, hair loss and possibly anti-tumour activity. In addition
it appeared that an increase in dose by a factor of two results in a
3-4 fold increase in AUC. The majority of patients treated at
2
800mg/m had an AUC of less than 130 and therfore a dose
increase of 50% which should approximately double the AUC was
selected for the next dose level.
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Dose : 1200mg/sqm Date start : 22 : 1 : 87
Patient Diagnosis Age Performance Major Disease
Status Site
DM Teratoma 27 1 Liver
GM Sarcoma 58 1 Abdomen
PC NSCLC 61 2 Lung
Prior XRT Prior Chemotherapy
DM none POMB/ACE
GM none Ifosfamide, Adriamycin
PC Mediastinum Ifosfamide




Nausea/vomiting Alopecia Pain Allergy
DM 3 3 0 0
GM 3 - 0 0
PC 2 - 0 0
Lethargy Light headed Diarrhoea
DM 7 days 60 min 0
GM 2 days 30 min 0
PC - 60 min 0
Pharmacokinetic data
AUC Clearance T1/2CX Tl/2jS
DM 361 92 1.1 13.8
GM 194 188 .06 6.9
PC 184 216 2.3 8.6
Plasma decay curves are shown in fig 18.
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fig 18 (cont) 1200mg/sqm : PC
hours
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fig 19 Plasma decay following 800mg/msq
orally and IV in patient JB
hours
o : oral dose
x : iv dose
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Conment
This dose was given as a two hour infusion in 500ml saline to
patients DM and GM and as a four hour infusion in 1000ml saline to
PC. All three patients experienced a feeling of light headedness for
30 - 60 min similar to that seen at lower doses. Again this was not
associated with cardiovascular or neurological abnormalities. In
addition all patients had varying degrees of nausea and vomiting but
nc episodes of pain or allergic phenomena were seen. The first
patient treated at this dose, DM, experienced an unusual feeling of
being unable to focus properly for 4 days in addition to somnolence
and profound tiredness for 7 days. This patient also developed
9
alopecia and neutropenia of 1.9 x 10/1 on day 14 with recovery
by day 21. Unfortunately due to rapidly advancing liver disease a
second course was not given.
The second patient, GM, was readmitted to hospital 48 hours after
completing therapy suffering from haematemesis, melaena and in a
state of collapse. The patient subsequently died but permission for a
post mortem was not given. The patient had a large abdominal mass
measuring 24 x 16 cm and it was considered that an intra-abdominal
catastrophe associated with this mass had taken place.
The third patient had minimal initial toxicity following the
infusion but 16 hours later suddenly developed a right hemiparesis
and died 12 hours later. At the time of the CVA the patient was
hypotensive but an ECG was normal. A post mortem examination was
performed. Infarcts were seen in the brain, spleen and both kidneys.
These were considered to be due to emboli from a loosely adherent
area of thrombus in the ascending aorta. Apart from a large mass of
tumour in the mediastinum no other abnormalities were seen and in
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particular there were no obviously drug related effects.
There were therefore two deaths within 48 hours of treatment at
this dose and although these did not appear to be due to the more
usual causes of toxic death it is difficult not to attribute these to
the drug. One possibility in the second case is that the high dose of
solutol administered, 24gm, resulted through its detergent like
action in destabilisation of an atheromatous plaque with subsequent
embolisation. Moreover the first patient (DM) experienced grade 3
vomiting, grade 3 somnolence and a very disturbing sensation of
inability to focus for 3 days. It was therefore felt that further
patients should not be entered at this dose.
Discussion
Amphethinile was introduced for phase I clinical trial because of
activity in pre-clinical systems, a novel stucture, and apparent
non-cross resistance with the vinca alkaloids. However a major
problem was the compound's insolubility and this was overcome by
using a formulation including Solutol HS15, a surfactant like
material that produces a molecular suspension of amphethinile in
aqueous solution. Unfortunately Solutol has not been used in man
before but it had been shown to be 10 - 20 x safer than the related
material Cremophor EL which has. However this meant that the current
study was a phase I trial of both amphethinile and solutol.
The highest dose given using the intermittent iv schedule was
2
1200mg/m . At this dose 2/3 patients died within 48 hours of
treatment possibly as a result of solutol induced vascular effects.
The third patient developed neurological toxicity comprising
lethargy, somnolence and visual disturbance which precluded further
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treatment. This dose clearly exceeded the MTD.
2
At 800mg/m all six patients experienced nausea and vomiting
lasting a few hours to 3 days and all experienced quite profound
lethargy for 3-7 days. In addition four patients noted a feeling of
light headedness for 15-30 min at the end of the infusion, three had
pain requiring opiate analgesia and two diarrhoea. This dose
therefore represents the maximum tolerated dose for the trial
although the degree and nature of toxicity varied considerably from
patient to patient.
Two patients during the study developed alopecia and neutropenia as
2
a result of treatment. One was treated at 800mg/m and one at
1200mg/m2 but both had an ACJC in excess of 230ug/l.h-l. These
effects are presumably due to the amphethinile and indicate that an
AUC above this level is required for cytotoxicity to occur. There was
however a consistent thread of neurotoxicity running through the
2
trial. At 400mg/m a bolus injection provoked a fit in one man
2
and at 800 and 1200mg/m the majority of patients experienced
light headedness and lethargy. In addition one patient at
2
1200mg/m had visual disturbance and another a CVA although the
latter appeared to be embolic in origin. Amphethinile is said to be a
spindle poison and therefore neurotoxicity might be expected as a
result of treatment. On the other hand solutol produced immediate CNS
toxicity in mice at high doses, particularly when the dose was given
as a rapid iv bolus. These solutol related effects were not seen with
the intraperitoneal injections. It is therefore also possible that
the neurotoxicity seen in this trial was due to solutol. Moreover at
2
800 and 1200mg/m the dose of solutol was 10 - 2 5 gm. This
represents approximately 10% of the LD50 of Solutol in the mouse and
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is therefore a considerable dose. Solutol is known to release
vasoactive substances such as histamine at high doses in dogs and it
is possible that local vasodilation was the cause of the pain in
three patients. In addition the detergent-like action of solutol may
lave had seme effect on the vasculature of the patients who died
2
following treatment at 1200ng/m . The patient who survived this
dose was considerably younger and would therefore have less chance of
having degenerative vascular disease on which the solutol might have
an effect. The one event that can definitely be attributed to the
solutol was the allergic reaction which occurred in one of the 14
patients entered in the trial.
2
Although it is possible to administer 800mg/m as an iv
infusion over 2 hours even this dose was associated with considerable
toxicity. Moreover only one of the patients treated at this dose
achieved an AUC that produced cytotoxic effects. Thus rather than
2
advocating 800mg/m as an appropriate dose for phase II testing
alternative methods of administration should be explored. In
particular different schedules should be tested. For example since
2
400mg/m was virtually non-toxic this dose could be given on
successive days starting with 2 doses and escalating to 3, 4, 5 etc
depending on toxicity. From the pharmacokinetic data available
2
400mg/m daily for 5 days would probably be needed to achieve a
relevant AUC. Alternatively in a manner analagous to the vinca
alkaloids a weekly schedule may be appropriate.
A potentially more interesting avenue for research is the use of a
solutol free oral formulation. Amphethinile is known to to be
absorbed when administered orally to mice. In addition a preliminary
trial using the iv preparation in one patient showed that the
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bioavailability of airphethinile given orally was close to 100% (fig
19). The development of an oral preparation not containing solutol
will allow more accurate determination of amphethinile related
toxicity.
Work in progress in the Department of Experimental Chemotherapy,
Raterson Institute for Cancer Research indicates that Amphethinile
acts at different sites compared to the vinca alkaloids confirming
that it may be non-cross resistant with these agents (McGown personal
communication). Amphethinile therefore appears to be a very
interesting compound and attempts to find a practical formulation and
schedule should be pursued.
Escalation Procedure
This trial employed a novel escalation procedure combining two
separate concepts. The first, derived from the phase I study survey
reported earlier, stated that if the starting dose was entirely
non-toxic and the AUC was less than 5% of the target AUC, then this
could immediately be escalated to 5 times the starting dose. This
proved to be entirely safe in this trial.
The second was based on the work of Collins et al (1986) and
involved the use of pharmacokinetic data in the mouse as a guide to
speed of escalation. This relies on the observation that the AUC at
the LDlO in the mouse is close to the AUC at the MTD in man. The use
of this concept allowed rational dose increments to be used based on
observed changes in amphethinile clearance with increasing dose.
Although it is likely that some of the dose limiting effects seen
were due to solutol, amphethinile toxicity appeared to occur when an
AUC close to the target AUC was achieved.
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As a result of the use of these procedures the final escalation
step which was 30 times the starting dose was reached in four dose
increments. Using the conventional modified Fibonacci scheme this
would have taken nine escalation steps. This therefore represents a
saving of 5 dose levels which would have increased the duration of
the trial by 9 - 12 months and the number of patients included by





The pharmacokinetic study carried out in conjunction with the phase
I clinical trial of Amphethinile had the dual aims of guiding dose
escalation and characterising the clinical pharnacology of the drug.
In order to fulfil these aims it was necessary to develop an HPLC
method for measuring the drug in serum and urine and also to
perform pharmacokinetic experiments in mice
Methods
An HPLC method was developed to measure amphethinile in the serum
and urine.
Detector
Amphethinile possesses no native fluorescence but significant UV
absorption occurs at 240 and 310nm (fig 20). Due to the considerable
background absorption from plasma at 240nm, 310nm was selected as the
most efficient wavelegth for this compound. Experimentation with the
PYE UNICAM PU4020 UV detector showed that maximum absorbance
occurred at 305nm and this was used in all subsequent assays.
Column
Amphethinile is a relatively small molecule, MW 265, alcohol
soluble and non-polar. A 5 micron ODS reverse phase column was
therefore chosen as most likely to provide adequate chromatography.
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Amphethinile is highly soluble in most organic solvents and thus a
water/methanol buffer was selected. Retention times with varying
proportions of water and methanol +/- 0.1% phosphoric acid are shown
below. The results for the compound selected as the internal standard
for the assay are also shown. This compound, 2-Nitro -5-Chloro
Aniline is formed during the synthesis of amphethinile and also
exhibited uv absorbance at 305nm.
Table 23 Retention time of Anphethinile with alteration in Mobile
Phase
Methanol Water H3P04 Standard Amphethinile
retention times in minutes
0% 100% 0 60+ 60+
25% 75% 0 60+ 60+
50% 50% 0 28 34
50% 50% 0.1% 24 32
70% 30% 0 4.83 8. 33
70% 30% 0.1% 2.33 6
100% 0% 0 2.66 2.66
100% 0% 0.1% 2.66 2.33
The shortest retention time occurred with 100% methanol but this
could not separate Amphethinile from the compound selected to be the
interal standard for the assay. A solution of 70% methanol/30% water
achieved excellent separation of these two compounds. The addition of
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0.1% phosphoric acid, by protonating the primary amine group,
increases the polarity of both the Amphethinile and the internal
standard and therefore reduces their retention times on the column by
approximately 100 seconds. The flow rate through the column during
these experiments was 1.25ml/min and the working pressure was 270 -
300 bar.
Extraction Procedure
In the first instance a methanol extraction was examined. It was
found that over 90% of the drug could be extracted from a 0.5ml serum
sample using 3 x 1ml extrctions. However this resulted in a 7:1
dilution of the sample and the lower limit of detection for this
method was comparatively high at 5ug/ml. Further studies were
therefore carried out using chloroform extraction. Amphethinile is
readily soluble in chloroform which can be guickly evaporated once
extraction has been carried out. This allows the extract to be
resuspended in a much smaller volume of solvent allowing the
detection of lower concentrations.
It was found that a single chloroform extraction using 8ml
chloroform : 0.5ml serum obtained extraction efficiencies of over 90%
at drug concentrations of 0.lug/ml falling to 70% at lOOug/ml. These
figures remained constant over a series of experiments and therefore
it was possible to use this method to construct linear standard
curves for assessing serum samples. The full extraction procedure
developed was as follows:
(1) 0.5ml serum + 8ml chloroform then vortex for 30seconds
(2) remove precipitate + agueous phase using phase separation filter
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(3) evaporate to dryness
(4) resuspend in 50ul methanol
(5) inject 25ul onto column
HPLC Equipment
PYE UNICAM PU4010 pump
PYE UNICAM PU4020 UV detector
PYE UNICAM PU4800 video control centre
5u ODS Hypersil column
Using this method the lower limit of detection of anphethinile was
0.lug/ml (lOOng/ml). 20ul (lmg/ml solution) of internal standard
(l-Nitro-5-Chloro Aniline) was added to each serum sample prior to
chloroform extraction as a measure of inter-assay variation. The
extraction efficiency of the internal standard was 90%.
Pre-clinical Pharmacology in BDF Mice
In order to use preclinical pharmacology data as an aid to dose
escalation in the phase I clinical trial (Collins et al 1986) a
pharmacokinetic study was carried out in BDF mice. A preliminary
experiment was performed to ensure that the LD10 for arrphethinile in
these mice was similar to that for the MFl strain used by BIBRA
Ltd. during formal pre-clinical toxicology testing.
Groups of 10 mice were treated with control solution, 150mg/kg,
175mg/kg and 225mg/kg amphethinile by intraperitoneal injection. The
control solution consisted of a 30% solution of solutol (500mg/ml) in
normal saline. The test solutions were given in normal saline to a
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total volume of lOml/kg.






These data show that the LD10 lies between 150 and 175mg/kg and is
therfore not significantly different to that found by BIBRA Ltd.
using the MF1 mice (138 - 169mg/kg).
Pharmacokinetic Study
The pharmacokinetics of anphethinile were studied in BDF mice at
2 2 2
400mg/m , the LD10, 200mg/m and lOOmg/m . Amphethinile was diluted
with normal saline to achieve a dose volume of lOml/kg. Injections
were given into the mouse tail vein using aseptic technique. In order
to obtain sufficient blood for assay mice were sacrificed at the
appropriate time interval following treatment. Three mice were used
for each time point which were: 5min, 15min, 30min, 60min, 2hr, 4hr,
6hr, 9hr. Blood was immediately centrifuged, serum separated and
stored at -20°C prior to assay.
Since only lOOul of serum was available from the mice the assay
was modified in the following manner:
(1) lOOul serum + 20ul standard + 2ml chloroform, vortex
(2) filter to remove protein + aqueous phase
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(3) evaporate
(4) resuspend in 50ul methanol
(5) inject 25ul on column
The limit of sensitivity using these volumes was lug/ml.
The most noticeable acute effect of amphethinile injection was a
2
catatonic like reaction which occurred mainly at 400mg/m but
2
also to a lesser extent at 200mg/m . A similar reaction was
noted in the pre-clinical toxicology experiments conducted by BIBRA




The data from this study were analysed using a non-iterative
computer programme. The serum decay of amphethinile in mice conformed
to a two compartment model with equation:
ct=Ae~ at + Be~ Ist
Results
The experimental data and the pharmacokinetic parameters derived
from the computer analysis are shown in tables 25 and 26.
These data show that in the mouse the kinetics of anphethinile
are approximately linear with no significant change in elimination
half life with increasing dose (fig 21) although the AUC increased by
a factor of 3 with each doubling of the dose. The AUC at the LD10
was 313ug/l.h-l and thus this represents the target AUC for the phase
I clinical trial.
During the HPLC analyses an addtional peak was consistently seen
that had a retention time of 140 seconds (fig 22). This peak
therefore eluted before amphethinile and thus is likely to be a more
224
Table 25 Serum Anophethinile concent rat ions in mice at LDlO,
LD5 and LD2.5
Hours











































































Table 26 Pharmacokinetic Parameteres of Amphethinile in mice
KE K2>1 K2<1 VI VDarea VDSS VPC
LDlO 1.2 8.2 10.3 "—1o .01 .01 .01
LD5 1.1 2.1 2.0 .01 .03 .03 .01
LD2.5 0.9 1.4 2.2 CMO GOO .07 .04
T1/2Q: Tl/2/3 Area CI
LDlO .03 1.34 313 .17
LD5 .14 1.36 95 .31
LD2.5 .15 2.06 34 .48
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Values represent the mean of three mice at each time point
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polar conpound. This may be a hepatic metabolite of amphethinile,
such as a glucuronide derivative. Although the absolute amounts of
metabolite formed could not be calculated fig 23 shows the mean
excretion in arbitrary peak area units at the three dose levels
studied. The AUC at these doses, again in arbitrary units are shown
in table 27.









The quantity of metabolite formed increases in a linear manner with
increasing doses of anphethinile. This suggests that in mice the
processes responsible for the metabolism of amphethinile are not
saturable and follow first order kinetics.
Pharmacokinetic study in Man
Sanple Collection
Prior to drug administration an indwelling catheter was placed in a
peripheral vein to facilitate blood sampling. Blood was taken at time
zero, 5 , 10, 20, 30, 60 and 90 minutes, and 2, 4, 6, 9, 12 and 24
hours. Samples were centrifuged for 10 minutes at 500G and stored at
-20°C prior to assay. Urine was collected during time intervals
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0-6, 6-12 and 12-24 hours. Total volumes were recorded and 5ml
aliquots stored at -20°C*
Results
2
At the starting dose of 40mg/m Amphethinile was was
undetectable in the serum five minutes after injection. At the four
higher doses studied the plasma decay following bolus injection or
short infusion conformed to a two compartment model. The
pharmacokinetic parameters for each patient are shown in table 28
and the amounts of unchanged drug recovered in the urine in table 29.
The mean AUC at 200mg/sqm was 11.2ug/l. h-1, at 400mg/sqm
39.7ug/l.h-l, at 800mg/sqm 160.3ug/l.h-l and at 1200mg/sqm
236.6ug/l.h-l. The mean terminal elimination half lives at these
doses were 1.94 hours, 3.66 hours, 9.12 hours and 10.18 hours (fig
23). This increase in terminal half life with increasing dose is
reflected in a concomitant fall in clearance from a mean of 524ml/min
at 200mg/sqm to 381ml/min at 400mg/sqm, 154ml/min at 800mg/sqm and
180ml/min at 1200mg/sqm.
Recovery of unchanged airphethinile in the urine ranged from
0.012-0.7% of the administered dose, mean 0.12%. In addition there
was evidence of a metabolite on HPLC. This additional peak had a
similar retention time, 140-180 seconds, to that seen in the mouse
experiments. At 200mg/sqm the metabolite peak was too small to be
measured accurately. An estimate of the metabolite AUC in arbitrary
units at the higher doses is given below (table 30) and the plasma
decay curves shown in fig 24.
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Table28Pharmacokineticamet rsofAmphethinileinMa PatientDose RH200 JCCourse 1 1 2KE 0.61 2.88 0.96K21 1.49 3.38 1.42Kl2 1.37 10.49 2.43
Vc 62.0 10.2 27.8
Vd 132.6 48.9 88.3
Vss 118.9 42.0 75.4
Vpc 56.9 31.7 47.6
Tl/20! 0.21 0.04 0.15
Tl/2/3 2.40 1.14 2.29
AUC 9.42 11.51 12.74

















































































































































































































































Table 29 Urinary Excretion of Anphethinile
Patient Dose Course 24hour excretion % dose administered
mg ug
RH 360 1 192 0.053
JC 340 1 42 0.012
340 2 58 0.017
GG 750 1 471 0.062
750 2 705 0.094
TL 550 1 829 0.150
550 2 491 0.084
MG 1350 1 1350 0.200
FL 1100 1 635 0.050
550 2 734 0.133
JB 1200 1 8407 0.700
NB 1280 1 513 0.040
AG 960 1 709 0.070
GM 2200 1 522 0.020
PC 2400 1 594 0.020
Table 30 Anphethinile Metabolite AUC in Man





fig 23 Plasma Decay Curves of Amphethinile in Man
Time, hours
Points represent mean values of all assays at each dose level
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fig24 Amphethinile Metabolite - Man
Cone units/ml
hours




The HPLC method developed for the measurement of amphethinile
proved to be easily performed and reproducible, with an inter-assay
variation of 5.4%. The limit of sensitivity of 0.lug/ml was well
below biologically relevant concentrations in the serum and was
therefore adequate for this study. At low concentrations the
extraction efficiency for the method used approached 100% and this
together with the comparatively low volumes of distribution seen in
the study in man (89 - 147 litres) suggests that amphethinile does
not undergo significant binding to plasma proteins.
In the study of the kinetics in mice there was no increase in the
terminal elimination half life of airphethinile with increasing dose.
However the AUC increase by a factor of 3 for each 100% increment in
dose indicating that the kinetics are not completely linear. Despite
this there was a linear increase in metabolite formation implying
that this reaction followed first order kinetics. Moreover there was
no suggestion that this metabolic process was saturable in the mouse.
The AUC at the LD10 in the mouse was 313ug/l.h-l and thus this was
adopted as the target AUC for the phase I clinical trial.
The kinetics in man followed a different pattern. There was a
progressive rise in terminal elimination half life with an
accompanying fall in plasma clearance. Moreover for each 100%
increase in dose there was an approximate fourfold increase in AUC.
Once again a presumed hepatic metabolite was seen on HPLC which had a
similar retention time to that found in the mouse experiments.
However in man metabolite formation rose to an early peak at around 2
hours subsequently remaining constant for several hours before
declining again (fig 23). Moreover the amount of metabolite produced
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in the first 24 hours after treatment did not increase
significantly at doses above 800mg/sqm. This evidence suggests that
the metabolism of amphethinile is saturable in man and explains the
increase in half life with increasing dose.
Although the kinetics of arnphethinile in man appear to conform to a
two compartment model this is probably an over simplification. In view
of the evidence suggesting that the metabolism of amphethinile is
saturable it is likely that the the log plot of the post distributive
phase should curve towards the x-axis with only the terminal portion,
where the kinetics become first order, being truly linear. In order to
demonstrate this further time points during the latter portion of the
decay curve would have to be examined.
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During the past thirty years many hundreds of thousands of compounds
have been tested in pre-clinical systems for potential anti-tumour
activity. However only a small minority have progressed to clinical
testing probably 100 - 200 in total, and a minute fraction have found
a place in regular anti-cancer therapy. At present a complete
revision of pre-clinical screening systems is being undertaken
involving a change from methods relying on rodent tumours to the
exclusive use of cultured human tumour cell lines and human tumour
xenografts. It is hoped that this radical departure will uncover a
new spectrum of agents with activity in the common solid tumours.
An important obstacle to the development of new agents has been the
requirements of various liscencing authorities for pre-clinical
toxicological testing. The extent and detail of these tests,
particularly those in large animals, has meant that a great deal of
time and money has had to be invested in an agent before it reaches
clinical trial. The delay caused by these procedures has often been
of the order of ten years. It is now appreciated, however, that the
qualitative predictiveness of such large animal testing for toxicity
in man is low and many important toxicities such as cardiotoxicity in
the anthracyclines and renal toxicity with platinum drugs were not
foreseen. The main aim of pre-clinical toxicology is to determine a
safe starting dose for phase I trials and since this can be done with
equal accuracy in mice and large animals it is now proposed that 1/10
of the LD10 in the mouse is used as a starting dose provided that
this is entirely non-toxic in the rat. The exclusive use of rodents
for pre-clinical toxicology dramatically reduces the time and expense
involved and thus will allow more drugs to reach phase I testing more
quickly.
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With these changes and improvements in the pre-clinical development
of new agents it is possible that increasing numbers will become
available for clinical trial. In order that much effort is not to be
wasted there should be certain changes made in phase I and II
methodology. Dose escalation schemes for phase I trials must be made
more efficient so that these studies can be completed rapidly with
more patients treated at potentially therapeutic doses. The most
promising way of achieving this is to use pre-clinical
pharmacological data as a guide to the speed of escalation. This is
based on the observation that the AUC at the LD10 in the mouse is
close to the AUC at the MTD in man. Using these principles
together with the data from the phase I survey it is possible to
reduce the number of dose escalation steps by up to 50% compared to
classical modified Fibonacci schemes. This increase in the pace of
phase I studies will allow drugs to pass more rapidly to phase II and
will also allow the exploration of alternative schedules without
requiring additional patient resources.
There must also be a change in the approach to phase II testing.
The main problem with this stage of drug development is that trials
are often performed in patient groups where the chance of a response
is very low. The two factors that militate most strongly against a
response occurring are the performance status of the patient and the
extent of prior chemotherapy. Investigators must be prepared to enter
patients in phase II trials who are in good general condition and who
have received no prior chemotherapy. In recent years this has been
done increasingly in diseases where existing chemotherapy produces
consistent response rates of less than 20% eg non-small cell lung
cancer and colon cancer. However it is equally important to identify
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new active agents in tumours such as breast cancer where although
many durgs are active the impact on survival is minimal, in these
conditions alternative protocols should be adopted allowing new drugs
to be used for a minimum of 2 courses in untreated patients before
crossing to a proven regimen if no response is seen. The evidence
from the trial of 4-demethoxydaunorubicin in breast cancer presented
in this thesis suggests that such a trial design does not predjudice
patient survival. The information obtained from one study conducted
in this way will be of greater value than several inconclusive trials
in heavily pre-treated patients. Answers to the inrportant questions
of the activity of a drug in a range of tumours can be obtained
rapidly and with greater certainty and in addition the chance of
erroneously rejecting an active compound will be reduced. The use of
protocols allowing early termination if no responses are seen in the
first 14 patients should ensure that a large number of patients are
not treated with inactive compounds.
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3.0 Selection of patients
Patients must fulfil all of the following criteria.
3.1 Histologically proven diagnosis of malignancy.
3.2 Recurrent or metastatic disease not amenable to curative
256
surgery and/or radiotherapy.
3.3 Measurable or evaluable lesions (see 4.0) with documented
progression within 2 months prior to entry into this study.
3.4 Performance status according to the WHO scale < 2
and a life expectancy of > 3 months.
3.5 Age of 75 or less.
3.6 At the start of treatment
WBC > 3 x 109/1, platelets > 100 x 10^/1
Bilirubin < 1.5 mg/dl (or < 25.6 umol/1)
Creatinine <1.5 mg/dl (or < 132 umol/1) and/or creatinine
clearance > 60 ml/min.
3.7 No prior radiotherapy and/or chemotherapy during the last 4
weeks (6 weeks for nitrosoureas and mitomycin C) and all toxic
manifestations of prior treatment must have resolved.
3.7.1 No prior therapy with any specified drugs if appropriate
3.7.2 Preferably not previously treated patients should be entered
into the study. (If appropriate)
3.8 No prior radiation therapy to all present areas of measurable
or evaluable disease.
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3.9 No brain involvement.
3.10 No previous or current malignancies at other sites, with the
exception of cone biopsied in situ carcinoma of the cervix
uteri and adequately treated basal or squamous cell carcinoma
of the skin.
3.11 Patients who are poor medical risks because of non-malignant
systemic disease as well as those with active, uncontrolled
infection are not eligible for the trial.
3.12 Written informed consent is not mandatory. However, oral
informed consent will be obtained. This will be noted on the
patient case report form. Informed consent procedures for
this trial will be in compliance with in-country laws pertain¬
ing to patient informed consent and rights of human subjects.
4.0 Measurability of the disease
4.1 Are not considered measurable or evaluable
- lesions in previously irradiated fields;
- ascites, pleural effusions, and/or bone metastases;
4.2 The following parameters are considered measurable
- lesions measurable by two perpendicular diameters;
- lung lesions surrounded by aerated lung;
- superficial lymph nodes with positive fine needle biopsy;
- skin nodules with positive fine needle biopsy.
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4.3 Are considered evaluable, lesions that are measurable in one
diameter as well as lesions that are deeply located and
measurable in two diameters
- a lung tumour not completely surrounded by aerated lung;
- a palpable and measurable deep lymph node.
- a palpable and measurable abdominal tumour.
Malignant hepatomegally may be measured if the inferior
edge is palpated at 5 cm below the costal margin and the
tip of the xyphoid. Measurements below the costal margins
will be made in the respective midclavicular lines or at
other defined points during quiet respiration;
- lesions demonstrated by CT scan provided that they have a
diameter of at least 5 cm and that their malignant nature is






5.2.2 Dosage schedule modifications
Drug administration is postponed by one week if there is not
3
full hematologic recovery (WBC > 3,000/mm , platelets
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3
> 100,000/mm ) from the prior course at scheduled retreat-
ment. If treatment is delayed by more than 5 weeks the patient
is withdrawn from the study.
Dosage adjustments are made according to the lowest value of
WBC and/or platelets measured weekly in the previous course
and according to treatment delay due to myelosuppression.
(If appropriate)
If treatment is delayed because of myelosuppression at
2
scheduled retreatment, drug dosage must be reduced to X mg/m
if not already indicated by blood counts in the previous
course.
5.3 Treatment duration
5.4 Drug supply and distribution
5.5 Other treatments
5.5.1 Ancillary treatment will be given as medically indicated but
must be specified in the flow sheets.
5.5.2 Radiotherapy may be given concomitantly for control of bone
pain provided that all evaluable lesions are not included in
the irradiated field. The treated area cannot be used as a
measurable or evaluable parameter.
260




History + Physical Examination
Performance scale (WHO)







Urine analysis (Chem, sed)
ECG
Chest x-rays (PA and lateral)
CT-Scan a/o ultrasound abdomen
and liver















(a) Colour photographs of all visible lesions together with
identifications, date and rule (cm) should be repeated
every 3 months or sooner if changes occur.
(b) Include BUN, uric acid, electolytes, calcium, glucose,
bilirubin, alk. phosphatase, SGOT or AST, LDH.
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(c) Only in patients who respond; beginning at the time of
response and continuing every two months for the duration
of the response.
7.0 Criteria of Response
Idealy, all measurable and evaluable lesions should be
measured at each assessment. When multiple lesions are
present, this may not be possible and, under such circum¬
stances, the most representative lesions may be selected.
Neither the development nor the healing of skin or mucosal
ulcers should be taken as sole evidence of change.
7.1 Complete response: disappearance of all known disease, and no
new lesions in other sites, determined by two observations not
less than 4 weeks apart.
7.2 Partial response: decrease by at least 50% in the sum of the
products of the largest perpendicular diameters of all measur¬
able lesions plus the sum of the diameters of all evaluable
lesions as determined by two observations not less than 4
weeks apart. See 4.0 for the definition of measurable and
evaluable lesions. For the liver, 3 measurements must be con¬
sidered (see 4.0). It is not necessary for all lesions to
have regressed to qualify for partial response, but no lesions
should have progressed and no new lesions should appear.
There should also be an objective improvement in non-eval-
uable but clinically evident malignant disease (e.g. pulmonary
or skin infiltration). Serial evidence of appreciable change
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documented by radiography or photography must be obtained and
be available for subsequent review. The assessment must
always be objective. If non-evaluable but clinically evident
disease represents the bulk of disease and this clearly does
not respond, even though significant tumour shrinkage is noted
in measurable and/or evaluable lesions, then this is to be
considered as "no change" not "objective regression".
7.3 No change: a 50% decrease in total tumour size cannot be
established nor has a 25% increase in the size of one or more
measurable or evaluable lesions been demonstrated.
7.4 Progressive disease: a 25% or more increase in the size of at
least one measurable or evaluable lesion or the appearance of
a new lesion. The occurrence of pleural effusion or ascites
is also considered as progressive disease if this is substan¬
tiated by positive cytology. Pathological fractures or coll¬
apse of bones are not necessarily evidence of progressive
disease.
7.5 Early death: death during the first four weeks without severe
toxicity.
7.6 Toxic death: any death to which drug toxicity is thought to
have made a major contribution.
8.0 Duration of Response and Survival
The duration of response will date from the commencement of
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treatment until the documentation of progression. Survival
will be dated from the commencement of treatment.
9.0 Statistical considerations
All eligible patients with disease X will be entered into
the trial until accrual is completed for patients treated
with at least 2 courses of drug Y.
The trial will consist of two stages. In the first stage, 14
patients will be entered. If there are no responses (complete
or partial) in 14 patients with no prior chemotherapy the trial
will be terminated. If there are one or more responses in the
first 14 patients, additional patients will be added (see
below) so that the standard error of the observed response
rate will be less than or equal to 0.10. This scheme ensures
that if the drug is active in 20% or more of patients, the
chance of erroneously rejecting the drug after the first 14
patients is .044. The advantage of a two stage scheme is that
it allows early rejection of an ineffective drug.
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No. of response in the No. of additional











All eligible patients must be registered with the Data
Centre within 24 hours of initial drug administration.
- protocol number
- name of institution
- code number of institution
- name of patient
- name of the responsible investigator
- date treatment started
Clinical Trials Forms are to be used for
this study. The on-study form should be sent within one week
of registration of the patient to the Data Centre.
Flow sheets and measurement forms should be sent as soon as
they are complete to the Data Centre.
The study chairman is called at once in case of pronounced
toxicity, serious side effects or toxic death of the patient.
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